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Abstract 
 
 
Optical imaging is an emerging field of clinical diagnostics that can address the growing 
medical need for early cancer detection and diagnosis. Various human cancers are 
amenable to better prognosis and patient survival if found and treated during early 
disease onset. Besides providing wide-field, macroscopic diagnostic information similar 
to existing clinical imaging techniques, optical imaging modalities have the added 
advantage of microscopic, high resolution cellular-level imaging from in vivo tissues in real 
time. This comprehensive imaging approach to cancer detection and the possibility of 
performing an ‘optical biopsy’ without tissue removal has led to growing interest in the 
field with numerous techniques under investigation. Three optical techniques are 
discussed in this thesis, namely multispectral fluorescence imaging (MFI), hyperspectral 
reflectance imaging (HRI) and fluorescence confocal endomicroscopy (FCE). MFI and 
HRI are novel endoscopic imaging-based extensions of single point detection techniques, 
such as laser induced fluorescence spectroscopy and diffuse reflectance spectroscopy.  
This results in the acquisition of spectral data in an intuitive imaging format that allows 
for quantitative evaluation of tissue disease states. We demonstrate MFI and HRI on 
fluorophores, tissue phantoms and ex vivo tissues and present the results as an RGB 
colour image for more intuitive assessment. This follows dimensionality reduction of the 
acquired spectral data with a fixed-reference isomap diagnostic algorithm to extract only 
the most meaningful data parameters. FCE is a probe-based point imaging technique 
offering confocal detection in vivo with almost histology-grade images. We perform FCE 
imaging on chemotherapy-treated in vitro human ovarian cancer cells, ex vivo human 
cancer tissues and photosensitiser-treated in vivo murine tumours to show the enhanced 
detection capabilities of the technique. Finally, the three modalities are applied in 
combination to demonstrate an optical viewfinder approach as a possible minimally-
invasive imaging method for early cancer detection and diagnosis.  
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This thesis is a multidisciplinary body of work involving the assistance and collaborative 
efforts of biomedical researchers and clinicians from Imperial College London and her 
affiliated hospitals. Its broad aim is the evaluation of a trio of novel optical endoscopic 
imaging modalities for minimally invasive cancer detection and diagnosis, with the 
underlying view of reducing customary reliance on conventional clinical imaging systems 
in developed nations and the more long-term vision of providing affordable and effective 
diagnostic technologies in countries of the developing world. Optical techniques under 
investigation are systematically validated using tissue-simulating phantoms, in vitro cell 
lines, ex vivo tissue specimens and in vivo tissues. Results are further compared with 
histopathology where possible to assess overall diagnostic effectiveness with the 
prevailing gold standard method.   
 
This chapter provides a brief overview of recent cancer statistics, socio-economic factors 
and clinical motivations relating to the implementation of optical imaging modalities for 
early cancer detection and diagnosis. As the utility of optical imaging techniques for early 
cancer detection becomes more apparent, so has clinical and biomedical research interest 
in the field increased with numerous optical modalities currently under investigation. 
Three novel optical detection methods are examined in this thesis, namely multispectral 
fluorescence imaging (MFI), hyperspectral reflectance imaging (HRI) and fluorescence 
confocal endomicroscopy (FCE) for minimally invasive in vivo in situ monitoring of 
22 
 
dysplastic conditions in humans. The outline of contents in proceeding chapters of the 
thesis is also mentioned. 
 
 
1.1. The pivotal role of medical imaging in cancer detection and diagnosis 
 
Recent statistics from the World Health Organisation’s International Agency for 
Research on Cancer (WHO IARC) estimated that around 7.6 million people worldwide 
died from cancer in 2008 (GLOBOCAN 2008). Taking into account future demographic 
shifts and growth in the world population, this number is projected to rise to 
approximately 12 million cancer deaths annually by 2030 (Mathers and Loncar, 2006). In 
an effort to alleviate this global chronic disease burden, besides raising public awareness 
about cancer prevention and its related symptoms, clinicians and researchers have relied 
on medical imaging as an important means of early cancer detection and diagnosis. This 
is especially critical since the stage of diagnosis has been identified as being one of the 
most fundamental determinants for patient survival for most human cancer types 
(Pontén et al., 1995; Teppo et al., 1999; Sommerton et al., 2000).  
 
The central aim behind performing an early cancer diagnosis is to allow for recognition 
of early phenotypic dysplastic/cancerous signatures in situ. During which time, it is 
expected that the tumour remains localised to the organ of origin and has yet to invade 
surrounding normal tissue regions i.e. undergone metastasis. This is motivated by the fact 
that the chance for a potential cure is raised many fold if appropriate treatment is 
administered in a timely way during early disease onset. Cancers found to be amenable to 
better prognosis and patient survival if found and treated during early onset include the 
cancers of the breast (Carter et al., 1989; Maguire et al., 1994; Porta et al., 1991; Richards et 
al., 1999; Sant et al., 2003), stomach (Porta et al., 1991; Barchielli et al., 2001), cervix (Horn 
et al., 2007), lung (Maguire et al., 1994; Porta et al., 1991), liver (Wang et al., 2008), prostate 
(Gann, 1997; Vis et al., 2008) and bladder (Maguire et al., 1994; Hellsten et al., 1983). The 
stage of the tumour during time of initial diagnosis and treatment was also found to be 
closely related to rates of morbidity and mortality for oral (Sargeran et al., 2008; 
Subramanian et al., 2009) and colorectal (Maguire et al., 1994; Porta et al., 1991; Cicolallo et 
al., 2005; Ponz et al., 2000) cancers.  
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1.2. The drive towards multispectral optical imaging techniques 
 
Clinical imaging systems currently in widespread use include X-rays, magnetic resonance 
imaging (MRI), computed tomography (CT), single-photon-emission CT (SPECT), 
positron emission tomography (PET), and ultrasound. These macroscopic, wide-field 
imaging techniques allow for anatomical and structural information to be obtained at 
resolutions of between 50 !m and 3 mm from a particular tissue region (Weissleder and 
Pittet, 2008). Although sufficient for gross interrogation, such techniques usually require 
biopsies to be taken of the diseased region after imaging. This is followed by histological 
confirmation before a final comprehensive diagnosis can be made. While it is fair to 
conclude that macroscopic clinical imaging systems will no doubt continue to enhance 
patient care and prognosis in the future, the entire imaging process is costly and resource 
intensive, requiring not only skilled operators but also the support of hospital and 
histopathology infrastructures. This limits their implementation mainly to larger regional 
healthcare centres in urban areas with generally middle- to upper-middle income 
population brackets (Bedard et al., 2010). 
 
With rising treatment costs and increasingly ageing populations, it is not only individual 
patients who feel the financial strain but also publicly funded healthcare systems in some 
developed countries as a whole. One such example is the United Kingdom’s National 
Health Service (NHS), whose funding budget for England since its founding has swelled 
by over ten times that amount to approximately £102 billion in 2009/10 (NHS website). 
Although the UK government’s allocation for the NHS healthcare budget has seen a 
steady yearly increase (Figure 1.1), a recent report by the NHS has warned that these 
“modest cash increases could be outstripped by rising costs within the health service” 
(Jeffreys, 2009). In addition, such financial worries are compounded by mismatches in 
income tax and budgets on expenditure, a problem facing many European governments 
of today. To alleviate the financial strains on the UK healthcare system, Andy Burnham, 
the British government’s Health Secretary in 2009, remarked that emphasis had to be 
made on prevention, quality and innovation so as to maximise overall efficiency of the 
NHS (Smith, 2009). Novel multispectral optical imaging techniques are expected to play 
a major role in this process.  
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Figure 1.1. NHS budget for England from 2007/8 to 2010/11. (Source: HM Treasury) 
 
Of the 12.7 million new cases of cancer diagnosed worldwide in 2008, more than half 
that number presented in less developed regions of the globe (GLOBOCAN, 2008) 
where 80% of patients were found to be at advanced stages of the disease during the 
time of diagnosis (Tunstall-Pedoe, 2006; Jones et al., 2006). This is attributed most likely 
to poor healthcare coverage and inadequate cancer diagnostic facilities at the primary care 
levels in local communities. As the world population continues to grow exponentially, 
the largest increase is expected to come from Asia and other less developed countries of 
the world. Consequently, this implies an ever-greater need for affordable yet effective 
early diagnostic and treatment modalities, which can be easily integrated into local 
community healthcare systems.  
 
Multispectral optical imaging is an emerging field of medical diagnostics that has the 
potential to address the current global need for effective early cancer detection in a more 
affordable, portable and easy-to-use package. In contrast to macroscopic clinical imaging 
techniques, optical imaging systems can provide not only wide-field macroscopic 
diagnostic information (with a field of view measuring several square centimetres), but 
also microscopic cellular-level images of in vivo tissue surfaces with resolutions less than 
10 !m. As a result, multimodal optical imaging techniques offer a more comprehensive 
and truly ‘early’ imaging approach to cancer detection and diagnosis. Furthermore, 
technological advances in the optics, photonics and microelectronics industries have lead 
to greater miniaturisation of optical imaging devices; various examples include the 
PillCam platform (Given Imaging, USA) for capsule-based endoscopic imaging of the 
gastrointestinal tract and ‘chip on a tip’ flexible video laryngoscopes (Karl Storz 
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Endoskope, Germany) for otolaryngological applications. As a solution to third world 
countries lacking expensive diagnostic facilities and stable electricity, a group led by 
Richards-Kortum at Rice University in Texas, USA recently reported a US$240 
fluorescence microscope system powered only by AA batteries (Miller et al., 2010). The 
system weighs two and a half pounds and is described to be as effective at diagnosing 
tuberculosis as professional US$40,000 laboratory systems. Overall, this therefore 
translates in the long term to greater affordability, enhanced portability and easier 
implementation of optical diagnostic techniques outside of the hospital setting.    
 
The vast majority of carcinomas, comprising almost 90% of all human cancers, originate 
from the topmost epithelial tissue layer. This layer comprises of thin sheets of tightly 
packed cells that line most surfaces of internal structures within the body, the internal 
cavities (lumens) of hollow organs, as well as the surface of the skin. The epithelial layer 
lies directly above a fibered meshwork of extracellular proteins known as the basement 
membrane. This second tissue layer, known also as the basal lamina, effectively separates 
the epithelia above it from the underlying connective tissue layers it is anchored upon, 
termed the stroma. The basement membrane serves many functions: 1) a scaffold on 
which cells of the epithelial layer are adhered to (Weinberg, 2007), 2) a point of 
attachment for various biological signalling molecules (Tanjore and Kalluri, 2006; 
Weinberg, 2007), 3) a source of essential proteins required for angiogenesis (Kubota et al. 
1988), and 4) a mechanical barrier preventing entry of cancer cells originating from the 
epithelial layer into the stromal tissue beneath (Fenyvesi, 2003; Weinberg, 2007).  
 
Given its high-resolution imaging capabilities, the unique proposition of optical imaging 
modalities for early cancer detection may therefore be the ability to accurately identify 
dysplastic/cancerous cells in the surface epithelia before they have broken through the 
basement membrane and invaded underlying stromal tissue. With this ability to detect the 
very first signs of cancer with fine detail in real-time, some researchers have coined the 
phrase ‘optical biopsy’ to describe various optical imaging approaches such as 
fluorescence spectroscopic imaging, optical coherence tomography (OCT), diffuse 
reflectance spectroscopic imaging and fluorescence confocal microendoscopy (FCE), 
amongst many others. 
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Further motivations behind the implementation of optical imaging techniques for cancer 
diagnosis include: 
 
i. Eliminating the need for non-targeted and highly random tissue biopsies for 
histological analysis; rather, a thorough inspection of suspect tumour tissue 
regions can be performed in vivo using high-resolution optical probes. 
ii. Immediate acquisition of diagnostic information that can then be relayed 
quickly to the clinician and patient. 
iii. Reducing healthcare costs as a result of decreasing the need for time-
consuming tissue biopsy and histology procedures. 
iv. Surgical guidance during the removal of confirmed malignant lesions once 
they have been accurately identified. 
v. Post surgical assessment of tumour resection margins to ensure complete 
removal of all cancerous tissue and that no remnants are left behind which 
would otherwise lead to tumour re-growth. 
 
 
1.3. Overview of the thesis 
 
The work discussed in this thesis concerns the development of a multimodal 
supercontinuum fibre laser prototype system as applied to multispectral fluorescence 
imaging (MFI) and hyperspectral reflectance imaging (HRI) procedures, together with the 
use of a commercially available fluorescence confocal endomicroscopy (FCE) system for 
novel imaging applications.  
 
Chapter 2 serves as the main introduction to this thesis, setting the overall tone by 
presenting several key concepts and motivations for the multidisciplinary work being 
performed. Besides detailing various light-tissue interaction events that are integral to all 
optical imaging approaches, three mini literature reviews are also included as preambles 
to the techniques investigated.  
 
Chapter 3 describes MFI experiments on fluorescent dyes and collagen gel tissue 
phantoms for initial validation of a custom-built multispectral imaging-based 
spectroscopic system. The aim was to perform laser-induced, excitation-resolved MFI at 
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the macroscopic level with automated wavelength selection using either a motorised slit 
or a digital multimirror device (DMD). Also described in depth are two data 
dimensionality reduction techniques for processing of the acquired greyscale intensity 
image data, namely Principal Component Analysis (PCA) and fixed reference isometric 
mapping (FR-IsoMap), resulting in the generation of an RGB colour map for more 
qualitative analysis of the imaged region.  
 
Chapter 4 extends on work in the previous chapter by investigating the diffuse 
reflectance properties of lamb and human tissues with HRI in addition to MFI. As a step 
towards future in vivo application, the acquisition optics are now fully incorporated into a 
laparoscope setup. FR-IsoMap dimensionality reduction is later performed on the 
acquired fluorescence and diffuse reflectance tissue images for distinguishing between 
disease states. This demonstrates the potential application of our macroscopic imaging 
system as a ‘red-flag’ technique as well as a possible method for performing 
photodynamic diagnosis (PDD) on photosensitised tissues. Histopathological correlation 
with the imaging results is also discussed. 
 
Chapter 5 presents preliminary results from FCE performed on various in vitro human 
cancer cell lines with the commercial CellvizioGI FCE system. Our aim was to evaluate 
the microscopic cellular imaging properties of the system as a method for ex vivo cellular 
analysis and also for understanding the contrast to be expected during future in vivo in situ 
work. Additionally, FCE is applied on chemotherapy drug treated ovarian 
adenocarcinoma cell lines for monitoring chemotherapy response at the cellular level and 
as a faster alternative compared to conventional means. 
 
Chapter 6 describes the use of FCE for morphological and functional point imaging of ex 
vivo and in vivo tissues from humans and animal tumour models. Characterisation of 
cancer tissue morphology is performed on healthy and cancerous tissues with the aid of 
non-specific optical contrast agents. Later, functional tissue properties are investigated 
using photosensitised and fluorescent-labelled deoxygluocose-treated in vivo murine 
tumours. The chapter concludes with the proposition of a novel multimodal endoscopic 
viewfinder (MEV) imaging technique for early cancer detection and diagnosis 
incorporating the three previously described techniques. 
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Finally, Chapter 7 discusses the possible challenges faced when implementing such 
optical imaging techniques in a real-time clinical context, lists potential solutions to 
address these concerns as well as provides an outlook for future work to be performed 
with these optical diagnostic systems.  
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2.1. Introduction 
 
This chapter provides an overview of diagnostic imaging techniques for cancer detection, 
briefly summarising current clinical imaging techniques and discussing emerging 
multispectral optical imaging modalities in greater detail. Besides describing the various 
principles behind optical diagnostic approaches in depth, the chapter also contains short 
literature reviews that serve as introductions to the three optical imaging modalities 
explored in this thesis, namely multispectral fluorescence imaging (MFI), hyperspectral 
reflectance imaging (HRI) and fluorescence confocal endomicroscopy (FCE) together 
with various combinations of these three methods. The chapter concludes with a short 
discussion on the merits of optical ‘regional’ imaging over point-based spectroscopic 
techniques and the motivations for our work. 
 
 
2.2. Light-tissue interactions relevant to optical imaging 
 
Biological tissue comprises a myriad of different structural and biochemical components, 
all of which influence the behaviour of light as it interacts with tissue. When a photon of 
light arrives at the surface of a tissue boundary e.g. the mucosal epithelium of the colon, 
one of a series of events may take place as illustrated in Figure 2.1. Scenario A represents 
reflection events like regular surface reflections whereby the photon is returned directly 
from the surface of the tissue, yielding very little information about subcellular structures. 
Scenario B refers to an elastic scattering event where the photon has penetrated deeper 
into the underlying stroma, undergoes back scattering from various internal tissue 
structural components, and is then returned to the surface with no change in its overall 
energy. Scenario C depicts an absorption event whereby the photon’s energy is absorbed 
by chromophores in tissue such as oxyhaemoglobin (HbO2) and deoxyhaemoglobin 
(HbR), hence preventing it from being scattered back to the tissue surface. Scenario D 
illustrates inelastic scattering events such as fluorescence emission or Raman scattering, 
whereby the energy and wavelength of the proton is altered upon interaction with 
subcellular biochemical or structural components. Scenarios E and F refer to the 
majority of light-tissue interaction events whereby the photon penetrates the tissue 
boundary, becomes diffusely scattered in the underlying stroma and is later either 
absorbed by a tissue chromophore or diffusely reflected back to the surface respectively.  
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Figure 2.1. Graphical representation of various light-tissue interaction scenarios: reflection 
(Fresnel or regular) (A); elastic back scattering (B); absorption (C), inelastic events e.g. 
fluorescence emission or Raman scattering (D); diffuse scattering resulting in photons 
absorbed into the tissue or scattered back to the atmosphere respectively (E and F). 
(Adapted from Bigio and Bown, 2004) 
 
For the purposes of this thesis, the discussion shall be focused on fluorescence emission 
and reflectance events, both of which will be described later in greater detail.  
 
 
2.3. Fluorescence in biological tissue 
 
2.3.1. Definition and basic principles 
 
Fluorescence is defined as the radiative transition between two electronic states of the 
same spin multiplicity (Redmond, 2003). It is the emission of light by fluorescent 
molecules, known as fluorophores, within nanoseconds after absorbing light of a shorter 
wavelength (Lichtman and Conchello, 2005). This difference between the shorter 
exciting and longer emitted wavelengths is known as the ‘Stokes’ shift’, which arises due 
to a loss in energy during rapid decay to the lowest energy states (Lakowicz, 1999).  
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Figure 2.2. Jablonski energy level diagram indicating the ground (S0) and excited (S1, S2) 
electronic states as well as detailing the various electronic transitions that occur during the 
processes of absorption and relaxation. The S2 excited state contains the most energy 
followed by states S1 and then S0. 
 
Figure 2.2 shows a Jablonski energy level diagram indicating the ground (S0) and excited 
(S1, S2) electronic states, as well as detailing the various electronic transitions that occur 
during the processes of energy absorption and emission. After absorbing light energy 
(photons) in the UV/visible region, a fluorophore is rapidly elevated from its ground 
state (S0) to its excited state (S1) with an electron being moved into a different orbital that 
is further away from the nucleus (Lichtman and Conchello, 2005; Ramanujam, 2000). 
Occasionally the absorbed photon’s energy is large enough to cause the fluorophore to 
undergo a change in both vibration and rotation. The end result is the movement of an 
electron into the higher electronic orbitals (elevation to the higher excited state of S2) 
(Lakowicz, 1999; Ramanujam, 2000). Once the higher excited states have been reached, 
the fluorophore then loses its absorbed energy rapidly via processes known as vibrational 
relaxation and internal conversion until the lowest vibrational level of the S1 state is 
attained. From here the fluorophore emits its energy in the form of fluorescence and 
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returns to its ground state, S0. Alternatively, energy can also be lost as phosphorescence 
emission by a process known as intersystem crossing during a transition to the triplet 
states (Rhys-Williams, 2000). The minimum requirement for fluorescence to occur is for 
the absorbed photon to have enough energy to bring about the transition of an electron 
into a higher electronic orbital i.e. the S0 to S1 transition (Lichtman and Conchello, 2005). 
 
2.3.2. Fluorophores – the origins of fluorescence 
 
Two broad classes of fluorophores exist – endogenous fluorophores, which occur 
naturally in biological tissue, and exogenous fluorophores, which are foreign fluorescent 
agents applied to tissues for enhancing image contrast during various fluorescence 
imaging procedures.  
 
2.3.2.1. Endogenous fluorophores 
 
Naturally occurring endogenous fluorophores encompass a variety of amino acids, 
structural proteins, enzymes and their co-enzymes, vitamins, lipopigments and 
porphyrins, which contribute to the overall detected tissue autofluorescence signal. 
Through measurement of these autofluorescence signals, it would be possible in theory 
to elucidate the relative concentrations and redox states of these fluorescent compounds, 
ultimately revealing the biochemical and disease state of the tissue being studied without 
the application of exogenous fluorescent agents (Bigio and Bown, 2004; Xu and Povoski, 
2007). For most endogenous fluorophores, their excitation maxima range between 250 to 
450 nm (UV/visible spectral range), with emission maxima lying between 300 to 700 nm 
(UV/visible/near-infrared spectral regions) (Figure 2.3). Various endogenous 
fluorophores have been identified which are believed to be associated with tissue 
transformation processes around the onset of carcinogenesis (Ramanujam, 2000). These 
include the amino acids tryptophan (Hubmann et al., 1990) and tyrosine (Ganesan et al., 
1998), the structural proteins elastin and collagen (Bottiroli et al., 1995; Romer et al., 1995; 
Zonios et al., 1996), the metabolic co-enzymes NADH (Andersson-Engels et al., 1990) 
and FAD (Alfano et al., 1984), and porphyrins (Ghadially et al., 1963). Table 2.1 lists the 
of excitation and emission maxima of these fluorophores. 
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Endogenous fluorophores Excitation maxima (nm) Emission maxima (nm) 
 
Amino acids:   
       Tryptophan 280 - 295 345 - 350 
       Tyrosine 270 - 275 300 - 320 
 
Structural proteins:   
       Collagen 325 400, 405 
       Elastin 290, 325 340, 400 
 
Metabolic co-enzymes:   
       FAD 450 535 
       NADH 290, 351 440, 460 
   
Porphyrins 400-450 630, 690 
   
 
Table 2.1. Excitation and emission maxima of endogenous fluorophores identified as being 
associated with tissue transformation processes around the onset of carcinogenesis. (Adapted 
from Ramanujam, 2000 and Gillies et al., 2000)  
 
 
 
Figure 2.3. Excitation and emission spectra of various endogenous fluorophores present in 
biological tissue. Spectra are depicted under optimal excitation/emission conditions. 
(Reproduced from Webb, 2003; Adapted from Wagnieres et al., 1998) 
 
Amino acids  
 
Amino acids make up the fundamental subunits of proteins. Of the 20 different residues 
in existence, tryptophan, tyrosine and phenylalanine belong to the aromatic class, with 
each possessing polycyclic aromatic side chains that confer their fluorescent properties 
(see Figure 2.4, dashed red circles). These three amino acids jointly contribute to the 
overall protein fluorescence in biological tissue, dominated mostly by emissions from 
tryptophan which absorbs at the longest wavelength range out of the three residues 
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(between 280 to 295 nm). In addition, energy absorbed by both tyrosine and 
phenylalanine is frequently transferred to tryptophan residues of the same protein, 
further boosting its contribution to the overall observed fluorescence signal (Lakowicz, 
1999). Protein fluorescence is often observed at excitation wavelengths around 280 nm 
and is mainly attributed to tyrosine and tryptophan residues (quantum yields of 0.14 and 
0.13 respectively); due to the low quantum yield of phenylalanine (around 0.03), its 
fluorescence contributions have seldom been observed (Chen et al., 1967).  
 
 
 
Figure 2.4. Chemical structures of the amino acids tryptophan, tyrosine and phenylalanine. 
The aromatic rings in each structure (dashed red circles) confer fluorescent properties to 
these molecules.  
 
Differences in cellular protein content between normal and malignant human oral 
epithelial cell suspensions were studied by Ganesan and colleagues using a fluorescence 
spectroscopic approach (Ganesan et al., 1998). The group observed differences in the 
normalised excitation spectra at 340 nm emission between both cell suspensions and 
found that this was attributed to differences in the biodistribution of tryptophan and 
tyrosine between normal and malignant cellular classes. We do not expect elicitation of 
any fluorescence emissions from these amino acids because the optical systems utilised in 
this thesis generate laser excitation in the visible to near-infrared spectrum, which lie 
beyond the absorption maxima of these tissue fluorophores that fluoresce when excited 
in the ultraviolet range.    
 
Collagen and elastin 
 
Collagen and elastin make up a family of fibrous proteins that serve as mechanical 
scaffolds for structural support in nearly all organs of the human body.  
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Collagen proteins are the major proteins of the extracellular matrix (ECM). They form 
the main component of skin and bone in mammals and constitute approximately 25% of 
their total protein mass (Alberts et al., 2002). About 20 types of collagen proteins have 
been discovered to date, with types I, III, II and IV being the most commonly occurring. 
Type I collagen is the main collagen variety in humans and composes densely packed 
bundles of thick, coarse fibrils whose primary function is tension resistance. These are 
localised in areas of the body that experience high mechanical stress e.g. organ capsules, 
tendons and the adventitial layer of blood vessels (Montes, 1996). Type III collagen is 
composed of loosely arranged thin individual fibrils (characterised as reticulin fibres) and 
is found in the dermis of skin, wall linings of blood vessels and the inner muscular walls 
of the small intestine where they play a structural support role (van der Rest and 
Garrone, 1991; Montes, 1996). Type II collagen exists as thin fibrils that together make 
up a fine three-dimensional fibered network. These are found predominantly in hyaline 
and elastic cartilages of the larynx, trachea and bronchi (Montes, 1996; Mullazehi et al., 
2007). Type IV collagen is composed of neither discrete fibres nor fibrils, but rather fine 
microfibrils of ordered molecules (Montes, 1996). These form a major component of the 
basement membrane of epithelial tissue, performing a dual function of tissue support 
and as a filtration barrier against macromolecules (Tanjore and Kalluri, 2006; Fenyvesi, 
2003).   
 
Elastin is the main component of elastic fibres present in various vertebrate tissues such 
as the skin, blood vessels and lungs (Stryer, 1988; Alberts et al., 2000). The presence of a 
network of elastic fibres in the extracellular matrix of these tissues allows them to be 
tough yet elastic enough so that they can recoil after transient stretching (Alberts et al., 
2000).  
 
Fluorescence has been observed from both collagen (Fujimoto, 1977) and elastin (Deyl et 
al., 1980). This has been attributed to the occurrence of cross-links within both protein 
types: hydroxylysyl pyridoline and lysyl pyridinoline in collagen, and desmosine and 
isodesmosine in elastin (Eyre et al., 1984).  
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Pyridine nucleotides and flavoproteins 
 
Both pyridine nucleotides (PNs) and flavoproteins (FPs) play an important role in the 
electron transport chain during the process of adenosine triphosphate (ATP) synthesis 
(Stryer, 1988; Richards-Kortum and Sevick-Muraca, 1996). Both nicotinamide adenine 
dinucleotide and flavin adenine dinucleotide function as major electron acceptors during 
this process when they are in their oxidised forms of NAD+ and FAD respectively. The 
fluorescent forms of these electron carriers are the reduced form of PNs, NADH, and 
oxidised form of FPs, FAD, both of which emit fluorescence when excited with UV and 
blue light respectively (Ramanujam, 2000; Richards-Kortum and Sevick-Muraca, 1996). 
Figure 2.5 shows the nicotinamide ring of NAD+ (dashed red circles) that confers 
fluorescence to the molecule in this reduced form. 
 
 
 
 
Figure 2.5. Molecular structure of the oxidised form of nicotinamide adenine dinucleotide, 
NAD
+
. The molecule is one of two major electron acceptors during ATP synthesis. The 
nicotinamide ring (dashed red circles) confers fluorescence to the molecule in its reduced 
form - NADH. (Adapted from Stryer, 1988; Richards-Kortum and Sevick-Muraca, 1996) 
 
Porphyrins 
 
Porphyrins are precursors in the process of haem biosynthesis and have been found to 
be the only photosensitiser produced within the human body (Battle, 1993). These 
endogenous fluorophores give off a red fluorescence with emission maxima at 630 and 
700 nm when excited in the blue spectral region between 400 and 450 nm (Ramanujam, 
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2000) and have also been found to accumulate preferentially in cancerous tissue (Yang et 
al., 1987; Battle, 1993). Several hypotheses have been proposed to account for this 
occurrence: 
 
i. Cancer cells have upregulated expression of the low-density lipoprotein 
(LDL) receptor due to an increased cholesterol requirement. This arises 
because of increased membrane synthesis during rapid cellular proliferation 
(Hamblin and Newman, 1994). The increased number of LDL receptors 
therefore serves as possible points of entry for plasma lipoproteins, which 
are major carriers of lipophilic porphyrins in vivo (Jori et al., 1984). 
ii. Tumour regions contain a higher proportion of lipid bodies than the 
normal surrounding tissue with more hydrophobic cellular membranes. 
This may result in the preferential accumulation of hydrophobic 
photosensitisers within the tumour (Freitas, 1990). 
iii. Reduced lymphatic drainage to the tumour may result also in a build up of 
porphyrins, either in the form of aggregates or as protein complexes 
(Bugelski et al., 1981). 
iv. Porphyrin aggregates may be taken up by the tumour in increased amounts 
due to a higher occurrence of phagocytotic or pinocytotic activity (Jori, 
1989). 
v. Tumour-associated macrophages (TAMs) contain a high volume of 
porphyrins. Since TAMs make up about 20-50% of a tumour’s cellular 
content, this may account for the high porphyrin concentration in tumours 
(Milas et al., 1987). 
 
2.3.2.2. Exogenous fluorophores 
 
Exogenous fluorophores are fluorescent chromophores not naturally present in 
biological tissue, which may be either organic or synthetic in nature. Whilst various 
disease conditions have been successfully characterised via intrinsic optical signatures 
from tissues, image contrast may be further improved following application of these 
exogenous fluorescent agents for enhancement of certain tissue features or increasing 
existing levels of tissue autofluorescence during optical detection procedures. A vast 
selection is available to the biomedical researcher and the reader is directed to (Haugland, 
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2005) for a detailed list of fluorophores together with information on their spectral 
properties.  
 
Molecular dyes 
 
Optical imaging has regularly relied upon a variety of non-specific fluorescent dyes to 
induce observable changes in tissue morphology during disease progression from normal 
to cancer. Depending on the depth of tissue to be imaged, different dyes may be 
employed: dyes which absorb and emit fluorescence in the UV/visible wavelength range 
are often sufficient for imaging shallower, superficial layers of mucosa, while those which 
absorb and emit in the near-infrared (NIR) wavelength range have been employed for 
more effective visualisation of deeper mucosal regions. Some examples include 
fluorescein (and its derivatives), indocyanine green (ICG), cresyl violet, Lugol’s solution, 
acridine orange (AO) and acriflavine hydrochloride (AH), all of which are in current 
clinical use or trials for cancer detection and diagnosis. Some non-specific dyes have been 
found to localise to a certain extent in intra- or extracellular spaces due to their size or 
charge distributions e.g. AH and AO, which bind to DNA and have been previously 
used for evaluation of confocal microendoscopy imaging procedures (Polglase et al., 
2005; Udovich et al., 2007; Pierce et al., 2008), and ICG, which binds to plasma proteins 
present in blood such as human serum albumin (HSA) (Muckle, 1976; Desmettre et al., 
2000).    
 
Dye-antibody and dye-peptide conjugates 
 
With advances in the study of cancer biology, several tumour-associated surface 
receptors and antigens have been identified which serve as ideal targets for dye-antibody 
and dye-peptide conjugates.   
 
Work done previously was concentrated on the conjugation of monoclonal antibodies 
with cyanine dyes for specific binding to tumour cell receptors (Ballou et al., 1995; Ballou 
et al., 1997; Becker et al., 2001). Further studies by Ballou and colleagues demonstrated 
the possibility of performing effective tumour visualisation in animal models in vivo 
using Cy5.5 and Cy7 monoclonal antibody conjugates (Ballou et al., 1998). However 
various obstacles have impeded its translation to humans such as the possible elicitation 
44 
 
of an adverse immune response, high background fluorescence, long clearance times in 
the blood, and the fact that these conjugated antibodies require a sufficient amount of 
accumulation time to produce viable fluorescent signals in target tissues (Folli et al., 1994; 
Ballou et al., 1995; Xu and Povoski, 2007).   
 
To overcome the limitations posed by dye-antibody conjugates, various groups have 
investigated the application of dye-peptide conjugates composed of fluorescent dyes 
covalently bonded to a bioactive peptide molecule. Like dye-antibody conjugates, these 
are specific to targets over-expressed on tumour cells e.g. the integrin receptors, which 
play a key role in metastasis and neovascularisation. Studies on the !Vß3 integrin 
receptor subtype (ABIR) have shown that it interacts with a tri-peptide arginine-glycine-
aspartic acid (RGD) sequence on adhesion proteins like fibronectin and collagen. Based 
on this finding, several groups have developed ABIR-targeting RGD peptides conjugated 
to NIR fluorescent cyanine labels for in vivo optical imaging with encouraging results 
(Wang et al., 2005; Ye et al., 2006). Similarly, recent studies have also found that lysosomal 
vesicles play an important part in metastasis, sequestering proteolytic enzymes 
responsible for breaking down proteins of the ECM (Roshy et al., 2003). This finding was 
exploited by Li and colleagues who synthesised novel fluorescent probes consisting of 
glucosamine, an integral lysosomal amino sugar, and a covalently bonded carbocyanine 
NIR fluorophore, which exhibited efficient cellular uptake and strong intracellular 
fluorescence in human mammary epithelial cell lines (Li et al., 2006).   
 
Fluorescent and bioluminescent protein probes 
 
Green fluorescent protein (GFP) and luciferases are the two main photoproteins that fall 
into this class of optical reporters.  
 
GFP is one of the most extensively used fluorescent protein probes for studying sub-
cellular processes in tumour cells such as tumour-host interaction, metastasis, gene 
expression, protein localisation and drug response (Tsien, 1998; Zimmer et al., 2002; 
Ballou et al., 2005). Its importance in medical science was recognised when the Royal 
Swedish Academy of Sciences awarded the Nobel Prize in Chemistry 2008 to the original 
discoverer of GFP and two of its co-developers. To date there exists different variants of 
GFP such as blue, cyan and yellow fluorescent proteins (BFP, CFP, YFP), which possess 
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different excitation and emission wavelengths to the original; efforts to develop more 
variants with altered absorption/emission profiles are ongoing (Choy et al., 2003). For an 
in-depth review of fluorescent labelling using GFP, please refer to papers by Tsien, 2003 
and Lippincott-Schwartz and Patterson, 2003.  
 
Luciferases have been isolated from various sources (fireflies, bacteria, click beetles, sea 
pansies) and are currently used as bioluminescent reporters for a host of imaging 
applications, e.g. the development and monitoring of gene therapy treatment strategies 
(Achilefu, 2004). The main difference between fluorescence and bioluminescence 
imaging is that the former requires an external excitation light source for activation, 
whereas the latter technique only requires the presence of an enzyme substrate. As such, 
one big advantage bioluminescence imaging has over fluorescence imaging is the high 
sensitivity achieved due to low levels of background noise from autofluorescence (Choy 
et al., 2003; Achilefu, 2004).   
 
 
 
Figure 2.6. Three-dimensional structures of the green fluorescent protein (GFP) (A) and 
firefly luciferase (B). (Adapted from Yang et al., 1996 (A) and Conti et al., 1996 (B)) 
 
Photosensitiser probes 
 
Some exogenous fluorophores currently being evaluated for clinical use were originally 
developed as photosensitisers for photodynamic therapy (PDT), i.e. utilising light-
activated photosensitisers to destroy malignant tumours in the body. Examples of these 
are hematoporphyrin derivative (HpD), hypericin, phthalocyanine, pheophorbide-a, tin 
etiopurpurin (SnET2) and meso-tetra-(hydroxyphenyl)-chlorin (MTHPC) (Wagnieres et 
al., 1998; Ramanujam, 2000).  
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A notable example of employing a PDT agent for contrast enhancing imaging purposes 
was demonstrated by Ecker and colleagues, who set out to compare the discrimination 
obtained using 5-aminolevulinic acid (5-ALA) induced protoporphyrin IX (PpIX) as a 
tumour marker versus using autofluorescence alone (Ecker et al., 1999). 5-ALA is a 
precursor in heme biosynthesis. It is not a photosensitiser, but rather is converted 
intracellularly into the fluorescent photosensitiser PpIX, which accumulates in higher 
amounts in tumour tissue compared with normal tissue. This has been attributed to a 
deficiency in ferrochelatase (the enzyme required for PpIX to heme conversion) in 
tumours as well as other reasons mentioned earlier under the ‘Porphyrins’ of section 
2.3.2.1 of this chapter.  
 
The exploitation of photosensitisers as contrast agents has raised some issues concerning 
safety and toxicity e.g. skin photosensitivity and non-specific accumulation. To address 
this, research is being carried out to uncover non-photosensitising agents that bear 
similar absorption and fluorescent properties to photosensitisers so as to serve as 
alternative contrast agents. Examples of these are Nile blue and its derivatives as well as 
the family of carotenoporphyrins (Richards-Kortum and Sevick-Muraca, 1996).  
 
Quantum dots and nanoparticles 
 
Quantum dots (QDs) and nanoparticles (NPs) are small light-emitting particulates 
composed of polymers, lipids and metals that have emerged as a novel class of 
fluorescent labels for the early detection and treatment of cancer. These are delivered to 
tumours in vivo via passive or active targeting mechanisms (Gao et al., 2004): under 
passive conditions, QDs and NPs accumulate preferentially in tumour tissues because of 
ineffective lymphatic drainage and hyperpermeabilised ‘leaky’ neovasculatures, resulting 
in the “enhanced permeability and retention” effect (EPR effect) (Maeda et al., 2000; Jain, 
2001); in the active mode, QDs and NPs are ‘bioconjugated’ to biological ligands such as 
antibodies, peptides, growth factors and other small molecules for targeting receptors 
and antigens on the surface of tumour cells with added affinity and specificity (Akerman 
et al., 2002; Medintz et al., 2005).  
 
Several groups have also demonstrated the use of photosensitiser-conjugated QDs for a 
more targeted photodynamic therapeutic approach (Samia et al., 2003; Juzenas et al., 
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2008). Most photosensitisers are known to have poor water solubility and tend to form 
aggregates in solution, which may affect their photochemical and cell-penetrating 
properties (Allen et al., 2001). To address this issue as well as alleviate concerns regarding 
the possible toxicity of QDs (e.g. cadmium-based QDs), NPs are being studied as 
possible drug delivery vehicles to ensure accurate and efficient transport of 
photosensitisers to tumour sites. One example is the use of gold nanoparticles stabilised 
(coated) with a phthalocyanine (Pc) photosensitiser, which demonstrated an enhanced 
generation of cytotoxic singlet oxygen as compared to free Pc alone (Hone et al., 2002). 
In the same vein, silica-based nanoparticles containing water-insoluble photosensitisers 
have been shown to be efficient carriers of the drug in aqueous solution (Roy et al., 
2003).   
 
 
2.4. Absorption and scattering events 
 
Whilst the observation of fluorescence spectra from biological tissues provide 
information relating to biochemistry and therefore the functional properties of the 
tissues being studied, further investigation into absorption and scattering events 
occurring during light-tissue interactions also offers additional diagnostic information 
complementary to that obtained from fluorescence. This thus allows a more 
comprehensive elucidation of the tissue’s overall state of health.  
 
The main optical absorbers present in biological tissues are haemoglobin (Hb), melanin 
and water (Wang and Wu, 2007). The two forms of Hb, oxyhaemoglobin (HbO2) and 
deoxyhaemoglobin (HbR), each possess different absorption coefficients as seen in 
Figure 2.7 (Vogel and Venugopalan, 2003). To date, several Hb absorption bands have 
been identified and these have been found to be at the wavelengths of around 415 nm, 
542 nm, 572 nm and 930 nm (Shibuya et al., 2003). Melanin is localised only in the 
epidermal layers of the skin (top 50 to 100 µm) and in hair follicles (Zonios et al., 2001), 
and has been found to absorb in the UV-visible wavelength range with low absorption in 
the near-infrared (NIR) region. Water does not absorb in the UV-visible range and is 
negligible as an optical absorber when compared to Hb and melanin in this wavelength 
range. Other common optical absorbers such as proteins and DNA have been found to 
absorb only in the UV range and not the visible (Campbell and Dwek, 1984). As such, it 
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can be safe to assume that Hb is the principal optical absorber in the visible range within 
the human body. 
 
 
 
Figure 2.7. Absorption coefficients of the main endogenous absorbers present in biological 
tissue. (Adapted from Vogel and Venugopalan, 2003) 
 
Optical scattering occurs when light penetrates the tissue boundary and interacts with 
biological scattering components comprising several tissue microstructures from both 
the extracellular and intracellular domains. Examples of the former are collagen fibres 
that are present in the stromal layers of tissue (Saidi et al., 1995), whilst examples of the 
latter include cellular nuclei (Perelman et al., 1998; Mourant et al., 2000), mitochondria 
(Beauvoit et al., 1994), and lysosomes and vesicles (Wang and Wu, 2007). Scattering has 
been shown to occur most strongly when the size of the scatterer matches the optical 
wavelength of the incoming photon and when the scatterer’s refractive index is markedly 
different to that of its surrounding tissue medium (Wang and Wu, 2007). 
 
The study of optical absorption has allowed various cancer-related changes in tissues to 
be revealed, e.g. increased Hb concentration due to angiogenesis in malignant and 
premalignant lesions, as well as conditions of tissue hypermetabolism during 
tumourigenesis resulting in lowered Hb oxygen saturations (Zonios et al., 1999; Wang et 
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al., 2009; Brown et al., 2009; Li et al., 2010). Studies relating to optical scattering events in 
tissue have also shed light on the state of collagen fibres in mucosal tissue and size 
distribution of endogenous optical scatterers such as cellular nuclei (Ferdman and 
Yannas, 1993; Perelman et al., 1998; Mourant et al., 2000; Brown et al., 2009).    
 
    
2.5. Optical imaging techniques – the state of the art 
 
2.5.1. Overview  
 
Optical imaging techniques currently in clinical use or under investigation are classified 
under two broad categories: 1) wide-field imaging techniques and 2) localised point-based 
methods. The possibility of incorporating these optical imaging techniques into medical 
endoscope systems allows for minimally invasive in vivo in situ monitoring of the human 
body, hence presenting a novel means of disease detection and diagnosis.  
 
Wide-field imaging encompasses techniques like white-light endoscopy (WLE), 
chromoendoscopy, fluorescence endoscopy and narrow-band imaging (NBI), all of 
which have been employed in conjunction with high definition video endoscopes for 
visualising tissue regions with a field of view measuring a few squared cm. These 
techniques have been extensively studied especially in the gastrointestinal (GI) tract for 
investigating disease conditions such as Barrett’s oesophagus and ulcerative colitis, and 
also for discriminating between benign and adenomatous polyps in the colon.  
 
Point-based diagnostic techniques acquire data from single points on tissue surfaces 
owing to the use of fibre optic probes measuring a few mm in diameter. These can be 
further separated into two sub-categories: point spectroscopy and point (micro) imaging 
techniques. The former sub-category, which includes such spectroscopic methods as 
fluorescence, diffuse reflectance, elastic light scattering and Raman spectroscopy, 
acquires tissue information in the form of spectral data that is subsequently presented in 
a graphical format for disease diagnosis; this is based on the idea that different tissue 
disease states possess different spectral signatures. The latter sub-category covers imaging 
modalities like fluorescence confocal endomicroscopy and optical coherence tomography 
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- techniques that allow for the collection of high-resolution cellular-level tissue images 
over a small field of view.  
 
A myriad of commercial optical imaging systems are also available on the market today. 
Some examples are the Lucera Spectrum system from Olympus (Japan) for endoscopic 
narrow-band, autofluorescence and infra-red imaging, the D-Light C system from Karl 
Storz Endoskope (Germany) for photodynamic diagnostic applications, the VivaScope 
confocal system from Lucid Inc. (USA) for examination of skin disease conditions and 
the DySIS spectral imaging system from Forthphotonics (UK) for cervical examination 
during colposcopic imaging procedures. 
 
The next three sub-sections consist of short reviews that provide background 
information to the three optical imaging techniques applied in this thesis, namely 
fluorescence spectroscopy, diffuse reflectance spectroscopy and confocal fluorescence 
endomicroscopy. The use of each technique in a variety of human organs is covered, 
with the research papers quoted restricted as much as possible to highly cited examples 
within the last ten years.   
 
2.5.2. Fluorescence spectroscopy 
 
Fluorescence spectroscopy (FS) involves the optical detection and spectral analysis of 
light emitted by a fluorophore undergoing a transition from an excited electronic state to 
a lower electronic state (Vo-Dinh and Cullum, 2003). Different emission spectra are 
characterised depending on the excitation wavelength of light used, which is also affected 
by the morphological and biochemical characteristics of the tissue studied. Fluorescence 
contrast arises when endogenous fluorophores vary in concentration and distribution 
between different tissue types as well as between different regions and layers of the same 
tissue (Dacosta et al., 2004). Normal and dysplastic tissues exhibit different fluorescent 
spectra due to malignant transformations that may alter the type, concentration and 
micro-distribution of endogenous fluorophores, together with the overall biochemical 
makeup of the tissue. This thereby results in differences in the measured fluorescence 
signals (Dekker and Fockens, 2005).  
 
The idea that FS could be used as a quantitative technique to differentiate between 
normal and malignant tissue was first suggested by Lycette and Leslie in 1965, who 
51 
 
recorded the emission spectra from 330 nm excitation of normal and malignant tissue 
excised from the oesophagus, stomach, breast and thyroid of human patients (Lycette 
and Leslie, 1965). Emission spectra obtained from single-point measurements of all 
excised tissue samples were found to be in the range of 360 and 600 nm, with malignant 
tissues having lower fluorescence intensities than those of normal tissues from the same 
patient. Additional work by Alfano et al. in the early 1980s provided further evidence that 
FS could be used for tissue diagnosis: the group measured single-point fluorescence 
spectra from cancerous and normal kidney and prostate tissues from rats in addition to 
cancerous bladder tissues from rats and mice in vitro using an Argon ion laser emitting at 
488 nm (Alfano et al., 1984). Results obtained demonstrated a distinct difference in 
spectral profiles between normal and cancerous tissues, which the group attributed to 
distributional differences in flavin and porphyrin between the two tissue disease types.    
 
The ability of FS to detect premalignant and early-cancerous lesions using tissue 
autofluorescence depends on changes in one or more of the following properties:  
 
i. Concentration and spatial distribution of endogenous fluorophores, 
absorbers (e.g. haemoglobin (Hb)) and scatterers (e.g. cell membrane, 
nucleus and other organelles). 
ii. Metabolic status of the tissue: NADH is fluorescent only in its reduced 
form; it has been observed that an increase in NADH fluorescence and 
decrease in FAD fluorescence in dysplastic cells and tissue is correlated with 
an increase in cellular metabolic activity.  
iii. Biochemical and biophysical microenvironment of the tissue: these may 
affect the fluorescence quantum yield, position of spectral peaks and line 
widths, and 
iv. Tissue architecture, e.g. the vascular network and thickness of mucosal 
layers, all of which may affect the fluorescence signal measured at the tissue 
surface.  
 
Within the last decade, FS has been shown by various groups to have the ability to detect 
and diagnose different tumour types in vivo in various organs of the human body with 
high degrees of sensitivity and specificity. The following studies have relied solely on 
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tissue autofluorescence for generation of the emission spectra, without the aid of any 
exogenous agents for increasing fluorescence contrast. 
 
Chang and colleagues set out to determine the optimal excitation wavelengths for 
detection of cervical intraepithelial neoplasia through the analysis of fluorescence 
excitation-emission matrices (EEMs) generated through in vivo single-point fluorescence 
spectroscopic measurements (Chang et al., 2002). A fluorescence EEM often takes the 
form of a contour map in which fluorescence intensity is plotted as a function of 
excitation and emission wavelengths for the characterisation of fluorescence properties 
of a sample (see example in Figure 2.8). In the study using a prototype system, tissue 
autofluorescence was induced with a Xenon arc lamp at 16 different excitation 
wavelengths ranging from 330 to 480 nm. Spectral measurements were then taken from 
351 separate single-point cervical sites in 146 patients via a fibre optic probe with its 2 
mm diameter tip positioned against the cervical epithelium. The acquired data was later 
analysed with principal component analysis (PCA) and in pairs of diagnostic classes to 
determine optimal wavelengths that yielded classification algorithms with the greatest 
sensitivity and specificity. The group concluded that 330-340, 350-380, and 400-450 nm 
excitation produced the best performance, with sensitivity and specificity for 
discrimination of squamous normal tissue and high-grade squamous intraepithelial 
lesions standing at 71% and 77% respectively.  This study demonstrates the importance 
of PCA in the interpretation of FS results. 
 
 
 
Figure 2.8. Typical example of fluorescence EEMs obtained from the cervical epithelium of a 
single patient: normal squamous site (A); normal columnar site (B); high-grade squamous 
intraepithelial lesion (HGIL) (C). Contour lines in the graphs connect points of equal 
fluorescence intensity. (Adapted from Chang et al., 2002) 
 
The possibility of applying FS as an improved method for the early diagnosis of ovarian 
neoplasia was investigated by Brewer and colleagues by studying if spectral signatures 
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differed between normal variations within the ovary, benign neoplasms and ovarian 
cancer (Brewer et al., 2001). Tissue diagnosis was performed during exploratory 
laparotomy in patients with a Xenon arc lamp to induce fluorescence at 18 excitation 
wavelengths from 330 to 500 nm via a fibre optic probe. Fluorescence spectra were 
collected by the probe at single points on the tissue over a 2 mm circular diameter and 
used to create fluorescence EEMs for data analysis (Figure 2.9). From their results, the 
authors found that excitation at 330, 375 and 415 nm appeared the most useful 
diagnostically and a decrease in fluorescence at 400-430 nm excitation and 460 nm 
emission was found to be consistent for all the cancerous regions measured. They 
concluded that FS could serve as an alternative method for detection of subtle 
differences not apparent with either ultrasound or visual observation of the ovary.  
 
 
 
Figure 2.9. Fluorescence EEMs of a normal ovary with stromal hyperplasia and corpus 
albicans (A) compared against an ovary presenting high grade carcinoma (B). (Adapted 
from Brewer et al., 2001) 
 
The effectiveness of fluorescence endoscopy for detection of premalignant and early-
stage cancerous lesions in the lung, including carcinoma in situ (CIS), was demonstrated 
by Kusunoki and colleagues during a clinical trial of the commercial LIFE (laser-induced 
fluorescence endoscopy) imaging system (Xillix Technologies; Richmond, BC, Canada; 
and Olympus Optical; Tokyo, Japan) (Kusunoki et al., 2002). Such lesions are difficult to 
detect via white-light bronchoscopy (WLB) imaging even for experienced 
bronchoscopists. During the trial, a fibre optic fibre bundle was used to deliver blue light 
excitation at 442 nm from a helium-cadmium laser. Imaging results from the LIFE 
apparatus were later compared with that from conventional WLB and accuracy of 
diagnosis for each method was found to be 72.7% and 48.6% respectively. The emitted 
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fluorescence was also collected by a spectrofluorometry system for computer analysis of 
the emission spectra. Sensitivity of WLB alone for detection of severe dysplasia and 
cancer was found to be 61.2% with a specificity of 85%. However when coupled with 
results from LIFE, sensitivity and specificity improved to 89.8% and 78.4% respectively. 
This indicated that a combination of both techniques could improve the detection of 
endobronchial lesions, with results obtained via spectrofluorescence analysis giving a 
more objective basis than evaluation by the naked eye alone during conventional 
bronchoscopy. In addition, the study also noted that dysplastic and CIS regions exhibited 
less fluorescence than normal tissue, as seen when comparing white-light images to those 
obtained from the LIFE system (Figure 2.10). 
 
 
 
Figure 2.10. Comparison between a white-light bronchoscopic (WLB) image and LIFE 
image of a right lower-lobe bronchus. Under white light, the carcinoma in situ lesion (CIS) 
appears to occupy the whole area between the right basal bronchus and right bronchiole B
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(darker red region). This is however not the case in the LIFE image – the CIS lesion was 
found to be present only in a smaller region. This appears as a darkened patch in the LIFE 
image (indicated by white arrow). (Adapted from Kusunoki et al., 2002) 
 
Wang and colleagues demonstrated an endoscopic fluorescence imaging method to 
identify dysplasia associated with adenomatous polyps in the colon (Wang et al., 1999). 
Their imaging system consisted of an argon ion laser delivering excitation light at the 
near-UV range of 351 and 364 nm through an optical probe coupled with a standard 
videocolonoscope adapted for fluorescence identification in vivo. During the imaging 
process, the distance between the distal tip of the endoscope and mucosa was adjusted 
such that the polyp to be imaged appeared within an approximately 30 by 30 pixel region. 
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With this technique, dysplasia associated with 12 adenomatous polyps was identified with 
a sensitivity of 83% from a group of 30 patients, with the fluorescence threshold set to 
80% of the average intensity of normal mucosa. All hyperplastic polyps were correctly 
identified as being non-dysplastic. Adenomatous polyps were also discovered to have 
decreased fluorescence intensity compared to adjacent regions with normal tissue.  
 
Lane et al. described a hand-held imaging device that allowed fluorescence visualisation 
of precancerous and early cancerous lesions in the oral cavity (Lane et al., 2006). A 
mercury-based arc lamp was used to produce blue light excitation between the 
wavelengths of 400 to 460 nm, with green-red fluorescence obtained from endogenous 
fluorophores present in the oral mucosal tissue (Figure 2.11). By taking histology as the 
standard benchmark, the device achieved a sensitivity of 98% and specificity of 100% 
when discriminating normal oral tissue from regions of severe dysplasia, CIS, or invasive 
carcinoma out of a sample population of 50 sites.  
 
 
 
Figure 2.11.  Fluorescent images of oral cavity lesions obtained from three patients. White-
light and fluorescence images are shown on the left and right respectively: healthy mucosa of 
the ventral tongue showing a pale-green fluorescence (A and B); ventral tongue of a patient 
with an oral premalignant lesion, confirmed as severe dysplasia by histology (white arrow 
indicates biopsied region) (C and D); clinically occult lesion seen as a dark patch (indicated 
by white arrow) in the fluorescence image (E and F). (Adapted from Lane et al., 2006) 
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2.5.3. Diffuse reflectance spectroscopy 
 
Besides fluorescence spectroscopic approaches, another promising optical technique 
most frequently investigated for cancer detection is diffuse reflectance spectroscopy 
(DRS). DRS typically employs broadband light excitation in the ultraviolet/visible/near-
infrared range of the spectrum (from 300 to 800 nm) and has been demonstrated 
previously to be successful in diagnosing neoplastic changes in the human body, e.g. in 
tissues of the bladder (Bigio et al., 1995), colon (Zonios et al., 1999), ovary (Utzinger et al., 
2001), cervix (Mirabal et al., 2002) and breast (Volynskaya et al., 2008). The hallmark of 
DRS is its ability to detect light that has been transmitted to the tissue surface after 
having undergone absorption and scattering events in the deeper underlying layers; this 
consequently provides information on endogenous absorbers and scatterers present in 
biological tissue whose biophysical states have been found to become altered during 
neoplastic development.  
 
Alterations in the spectral reflectance properties of dysplastic/tumour tissues may arise 
due to:  
 
i. Changes in nuclear size and the resultant nuclear-to-cytoplasmic ratio of 
cells in the epithelium (Drezek et al., 2003; Mourant et al., 1998),  
ii. Neovascularisation, i.e. the formation of new blood capillaries (Dellas et al., 
1997; Zonios et al., 1999),  
iii. Changes in both HbO and HbR concentrations (Zonios et al., 1999), and  
iv. Changes in overall optical properties of the stromal tissue layers (Mirabal et 
al., 2002; Tromberg, 1998). 
 
Zonios and colleagues obtained DRS data from normal human colonic mucosa and 
adenomatous colon polyps, colon mucosal surface projections that are precursors of 
colon cancer, to demonstrate the potential of the technique for obtaining quantitative in 
vivo information of various tissue parameters, i.e. Hb content and relative concentrations 
of endogenous absorbers and scatterers. Data analysis was performed by means of fitting 
to an analytical light diffusion model derived earlier by Ferrall et al. (Zonios et al., 1999; 
Ferrall et al., 1992) and the results compared to that from standard histological 
examination. During the study, DRS spectra were obtained in vivo from adenomatous 
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polyps of 13 patients undergoing routine colonoscopy. A Xenon arc lamp was used as 
the white light excitation source, an imaging spectrograph dispersed the collected spectra, 
and a diode array detector was used to detect light between wavelengths of 360 and 685 
nm. Light was delivered and collected via a 1.5 mm diameter optical fibre probe that was 
passed down the accessory channel of a standard colonoscope and put in contact with 
single points on the tissue. Calibration was performed by means of division by a DRS 
reference spectrum obtained from a barium sulphate (BaSO4) powder suspension. 
Spectra were measured from various sites for each studied adenomatous polyp as well as 
from the normal surrounding colonic mucosa prior to its removal for histological 
examination (Figure 2.12). From analysis of their data, the group concluded that it was 
possible to obtain quantitative information from tissue such as Hb concentration, Hb 
oxygen saturation, effective scatterer size and effective scatterer density using DRS. They 
also made a number of key observations: 1) Hb is the major and possibly only significant 
absorber in colon mucosa, 2) adenomatous polyps are characterised by increased Hb 
concentration over normal mucosa, perhaps as a result of increased microvasculature 
volume, and 3) average effective scatterer size was larger and average effective scatterer 
density smaller in polyps compared to normal mucosa due to intracellular scatterer 
differences. 
 
 
 
Figure 2.12. Diffuse reflectance spectral data from normal tissue and an adenomatous polyp 
(thick curves) together with the modeled spectra (thin curves). (Adapted from Zonios et al., 
1999) 
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DRS was explored as a means of differentiating normal, benign neoplasmic and 
cancerous ovarian tissue by Utzinger et al. in order to improve on the currently 
inadequate conventional methods of ovarian cancer screening tests e.g. CA-125 markers, 
transvaginal ultrasound and pelvic examination (Utzinger et al., 2001; NIH Consensus 
1995). In their study, DRS spectra were collected at 64 sites from normal and neoplastic 
ovarian tissue at three different source-detector separations in 16 patients undergoing 
exploratory laparotomy and oophorectomy. Broadband illumination was provided by a 
Xenon arc lamp equipped with a 295 nm long-pass filter, and a fibre optic probe was 
used to transmit excitation light as well as collect the diffusely reflected light returning 
from the underlying tissue layers. The probe tip was put in direct contact with the tissue 
at single points during data acquisition and DRS spectra between 390 to 590 nm 
wavelengths were collected. Tissue biopsies were obtained from all interrogated ovarian 
sites and examined by a gynaecologic pathologist after haematoxylin and eosin (H&E) 
staining. The biopsied samples were then classified into eight pathological categories 
ranging from normal to cancer (see mean spectra in Figure 2.13). For data processing, 
wavelength calibration of the DRS spectra was performed using a mercury light source 
and the reflectance data were normalised using reference reflectance data recorded from 
a solution of polystyrene microspheres of 1.072 !m diameter. During data analysis for 
each diagnostic category (e.g. normal, benign neoplasm, cancer), the following were 
calculated: average value and standard deviation of spectral intensity at each wavelength, 
the slope at each wavelength, and integrated intensity between the wavelength ranges of 
390 to 590 nm and 440 to 590 nm. From their results, the group observed that both the 
slope and intensity of DRS spectra may have the ability to discriminate normal from 
dysplastic conditions of the ovary: slopes between 510 and 530 nm were found to be 
most promising at all source-detector separations and intensities between 530 and 585 
nm measured with a short 1.1 mm source-detector separation were found to provide the 
most useful discriminatory information. A combination of two parameters of either slope 
or intensity was found to separate normal ovary from benign neoplasms and cancers with 
an average sensitivity and specificity of 86 ± 6% and 79 ± 5%, whilst the ability to 
separate benign neoplasms and normal ovary had an average sensitivity and specificity of 
86 ± 4% and 80 ± 8% respectively. In conclusion, DRS was found to be a promising 
tool for the identification of normal and cancerous ovarian tissue via a minimally-
invasive procedure in near real time. 
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Figure 2.13. Mean reflectance spectra obtained for all eight tissue diagnostic categories with 
the optical fibre at position 1. (Adapted from Utzinger et al., 2001)  
 
In recent years, a reflectance imaging technique known as narrow-band imaging (NBI) 
has been generating a substantial amount of clinical results and uptake. The technique 
differs from conventional endoscopic white-light illumination methods in that it uses 
narrow illumination bandwidths with the aid of special optical filters for imaging of tissue 
mucosa. Due to these narrowed illumination wavelengths of light, tissue regions are 
imaged in shorter depth sections, therefore allowing more discrete and enhanced 
highlighting of tissue features at various depths as well as for effective visualisation of 
blood vessels and mucosal microvascular patterning. The technique is often compared 
with and has been shown to be superior to chromoendoscopy, which involves topical 
staining of the mucosa with biocompatible dyes such as indigo carmine or methylene 
blue prior to optical interrogation. 
 
One of the first groups to demonstrate the clinical benefits of NBI was Gono and 
colleagues who conducted a series of NBI experiments, each formulated to evaluate 
differences in image contrast and colour between narrow- and broadband illuminations 
(Gono et al., 2004). Comparisons were also made between NBI and standard screening 
methods applied during colonoscopy and oesophagoscopy such as magnified 
chromoendoscopy and magnifying video endoscopy. The medical video endoscope 
system used was a commercial CLV-U40 unit from Olympus Optical, Japan, consisting  
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Figure 2.14. Conventional white-light and NBI images of familial adenomatosis coli (A and 
B) and Barrett’s oesophagus (C and D). The area labelled X refers to an area of normal 
oesophagus tissue, whilst area Y corresponds to a mucosal region of Barrett’s oesophagus 
with a textured vascular pattern clearly visible. (Adapted from Gono et al., 2004)  
 
of a Xenon lamp and a filter disk where three optical interference filters could be 
mounted at one time for sequential illumination as the disk rotates. Experiments 
involved NBI imaging of the underside of the human tongue as well as the colon and 
oesophagus during colonoscopy and Barrett’s oesophagus (BO) endoscopy respectively 
using five narrow-band and three broadband illuminations. Imaging results obtained 
demonstrated that the appearance of vascular patters were dependent on the class of 
blood vessels present, central wavelength applied and illumination bandwidth. Contrast 
of the capillary pattern in the superficial tissue layer of the tongue was markedly 
improved when using narrow-band illumination at 415 ± 30 nm, an observation not seen 
with conventional white-light imaging. Later, different combinations of narrow- and 
broadband filter sets were studied for optimal pit pattern appearance during colour 
imaging of the tongue, and this was found to be the narrow-band filter set (415 ± 30 nm, 
445 ± 30 nm and 500 ± 30 nm). This narrow-band filter set was subsequently used for 
clinical tests during colonoscopy and oesophagoscopy. NBI images from colonoscopy 
showed a clearer representation of small polyps of familial adenomatous coli than white-
light images (see Figures 2.14A and B). These polyps appeared as brown patches in the 
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NBI image with blood vessels seen as a blue patterning (Figure 2.14B). NBI images from 
BO were also found to give clearer visualisation of BO pit patterns than conventional 
white-light images (Figure 2.14C and D). In conclusion, the group found that NBI 
displayed clear clinical benefits, preventing small adenomas and cancers in the colon 
from being missed, hence enabling more accurate biopsies for patients at high risk of 
developing cancer.   
 
Since its first applications in the GI tract, NBI has now been successfully applied for 
endoscopic cancer diagnosis in a host of other organs of the human body. Various recent 
examples include the use NBI for the detection of upper urinary tract urothelial tumours 
(Traxer et al., 2009); during videobronchoscopy for the assessment of tumour extension 
in centrally located lung cancers (Bojan et al., 2009); in combination with magnifying 
endoscopy for the detection of early squamous cell carcinoma in the oropharynx and 
hypopharynx (Saito et al., 2009); and for the improved detection of pancreaticobiliary 
diseases during cholangiopancreatoscopy (Shah and Chen, 2009). 
 
2.5.4. Fluorescence confocal endomicroscopy 
 
Fluorescence confocal endomicroscopy (FCE) is a novel endoscopic imaging modality 
based on the optical principles of bench-top confocal microscopes. The technique allows 
for real-time in vivo in situ imaging of intact tissues at subcellular !m resolution, allowing 
for en face, almost histological-grade assessment of the tissue region under investigation 
without the need for biopsy. Much interest has been generated since first publication of 
the FCE technique in 2004 with initial clinical studies concentrating on its diagnostic 
applications in the oesophagus and GI tract (Kiesslich et al., 2004; Goetz and Kiesslich, 
2010). Since then, FCE imaging has been applied for visualisation of diseases in the lung 
(Thiberville et al., 2006), oral cavity (Thong et al., 2007a), liver (Goetz et al., 2008), cervix 
(Tan et al., 2009), bladder (Sonn et al., 2009) and ovaries (Tanbakuchi et al., 2010). The 
method has also been extended to the detection of tumour-specific fluorescence signals 
e.g. from 5-aminolevulinic acid (5-ALA) induced protoporphyrin IX (PpIX) in 
photosensitised tissues (Thong et al., 2007b) and FITC-labelled anti-EGFR antibodies on 
the surface of tumour tissue (Goetz et al., 2009). 
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Two main FCE systems are being used for research today: both are commercial systems 
with one developed jointly between Pentax (Tokyo, Japan) and Optiscan (Victoria, 
Australia) and the other by Mauna Kea Technologies (Paris, France). Though the two 
systems differ markedly in optical setup, both perform a similar function and have been 
found to produce images of similar quality. More technical details of these two 
commercial FCE systems will be covered later in chapter 5 of this thesis. Other 
prototype FCE systems are also under investigation: one was first presented in its 
entirety by Rouse and colleagues in 2002, which has since been improved upon and 
packaged as a ‘confocal microlaparoscope’ as recently described in a publication by 
Tanbakuchi and colleagues (Rouse et al., 2002; Tanbakuchi et al., 2010). Another 
prototype system was recently used by Zhong and colleagues to detect tumour nodules in 
a mouse model of ovarian cancer by imaging fluorescence from the photodynamic 
therapy agent benzoporphyrin-derivative monoacid ring A (BPD-MA) (Zhong et al., 
2009).  
 
Wang et al. showed the effective use of the Cellvizio-GI FCE system from Mauna Kea 
Technologies for assessment of colonic mucosa in vivo (Wang et al., 2007). Using topically 
applied fluorescein contrast agent (5 mg/mL), their aim was to demonstrate functional 
differences in both uptake and distribution of the dye by colonic crypts in order to 
distinguish between normal, hyperplasia and adenoma conditions. A total of 54 subjects 
were included in their study (mean age 65 ± 10 years). FCE imaging was performed in 
vivo at 488 nm laser excitation with the instrument’s flexible confocal miniprobe passed 
down the instrument channel of a colonoscope and put in direct contact with the tissue. 
Image acquisition took two to three minutes per site and a pinch biopsy was obtained 
from each imaged site for histological comparison. From their imaging results, the group 
observed differences in fluorescein localisation and dynamics from the crypt lumen to 
lamina propria for different disease conditions. FCE diagnostic results were also well 
correlated with those obtained from histology with normal, hyperplastic and tubular and 
villous adenomatous mucosa showing distinct morphological characteristics (Figure 
2.15). The group also compared lamina propria / crypt fluorescence contrast ratios and 
found that a greater value was attained for normal than lesional mucosa across all 
subjects. On average, fluorescence contrast ratios were shown to decrease with severity 
of disease. Based on their findings, the group concluded that FCE represented a new 
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method of histopathological evaluation for real time in vivo assessment of the functional 
properties of disease tissues.    
 
 
 
Figure 2.15. Comparison between FCE and en face histology results of different colonic 
mucosal disease states: normal mucosa (A), hyperplasia (B), tubular adenoma (C), villous 
adenoma (D). Various structural tissue features can be distinguished from both image sets: 
crypt lumens (l), epithelial cells (c) and their apical (ap) and basolateral (bl) borders, and the 
lamina propria (lp). (Adapted from Wang et al., 2007)  
 
Sonn and colleagues recently reported on the use of FCE for visualising and 
distinguishing between benign lesions and malignant tumours in the human bladder 
(Sonn et al., 2009). The group hypothesised that FCE would serve as an adjunct to 
conventional white-light cystoscopy and improve on the accuracy of the technique by 
providing high resolution images of the bladder urothelium for pathological diagnosis. 
Fresh bladder tissue specimens obtained from four patients were imaged ex vivo by the 
fibred confocal miniprobe Cellvizio FCE system after topical application of fluorescein 
sodium (0.05%) for optical contrast. Following pathologic evaluation, specimens were 
found to have conditions ranging from high-grade invasive transitional cell carcinoma, 
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high-grade invasive primary bladder adenocarcinoma and multifocal CIS. Figure 2.16 
shows both FCE images and histological results obtained from the patient with 
multifocal CIS, which compares a grossly normal tissue region exhibiting uniform cellular 
structures (Figure 2.16A) with a region of CIS displaying denuded mucosa, lymphocytic 
infiltrate and local haemorrhage (Figure 2.16B). As observed, a good correspondence 
between both FCE images and histology was achieved. In conclusion, the group noted 
that whilst depth penetration of the confocal miniprobe would prove insufficient for 
providing information concerning the degree of tumour invasion, FCE would 
nonetheless complement other novel image techniques and ultimately improve on 
current white-light cystoscopic approaches.        
 
 
 
Figure 2.16. FCE images and correponding histological results obtained from ex vivo 
imaging of a bladder cystectomy tissue sample containing regions of normal mucosa (A) and 
multifocal carcinoma in situ (B). (Adapted from Sonn et al., 2009) 
 
An FCE approach for imaging the ovary epithelium in vivo was recently described by 
Tanbakuchi et al. as applied using a prototype confocal microlaparoscope system 
(Tanbakuchi et al., 2010). The pilot study consisted of 21 patients presenting with normal 
and cancerous ovarian tissue disease states. FCE imaging was performed using the 3 mm 
diameter objective lens at the positioned at the tip of the microlaparoscope, which 
provided a 450 !m field of view and lateral resolution of 3 !m. Image acquisition was 
carried out with the microlaparoscope tip in contact with the ovarian epithelium and 488 
nm laser excitation was used to excite the topically applied contrast agents, namely 
fluorescein sodium (FL; 1.0 %) and acridine orange (AO; 330 !M/L). The fluorescence 
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signal is subsequently collected by the objective lens and relayed back to the optical 
scanning unit via a coherent fibre-optic bundle. Further technical details about the 
system are discussed in separate papers by the same group (Rouse et al., 2004; 
Tanbakuchi et al., 2009). With regards to contrast agents, the group noted that FL binds 
non-specifically to tissue proteins, thus resulting in low contrast FCE images with limited 
diagnostic value for ovarian cancer detection as seen in Figure 2.17. The nuclear stain 
AO was therefore used as an alternative, which was previously demonstrated successfully 
for the detection of ovarian cancer (Srivastava et al., 2008). Ovarian tissue was first 
imaged in vivo within an endobag to prevent spreading of the dyes to nearby organs, 
followed by ex vivo imaging immediately after resectioning. Acquired images from both ex 
vivo and in vivo FCE imaging with AO are shown in Figure 2.18, showing good image 
contrast with sufficient resolution to differentiate between different cellular structures in 
both imaging settings. Based on the study’s results, the group commented that their FCE 
approach with a confocal microlaparoscope could be effectively used in a surgical setting 
for imaging of the ovary in vivo.          
 
 
 
Figure 2.17. Images obtained from in vivo FCE imaging of a human ovary using topically 
applied fluorescein sodium dye as contrast agent. Due to non-specific binding, the image 
suffers from low resolution and contrast with instances of uneven pooling of the dye 
observed. (Adapted from Tanbakuchi et al., 2010) 
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Figure 2.18. Images obtained from ex vivo (A and B) and in vivo (C and D) FCE imaging of 
human ovaries stained with the contrast agent acridine orange: normal ovarian epithelium 
(A and C); abnormal/adenomatous ovarian epithelium (B and D). Image contrast obtained 
was sufficient to identify various tissue structures associated with different ovarian disease 
states. (Adapted from Tanbakuchi et al., 2010)  
 
A novel application of FCE was demonstrated by Thong and colleagues who performed 
FCE imaging for detection of 5-ALA induced PpIX fluorescence in the oral cavity 
(Thong et al., 2007b). A prototype based on the Pentax/Optiscan FCE system with a 
rigid probe was used in their study to image three healthy volunteers and three patients 
with squamous cell carcinoma (SCC) of the tongue. 5-ALA (0.4 % in PBS) was applied 
topically in the oral cavities of all human subjects with an incubation period of at least 30 
minutes. FCE imaging at 488 nm laser excitation was then performed between 30 and 
120 minutes from the start of 5-ALA administration at. After imaging, tongue tissue 
from SCC patients was excised for histological processing. Figures 2.19A to C show FCE 
images of 5-ALA treated normal tongue tissue acquired at 45, 90 and 120 minutes after 
5-ALA application. Clear images were obtained as early as the 45-min imaging time 
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point. Figures 2.19D and E show an FCE image and white light microscope image of a 
histological section of an SCC tongue respectively. The authors noted that their system 
was able to distinguish between normal and SCC tongue tissue by highlighting that FCE 
images of the normal tongue in Figures 2.19A - C appear different to that of the SCC 
tongue in Figure 2.19D based on 5-ALA induced PpIX fluorescence. The FCE image in 
Figure 2.19D was also observed to be comparable to that of histology in Figure 2.19E. 
The study’s conclusion was that FCE had the potential of diagnosing oral cavity 
malignancies such as SCC of the tongue based on PpIX fluorescence emissions from 
tissue.    
 
 
 
Figure 2.19. FCE Images of 5-ALA treated normal (A to C) and SCC (D) tongue tissue, and 
a white light microscope image of a histological H&E section of SCC tongue tissue (E) from 
human subjects. FCE images of normal tongue tissue captured at 45, 90 and 120 minutes 
respectively after 5-ALA administration (A, B and C); FCE image of SCC human tongue 
tissue after 5-ALA application (no incubation time specified), with red arrows indicating 
SCC epithelium and white arrows representing inflammatory cells (D); white light 
histological section of SCC human tongue tissue, with SCC region indicated by red arrows 
and surrounding inflammatory cells indicated by black arrows (E). (Adapted from Thong et 
al., 2007)       
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2.6. From point-measurements to region-based detection 
 
Conventional optical spectroscopic modalities such as FS, DRS and Raman spectroscopy 
(RS) typically employ fibre optic probes for the simultaneous delivery and collection of 
excitation light and emitted signals from single points on tissue samples. In line with 
improvements in optical systems design and the long-term view of performing minimally 
invasive in vivo in situ procedures, these fibre optic probes have also been greatly 
miniaturised and currently measure only a few millimetres in diameter. Some limitations 
exist however with these improvements in probe design, such as a small and limited field 
of view (FOV) or sensing area and acquisition of inconsistent tissue spectral data. 
 
Owing to the spatially restricted sensing area of the small fibre optic probe lens and point 
sampling process, the spectral information acquired from a single point is usually 
insufficient to reach a full and proper diagnosis. Consequently, spectral data has to be 
sampled from other points around the same organ to attain a more complete diagnostic 
picture. Such tissue sampling is performed randomly most of the time, akin to random 
tissue biopsies, due to the large tissue area and multiple points to be sampled. Like 
random biopsies, this may also result in high miss rates and false-negative results. One 
possible solution is to combine optical imaging methods with more established clinical 
diagnostic approaches like MRI, PET or ultrasound for image co-registration. This would 
however detract from our original purpose of creating a solely optical approach to tissue 
diagnosis. 
 
Inconsistent spectral data collected during inter- and intra-session data acquisitions arises 
as a result of different probe-tissue contact pressures. This occurs because of direct 
contact of the probe with tissue and the lack of any force feedback mechanisms, leading 
to tissue deformation and interruption of vasculature perfusion. With conventional 
probe-based optical techniques, such a problem is usually unavoidable; direct probe-
tissue contact is needed to prevent induction of any spectral artifacts caused either by 
refractive index mismatches between the tissues and surrounding medium or as a result 
of possible inconsistencies in spectral illumination-collection geometry. A study of probe 
contact on rat liver and heart tissues found that increasing contact pressure lead to 
considerable increases in diffuse reflectance spectra intensities between 450 and 600 nm, 
with a marked increase also in the overall fluorescence spectra intensity (Ti and Lin, 
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2008). The explanation was that high probe contact pressures lead to decreases in local 
blood volume (ischemia), essentially reducing the amount of light-absorbing 
haemoglobin at the sampled points and causing a corresponding increase in detected 
amounts of diffuse reflected light. As a result of this local ischemic state, metabolic 
activity was slowed down in turn, hence causing an accumulation of NAD+ and FAD 
and a concomitant increase in flavin fluorescence emissions (Vishwasrao et al., 2005). 
 
Imaging work in this thesis is geared towards developing novel optical imaging modalities 
with the aim of overcoming limitations posed by standard spectroscopic approaches. All 
techniques investigated are imaging-based extensions of conventional optical methods, 
each incorporating the latest advancements in optical hardware and design for achieving 
enhanced detection over their predecessors. These techniques shall be described in 
greater detail in the subsequent chapters with all imaging experiments performed within 
the context of early cancer detection and diagnosis in vivo in situ.   
 
 
2.7. Summary and conclusions 
 
This chapter provided a brief overview of the rationales behind the use of emerging 
optical imaging techniques for early cancer diagnosis. Various principles behind such 
optical diagnostic approaches were mentioned together with a series of short reviews 
covering the multimodal and multispectral optical imaging techniques used throughout 
this thesis for disease detection, staging and surgical planning. The section concluded 
with motivations for our current work involving the move towards more ‘regional’ 
cancer detection in a minimally invasive in vivo in situ setting. 
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3.1. Introduction 
 
This chapter discusses the development of a new multispectral imaging-based 
spectroscopic system for performing laser-induced fluorescence imaging on tissues at the 
macroscopic level (and reflectance imaging in subsequent chapters). It is our aim to 
incorporate the system onto a laparoscope or flexible endoscope, allowing for the 
possibility of minimally-invasive in vivo in situ multispectral fluorescence imaging (MFI). 
 
Conventional point-based fluorescence spectroscopy (FS) studies performed by other 
groups have successfully demonstrated the technique’s ability to quantitatively detect 
malignant changes in a host of different human tissues as well as detect signals from 
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specific molecular contrast agents in vivo. Our imaging approach differs from these single 
point spectroscopy systems in that instead of acquiring only point-based quantitative 
tissue information, the technique results in the generation of larger region-based tissue 
colour maps of the interrogated area. This takes into account quantitative tissue spectral 
data, whilst allowing the diagnostic results to be presented in an easily accessible colour 
image format for qualitative assessment. Compared to other spectroscopy techniques, we 
believe that our excitation-resolved MFI approach has some advantages over emission-
resolved methods, while still being useful for disease detection and classification. One 
major advantage of this unique approach is that light from our supercontinuum fibre 
laser source is rapidly tuned without requiring many emission filters, therefore allowing 
easier adaptation of laparoscopes and endoscopes and integration with multispectral 
reflectance and polarization resolved imaging techniques in the future.  
 
MFI experiments performed in this chapter are focused on macroscopic imaging and 
serve as initial system validation for our tuneable supercontinuum laser system. Two 
different optical system setups were used in this chapter for imaging two distinct sets of 
fluorescent samples. The first setup utilised a mechanical wavelength selection method 
with a limited number of excitation wavelengths for imaging fluorescent dye solutions 
possessing excitation wavelengths similar to that of naturally-occurring endogenous 
fluorophores. The second setup expanded on this wavelength range towards a 
hyperspectral imaging system by utilising a digital multimirror device (DMD) during 
imaging of collagen gel tissue phantoms containing the same fluorescent dyes with the 
addition of the endogenous fluorophores flavin adenine dinucleotide (FAD) and 
protoporphyrin IX (PpIX). 
 
The ability of two different dimensionality reduction algorithms to discriminate between 
different fluorescent species is also assessed and compared using the generated spectral 
image data, namely principal component analysis (PCA) and fixed-reference isomap (FR-
IsoMap). A one-way multivariate analysis of variance (MANOVA) is applied on the 
resulting PCA and FR-IsoMap colour images as a means of comparing the specificity and 
sensitivity achieved by the two different dimensionality reduction techniques. 
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3.2. Fluorescence detection of diseased tissue states 
 
Conventional procedures for the detection of dysplasia and carcinoma in biological 
tissues involve a series of random biopsies followed by histological examination of the 
resectioned tissue specimens. Although considered the current gold standard, this 
process is highly intrusive and results in a considerable amount of bleeding during 
resectioning, making it more difficult to clearly identify dysplastic/cancerous regions 
during the procedure. The untargeted nature of the tissue biopsy also results in sampling 
errors, which increases cost and further delays the time taken for correct diagnosis. The 
use of FS as an alternative ‘optical biopsy’ technique is therefore potentially useful as it 
causes considerably less trauma to the patient, has no or very few side effects, is a simple 
and quick procedure to carry out with results known within a matter of minutes, and can 
detect small cancerous lesions better than currently available diagnostic methods 
(Ramanujam, 2000a).  
 
FS has been demonstrated by various groups to have the ability to detect and diagnose 
different tumour types in vivo in a range of biological tissues including the oral cavity 
(Müller et al., 2003; Lane et al., 2006), oesophagus (Georgakoudi et al., 2001, Wallace et al., 
2005), colon (Mycek et al., 1998; Wang et al., 1999), cervix (Georgakoudi et al., 2002; 
Chang et al., 2002), and ovary (Brewer et al., 2001) with a high degree of sensitivity and 
specificity. All of the above studies solely exploited tissue autofluorescence, i.e. no 
exogenous fluorescent agents were employed for increasing fluorescence contrast.  
 
In contrast to the various FS studies that utilise tissue autofluorescence for disease 
detection such as those mentioned above and outlined in section 2.5.2 of chapter 2, 
several others have also relied upon the application of exogenous contrast agents for 
discriminating between tumourous and healthy tissues. These applied fluorescent agents 
may either be untargeted, e.g. fluorescein (FL) or indocyanine green (ICG), or tumour-
targeting, e.g. tumour cell receptor-targeting dye-peptide or dye-antibody conjugates. 
Although the current specificity of FS is not as high as histopathological analysis, the 
high sensitivity of the technique means that it may serve as a useful ‘red flag’ technique 
for tissue biopsy guidance. 
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3.3. Multispectral fluorescence imaging of various fluorescent samples 
 
As an extension to current point-based fluorescence detection methods, we propose a 
new excitation-resolved imaging based technique whereby spectral information is 
acquired on a larger regional basis (approximately 10 squared cm area) as opposed to a 
single point (a few mm squared area) by convention. The rationale is that since tissues are 
sampled over a wider area with our MFI approach, this would result in reduced 
procedure times, lower sampling errors and ultimately improved imaging efficiency and 
detection specificity.  Additionally, it has often been noted that there are large amounts 
of inter- and intra-subject variability in the fluorescence spectral signature. As such, 
imaging over such a large area is likely to provide a useful background reference signal 
from the normal tissue signal for a particular patient. Imaging tissues via an excitation-
resolved approach with application of a larger wavelength range will also elicit more 
comprehensive fluorescence contributions from the myriad of different endogenous 
fluorophores present in biological tissues. This therefore maximises the spectral 
information acquired and gives a better overall indication of the tissues’ state of health.  
 
As a prelude to MFI experiments in the next chapter involving actual biological tissue 
samples and for the purposes of initial system validation, we performed preliminary 
imaging experiments on fluorescent samples, namely fluorescent dye solutions and a 
collagen gel-based tissue phantom containing fluorescent dyes and endogenous 
fluorophores. For presentation of the final diagnostic imaging data, ‘regional’ images 
captured at different excitation wavelengths are subjected to post-processing by a 
dimensionality reduction technique: this selects only the most meaningful quantitative 
data parameters and generates colour maps of the interrogated tissue regions, thereby 
resulting in a final imaging format containing tissue diagnostic information that is 
intuitive and less complicated to interpret.  
 
3.3.1. Optical instrumentation  
 
All MFI work performed in this chapter utilised a newly developed supercontinuum fibre 
laser system emitting broadband pulsed light generated in highly non-linear holey fibre 
between the wavelength ranges of 460 – 1800 nm (see diagram of setup in Figure 3.1).  
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Figure 3.1. Diagrammatic representation of the supercontinuum fibre laser system used for 
MFI experiments in this section of the thesis. The sample shown is a multi-well PCR plate 
containing fluorescent dyes and fluorophore solutions of known excitation wavelength.     
 
The experiment on different fluorescent dye solutions described in section 3.3.3 used a 
mechanical wavelength selection method and a limited number of excitation 
wavelengths. The system in section 3.3.4 expanded on this wavelength range by utilising 
a digital multimirror device (DMD) for rapid and automated wavelength selection. 
Output from the supercontinuum fibre laser source (Fianium SC450-2, replaced in 
subsequent chapters by Fianium SC400-4, producing light down to 400 nm) was 
transmitted through a home-built computer controlled spectral filter that consisted of a 
dispersive prism (SF2 or SF11) and motor controlled slit (based on a scheme by Dunsby 
et al., 2004). The spectrally filtered light was then coupled into two metres of high NA 
(numerical aperture) polymer-clad 200 !m core diameter optical fibre (Thorlabs BFL37-
200) using a x20 achromatic microscope objective. This fibre was selected to efficiently 
deliver light to the sample, whilst simultaneously illuminating a large field of view. The 
tip of the optical fibre was positioned approximately 120 mm away from the horizontal 
samples, pointing upwards at the underside of the samples during imaging. Emitted 
fluorescence from the samples was imaged onto a CCD (QImaging Retiga EXi) by two 
achromatic lenses with focal lengths of 50 and 100 mm respectively separated by a mirror 
at 45 degrees to allow the camera to be mounted horizontally. Although the excitation 
source is tuned in excitation spectroscopy, the emission filter also needs to be changed in 
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coarse steps to ensure that the excitation wavelength is always below the long-pass cut-
on wavelength.  For the selection of these emission filters, an electronically controllable 
filter wheel containing three longpass interferometric filters (cut-on wavelengths of 500, 
550 and 600 nm) was positioned between the two lenses. Depending on the excitation 
wavelengths applied, a corresponding filter with suitable cut-on wavelengths was 
employed for obtaining sufficient signal for the fluorescence emission data. Additionally, 
light above 800 nm was filtered in a special filter block such that no infrared light passed 
into the spectral filter. 
 
3.3.2. Data dimensionality reduction and image analysis technique 
 
The key advantage of the supercontinuum fibre laser imaging system described earlier in 
section 3.3.1 is its unique ability to utilise combinations of several acquisition parameters 
(e.g. excitation and emission wavelengths), thus increasing its discrimination capability. 
As a consequence, analysis of the acquired image data is not as straightforward due to the 
large number of data dimensions generated. One solution to overcome this is to reduce 
the number of dimensions to a few underlying axes, whilst preserving the degree of 
variability that was present in the original data set as much as possible. This is performed 
with the aim of producing a new intuitive format for characterisation of biological tissue. 
One such approach is to reduce the data dimensionality to three components and to 
subsequently construct a representative colour map of the imaged region using the new 
3-dimensional coordinates as the respective red, green and blue channels of the final 
RGB colour map image.    
 
To achieve this, we first applied principal component analysis (PCA; Jolliffe, 2002; 
Jackson, 2003) to our data using the MatLab software package (Mathworks Inc., Natick, 
MA). PCA is a widely used technique for dimensionality reduction. It is a linear 
orthogonal transformation that aims to find directions that exhibit the maximum amount 
of variation in the cloud of original pixel data points. The technique involves the use of 
eigenvalue decomposition or singular value decomposition to extract a set of orthogonal 
axes from the covariance matrix of the original data. The end result is the generation of a 
linear model incorporating the axis with the main variation that can then be used to 
describe the tissue data. 
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However, PCA is not the most optimal dimensionality reduction technique to employ if 
the data cloud to be analysed lies on a more complex manifold with non-linear 
characteristics. To address this, a non-linear method of dimensionality reduction should 
be used instead, a number of which have been developed in recent years. One such 
technique is isometric mapping (Isomap) (Tenenbaum et al., 2000), which preserves the 
inter-point dissimilarity relationships in the manifold in a manner similar to 
multidimensional scaling (MDS), whilst using geodesic distances to describe the shape of 
the manifold and thus the non-linear characteristics of the data.  
 
The difference in approach between PCA and Isomap may be intuitively described by 
referring to the “Swiss roll” diagram depicting a non-linear data set (Figure 3.2; 
Tenenbaum et al., 2000). This cloud of data points represents some real physical signal 
expressed in three dimensions.  The points can all be said to lie on a curved plane in 
three dimensions and a non-linear method of finding the distances between the different 
points is desirable before applying MDS.  PCA effectively only considers the Euclidian 
distance, or shortest distance between the points (blue line), which clearly underestimates 
the distance between the points when the underlying curved plane is taken into account.  
Conversely, Isomap takes into account the shortest geodesic distance (red line), between 
the two circled arbitrary points and hence accounts for the non-linearity of the data.  In 
this case the points appear to be deceptively close in the data cloud when in actual fact 
they are not when considering the manifold. The results of applying PCA and 
Isomap/MDS to this data set and projecting onto a two dimensional (2D) space is 
illustrated in Figure 3.3. PCA fails to detect the true dimensionality of the data cloud, 
hence resulting in non-optimal processing of the non-linear information as illustrated by 
the mixing of coloured points in the 2D data plane (Figure 3.3B). On the other hand, 
Isomap faithfully preserves the local geometry of nearby data points in the 2D plane as 
seen by retention of the coloured pattern from the original 3D manifold (Figure 3.3C) 
(Law and Jain, 2006).  
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Figure 3.2. The “Swiss roll” example of a non-linear data set demonstrating the manner in 
which Isomap exploits geodesic distances (red line) on a non-linear manifold  for accurate 
dimensionality reduction. This is in contrast to PCA, which utilises the Euclidean distances 
(blue dashed line) of the manifold, hence resulting in non-optimal processing of non-linear 
data sets. (Adapted from Tenenbaum et al., 2000) 
 
 
 
Figure 3.3. Diagrammatic representations illustrating the unfolding (dimensionality 
reduction) of the non-linear three-dimensional “Swiss roll” data set (A) onto a two-
dimensional space by PCA (B) and Isomap (C) respectively. (Adapted from Law and Jain, 
2006) 
 
When the Isomap technique is applied to different datasets from the same tissue type 
however, results produced have been found to be non-comparable. This has been 
attributed to the fact that Isomap produces an optimal embedding only up to a 
geometrical transformation of the axes. To address this issue, IsoMap was adapted to 
generate consistent embedding between samples. This new method is called fixed-
reference isomap (FR-IsoMap), which is based on the construction of a coordinate 
system that is fixed by applying Isomap to a training set that was selected as best 
representing the variation and tissue characteristics of the specific experiment. Therefore 
for the treatment of new test data, instead of reapplying Isomap, a mapping is computed 
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for each pixel onto the training set such that the inter-point distances to the nearest 
neighbours in the training set are well preserved. This therefore allows the generation of 
consistent mappings across samples and more meaningful and comparable colour maps 
for accurate tissue characterisation. More technical details about the method can be 
found in the papers on this topic (Lekadir et al., 2006; Koh et al., 2007).  
 
The end result of our image processing procedure is the generation of an RGB colour 
map of the interrogated tissue region, with R, G and B dimensions of each pixel 
comprising the intensities from each of three dimensions representing the most 
meaningful data from the original manifold. In our case these three dimensions are 
obtained via dimensionality reduction of the original data set using either the PCA or FR-
IsoMap techniques.  
 
3.3.3. Initial system validation using fluorescent dye solutions 
 
3.3.3.1. Sample preparation and imaging procedure 
 
Various fluorescent dyes were chosen for imaging that possessed excitation wavelengths 
similar to that of flavin adenine dinucleotide (FAD) and porphyrins – endogenous 
constituents of biological tissue that are believed to be involved in the transformation 
processes around the onset of carcinogenesis (Ramanujam, 2000b). These were chosen 
to demonstrate the system’s ability to distinguish dyes with similar fluorescence spectra 
and in various different concentrations.   
 
The fluorescent dyes imaged (and absorption maxima) consisted of coumarin 334 (C334; 
450 nm), fluorescein (FL; 512 nm), rhodamine 6G (R6G; 530 nm), rhodamine B (RB; 
552 nm) and cresyl violet perchlorate (CV; 601 nm). Each dye solution was made up to 
various concentrations in 99% ethanol, which has been found to only absorb in the 
ultraviolet range between 200 to 250 nm (Liu et al., 2003; Liu et al., 2005). This is below 
our intended excitation range in the visible and near-infrared (Vis-NIR) spectrum, 
implying that ethanol may therefore be used as a suitable solvent for our fluorescent 
dyes. In fact, no fluorescence was observed in a control solution of 99% ethanol alone.  
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Figure 3.4. Normalised excitation spectra applied by the supercontinuum imaging system. 
 
Dye solutions were pipetted into 100 !l multi-well clear glass bottomed PCR (polymerase 
chain reaction) plates for imaging. Two validation tests were performed: the first test set 
consisted of single dye solutions of varying concentrations (0.3 !M, 1.0 !M, 3.0 !M and 
10.0 !M) and the second test set of two-dye mixtures made up in various proportions to 
a final combined concentration of 3.0 !M. Imaging experiments were performed using 
the supercontinuum fibre laser imaging system described in section 3.3.1. The system 
was set up to generate five different excitation wavelengths as shown in Figure 3.4, and 
these were paired up with longpass interferometric filters with cut-on wavelengths of 
500, 550 and 600 nm as listed in Table 3.1. 
 
  
Table 3.1. Combinations of excitation wavelengths and corresponding emission filters used. 
 
 
Excitation wavelength (nm) Excitation bandwidth (nm) Emission filter 
 
470 10 Longpass 500 nm 
490 20 Longpass 500 nm 
490 20 Longpass 550 nm 
510 20 Longpass 550 nm 
530 25 Longpass 600 nm 
560 35 Longpass 600 nm 
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3.3.3.2. Imaging results 
 
Two sets of raw intensity images (Figure 3.5) were captured during excitation-resolved 
fluorescence spectroscopic imaging of single dye solutions and dye mixtures using the 
supercontinuum laser imaging system described previously in section 3.3.1. The samples 
were excited with six different combinations of excitation spectra and emission filters 
(500, 550 or 600 nm longpass) as listed in Table 3.1. 
 
 
 
Figure 3.5. Raw fluorescence intensity images of single dye solutions (blue outlines) and dye 
mixtures (red outlines) acquired at six different combinations of excitation wavelengths and 
long pass (LP) emission filters (listed in Table 3.1). 
 
Prior to processing with either the PCA or FR-IsoMap dimensionality reduction 
techniques, both sets of raw intensity images were subject to some pre-processing using 
the MatLab software package (Mathworks Inc., Natick, MA). First, pixel values from the 
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recorded background images i.e. images recorded without any sample, were subtracted 
from the respective raw intensity images of single dyes or dye mixtures for each 
excitation spectrum/emission filter combination (see examples in Figure 3.6). Bright-field 
images recorded using a reflectance standard as the sample (Figure 3.6B) also had their 
respective background images subtracted. In the final normalisation step, background-
subtracted intensity images were divided by background-subtracted bright-field images 
for each respective wavelength/filter combination. The presence of noise meant that the 
signal error would propagate through and it was therefore important to achieve good 
signal to noise ratios to avoid this. Resultant image pixel values obtained from this last 
pre-processing step were subsequently processed by PCA or FR-IsoMap for generation 
of the final RGB colour images of the interrogated regions. 
 
 
 
Figure 3.6. Example images used to illustrate the image pre-processing step performed prior 
to data dimensionality reduction with either PCA or FR-IsoMap: intensity image (A); 
bright-field image (B); background image (C). 
 
Figure 3.7 represents the MFI images of fluorescent dye solutions obtained after 
processing of pixel data with PCA (Figures 3.7A and C) and FR-IsoMap (Figures 3.7B 
and D). For FR-IsoMap, pixel data from the acquired images were treated as the training 
data set. Figures 3.7A and 3.7B are processed images of single dye solutions at 
concentrations of 0.3 µM, 1.0 µM, 3.0 µM and 10.0 µM, whereas Figures 3.7C and 3.7D 
are the processed images of two-dye mixtures mixed in different proportions to a total 
concentration of 3.0 µM. 
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Figure 3.7. PCA and FR-IsoMap processed images of single dye solutions made up to 
different concentrations in 99% ethanol (marked in µM) (A and B) and two-dye mixtures of 
3.0 µM total concentration (C and D). For rows 2 and 4 of the dye mixtures (C and D), the 
asterisks (*) denote the dyes that are present in higher proportions (75%) in the two-dye 
mixture. Dyes in row 3 are present in equal amounts. Note that the fourth columns of C and 
D are presented the opposite way round from the others.   
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PCA and FR-IsoMap processed images of single dye solutions (Figures 3.7A and B) 
clearly indicate that both techniques can accurately distinguish between different dye 
solutions with different excitation maxima based on their final mapped RGB values.  It 
also demonstrates that different dye concentrations i.e. different overall fluorescent 
intensities, still result in the same colour being generated for each dye in the RGB colour 
space regardless of whether PCA or FR-IsoMap is applied to the data. When comparing 
Figures 3.7A and B qualitatively by eye, the colours and contrast between each dye 
displayed in the PCA image (Figure 3.7A) and FR-IsoMap image (Figure 3.7B) appear 
similar. Therefore to investigate and quantify the actual degree of separation of pixels in 
the 3D RGB colour space of each technique, more in-depth analysis will have to be 
performed later. 
 
The PCA and FR-IsoMap-processed images of the two-dye mixtures (Figures 3.7C and 
D) displayed a smooth gradation of colour when transitioning from one dye type to the 
next. This demonstrated the possibility of applying both dimensionality reduction 
techniques to discriminate between mixtures of fluorescent dyes of different absorption 
maxima. An interesting observation is in row three of the two-dye colour images where 
both dyes are present in equal amounts: regardless of the difference in absorption 
maxima between the two dyes, e.g. a large 102 nm gap between C334 and RB or a small 
18 nm difference between FL and R6G, both PCA and FR-IsoMap can effectively map 
the dye combinations to their own distinct three-dimensional RGB colour space. This 
implies a high degree of specificity of both techniques for discrete classification of 
samples of different fluorophores and combinations of fluorophores and may therefore 
be useful for tissue imaging where the relative abundance of different fluorophores 
conveys diagnostic capability.  
 
Whilst the above explanation of these results provides an intuitive interpretation of the 
experiment, it is desirable to compare the two techniques quantitatively.  For this we 
have carried out a Multivariate Analysis of Variance (MANOVA) to both PCA and FR-
IsoMap processed images. This technique assesses the null hypothesis that the colour 
pixel means of dye solutions in each well are of the same n-dimensional multivariate 
vector, and that any observable difference within each well is as a result of random 
chance. To perform this analysis, a test region of roughly 1900 - 2000 pixels was 
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manually chosen from each well in the image (approximately 4/5th of the total pixels in 
each well). Information obtained after applying MANOVA with MatLab included: 
 
i. d, the number of dimensions of the means in the analysed dataset,  
ii. the p values i.e. the calculated probability for each dimension, which is the 
estimated probability of rejecting the null hypothesis; p values less than 0.05 
imply that the result obtained is significant and the null hypothesis may be 
rejected, and  
iii. a vector of Mahalanobis Distances (MDs) measured from each pixel to the 
mean of its chosen region, and a matrix of average MDs between the 
selected regions. The MD is a quantifiable distance measure of likeness 
between two or more classes (where the classes in this case are the pixels of 
wells containing different fluorescent samples) or the likeness within a class 
(i.e. the pixels within each fluorescent well sample) where different data 
patterns can be distinguished and analysed. The greater the MD between 
two classes, the higher the degree of separation between them in the 
Euclidian space and hence the more dissimilar they are, and vice-versa. 
 
The MD is calculated using the following equation: 
 
    – 
    
   for i = 1 to n 
 
where  is the input intensity of a given pixel in the sampled region within 
each well, 
 is the mean intensity of the pixels in that selected region,  is 
the inverse of the covariance matrix of all pixel intensities within that 
selected well region and     
 is the transpose of the vector   – 
.  
 
Following MANOVA analysis of Figures 3.7A and B of the single dye solutions, the 
algorithm returned values of d = 3 and p < 0.005, which signified highly accurate 
identification of the classes when represented as three RGB colour channels for both 
PCA and FR-IsoMap dimensionality reduction techniques. Table 3.2 shows the average 
MDs obtained between combinations of single dye-pairs of 0.3 µM concentration and 
the average MD within each well for each dye. For accurate classification, it is desirable 
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for measured intra-dye MDs to be small, meaning that the cloud of data points mapped 
onto the three-dimensional colour space is well localised and therefore similar in colour. 
For the converse reason, it is also desirable for the inter-dye MDs obtained to be large. 
The low 0.3 µM dye concentration was selected to compare the sensitivity of both PCA 
and FR-IsoMap techniques – a test to see which method could accurately distinguish the 
various dyes in this ‘worst-case scenario’ of least fluorescence and therefore highest 
relative background and noise levels.   
 
 
  
C334 FL R6G RB CV 
C334 
7.56             
0.17 
155.58              
534.78 
342.34  
1534.00 
445.75  
1476.04 
610.43 
1317.62 
FL 
155.58         
534.78 
7.38              
0.19 
104.15  
1337.89 
228.42  
1311.31 
382.92 
1128.52 
R6G 
342.34       
1534.00 
104.15  
1337.89 
0.23                     
0.24 
63.19          
161.59 
308.05 
498.41 
RB 
445.75     
1476.04 
228.42  
1311.31 
63.19           
161.59 
0.48              
0.28 
131.14 
109.31 
CV 
610.43  
1317.62 
382.92  
1128.52 
308.05  
498.41 
131.14     
109.31 
19.99 
0.08 
 
Table 3.2. Average interclass Mahalanobis Distances between single dye solutions of 0.3 µM 
concentration after PCA (normal text) and FR-IsoMap (bold text) processing (unshaded).  
The average intraclass MD is also shown (shaded). 
 
From Table 3.2, it can be observed that a larger average inter-well MD was obtained 
between almost all single dye solutions of 0.3 µM concentration when results were 
processed by FR-IsoMap. This indicates that single dyes were better separated from each 
other with this dimensionality reduction technique compared to PCA. Intraclass MDs 
within the same dye solution obtained after FR-IsoMap processing were also much 
smaller compared to PCA for almost all dye solutions. This again signified more discrete 
and accurate classification of each single dye type to within its own distinctive RGB 
colour space. Note that the ratio of inter- to intra-MDs is far greater for FR-IsoMap than 
PCA, providing further evidence that this technique distinguishes the different dyes 
better. 
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Figure 3.8.  Average interclass Mahalanobis distances between dye pairs (A) and within the 
same dye (B). FR-IsoMap performance declined as dye concentrations increased from 1.0 
µM to 10.0 µM, with corresponding decreases in the average interclass distance between 
almost all dyes (A) and increases in the average interclass distance within each dye (B). 
 
MANOVA was later applied to the PCA and FR-IsoMap-processed images of 1.0 µM, 
3.0 µM and 10.0 µM single dye concentrations (Figures 3.7A and B). The results 
demonstrated a decline in FR-IsoMap performance as dye concentration increased from 
1.0 µM to 10.0 µM, with decreases in average interclass MDs between almost all dyes 
and increases in interclass MDs, as shown respectively in Figures 3.8A and B. The 
decline in FR-IsoMap performance was most significant compared to PCA at 10.0 µM 
dye concentrations, implying that the FR-IsoMap technique performs most optimally at 
lower dye concentrations, i.e. low fluorescence emission levels, up to a threshold of 
about 3.0 µM concentration in this instance. 
 
MANOVA was then applied for the analysis of PCA and FR-IsoMap processed images 
from the second test set of two-dye mixtures of 3.0 µM concentration (Figures 3.7C and 
D). The analysis returned values of d = 3 and p < 0.005 across all images indicating a 
significant result in the three dimensional representation, with MDs having much larger 
values overall compared to those from the first test set of single dye solutions (results not 
shown). 
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Figure 3.9. Graphical representation of variation in average Mahalanobis distances from 
sequential MANOVA analyses of two-dye mixtures of 3.0 µM total concentration. In each 
case, the pure dye of interest is positioned in the centre of the x-axis. On the left and right of 
this central dye is an increasing concentration of one of the other dyes. Red dashed curves 
represent the FR-IsoMap technique and blue curves represent PCA. Sequential analyses are 
shown for various dye groups: C334–FL–R6G (A); FL–R6G–RB (B); R6G–RB–C334 (C); 
RB–C334–FL (D). The asterisks (*) denote the dyes that are present in higher proportions in 
the two-dye mixture.  
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To determine the data dimensionality reduction technique that best discriminated two-
dye mixtures, MDs obtained from the sequential MANOVA analysis of selected PCA 
and FR-IsoMap-processed images of two-dye mixtures were plotted and compared as 
shown in Figure 3.9. This served to ‘unwrap’ the pixel data from the RGB colour space, 
allowing a clearer display of the spread in MD values obtained from MANOVA of both 
techniques in two dimensions. It is evident from the figure that FR-IsoMap (red dashed 
curve in graphs) gave a wider spread of MDs than PCA (blue curves) - more than two 
times in some instances - indicating better discrimination.  This type of test has 
implications for the distinction of a specific spectral signature of varying intensity upon a 
background signal of varying intensity, for instance when attempting to detect a specific 
fluorophore on top of a fluorescent background. Although FR-IsoMap does not produce 
better discrimination across all samples, it should be noted that the smaller inter-sample 
MDs for FR-IsoMap is not represented in Figure 3.8 and FR-IsoMap is a better 
technique for overall discrimination. 
 
The effects of dye concentration were next investigated on PCA and FR-IsoMap 
processing results. To test this, MANOVA analysis was performed on PCA and FR-
IsoMap processed single-dye images of 0.3 !M, 1.0 !M, 3.0 !M and 10.0 !M 
concentrations (Figures 3.7A and B) to investigate the average intraclass MDs within 
each dye. As seen in Figure 3.10, results indicated that both techniques demonstrated a 
minor change in MDs following the increase in concentration from 0.3 !M to 3.0 !M for 
most dyes. Greater increases in MDs occurred during the 3.0 !M to 10.0 !M transition 
for both PCA and FR-IsoMap techniques, with the latter demonstrating a larger change 
overall. However, the scales of these graphs have been exaggerated compared with the 
graphs comparing the MDs between dye groups and overall these changes are all very 
small.  This finding demonstrates that both dimensionality reduction techniques can 
function relatively independent of concentration changes and therefore across a wide 
range of intensity values. 
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Figure 3.10. Variation in the measured average intraclass Mahalanobis distances from PCA 
(blue curve) and FR-IsoMap (red curve) processed images of single dyes of increasing 
concentration (0.3 to 10.0 !M.): C334 (A), FL (B), R6G (C) and RB (D). Greater changes 
occurred during the 3.0 !M to 10.0 !M concentration increase for both PCA and FR-
IsoMap.   
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3.3.4. Further validation using fluorescent collagen gel tissue phantoms 
 
Optical tissue phantoms have been used since the early 1980s to simulate properties of 
biological tissues in the fields of biology and medicine. Besides allowing better 
understanding of the optical characteristics of tissues, they also serve as useful tools for 
the development of clinical imaging modalities like magnetic resonance imaging and 
computer tomography systems as well as those found in the field of biomedical optics 
(Das et al., 1997; Wagnieres et al., 1998).  Several types of liquid and solid phantoms have 
been created to date which attempt to mimic the inhomogeneous properties of human 
tissue (Moffitt et al., 2006).  
 
As the next step towards tissue-based experiments and also to investigate if fluorescence 
originating from tissue-simulating media could be detected by our MFI system, a 
biologically relevant collagen gel tissue phantom was fabricated based on a protocol 
described by Sokolov and colleagues into which fluorescent dye and endogenous 
fluorophores were included (Sokolov et al., 2002).  
 
3.3.4.1. Tissue phantom preparation and imaging procedure 
 
Type I collagen used for fabricating the gel phantom was harvested manually using a 
surgical scalpel from tail tendons of adult (200 – 400 g) Sprague-Dawley rats provided by 
Central Biomedical Services, Imperial College London, UK. Once extracted from tail 
tendons, the collagen fibres were placed out to dry on a paper towel, weighed, and then 
transferred into 0.1% v/v acetic acid solution at 4 °C for a period of five days until 
complete solubilisation was achieved. Collagen fibres were added to the acid solution at a 
ratio of 1 g dried collagen to 300 ml acetic acid. After being completely solubilised, the 
resulting collagen solution was cleared by centrifugation (20 minutes at 10,000 rpm) and 
the supernatant (i.e. the solubilised collagen solution) subsequently removed and stored 
separately at 4 °C. To bring about gel formation, eight parts of the collagen solution were 
mixed with one part sterile 10x PBS buffer and one part sterile 0.2 M HEPES (pH 7.3). 
The mixture was then placed in an incubator set at 37 °C for gelation to occur, with the 
entire process complete in about 45 minutes.  
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For the purpose of imaging, collagen gel phantoms were made up in 24-well cell culture 
plates (15.0 mm well diameter) to a final gel thickness of 3 mm. Mixed into the collagen 
gel solution prior to gelation were fluorescent dyes and endogenous fluorophores made 
up to a final concentration of 3.0 !M. Dyes used were similar to those described in 
section 3.3.3.1, together with inclusion of the endogenous fluorophores flavin adenine 
dinucleotide (FAD; 450 nm absorption) and protoporphyrin IX (PpIX; absorption 
between 400 to 450 nm). Optical absorbers and scatterers were also added to the 
collagen gel solutions in each well before gelation to create a more realistic tissue 
phantom. Human haemoglobin (Sigma-Aldrich, UK) was added as the absorbing agent at 
5.0 mg per well. The scattering agent consisted of 0.97 !m diameter silicon microspheres 
(Polysciences Europe GmbH) added at an amount of 3.0 mg per well. This was to 
simulate scattering from tissue microstructures such as cell nuclei, mitochondria, and 
lysosomes due to a difference in refractive index between the microspheres and collagen 
gel medium. We expect the type of scattering to be Mie scattering as a result of the 0.97 
!m diameter size of the homogenous microspheres. 
 
The supercontinuum fibre laser system used for this set of experiments was similar to the 
system described previously in section 3.3.1 but with a few modifications. The main 
difference was the addition of a digital micromirror device (DMD; Texas Instruments, 
USA), which allowed for faster and more automated selection of a wider excitation 
wavelength range from the filtered output of the fibre laser source (450 – 800 nm) 
compared to the original motor-controlled slit. In the optical setup, the retroreflecting 
mirror was replaced with the DMD and angled 45° to the incident beam to reflect light at 
an approximately 90° angle of deflection. The DMD is made up of hundreds of 
thousands of movable and highly reflective micromirrors measuring approximately 10.8 
by 10.8 microns in size (Texas Instruments product brochure). Movements of each of 
these micromirror elements may be electronically controlled. When an incident ray of 
light arrives at the surface of the mirror elements, applying a voltage to one or more of 
these movable elements may modulate its reflected path. The applied voltage switches 
the mirror postition by an angle of +/- 12°. Since each element may be individually 
controlled, it is thus possible to select a predetermined set or combinations of elements 
on the DMD and switch them on or off. When a spectrum of light is incident on the 
DMD, switching on a predefined combination of micromirror elements would therefore 
allow only selected wavelengths to be reflected towards a target whilst rejecting the 
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remaining wavelengths. As such, even different combinations of wavelengths may be 
selected simultaneously for sample excitation. Due to significant diffraction occurring 
from the DMD, only one of the output orders was used during our imaging procedures. 
 
During imaging, a total of 13 different excitation wavelengths were used (shown in 
Figure 3.11), which were paired up with three longpass interferometric filters of 500, 550 
and 600 nm cut-on wavelengths respectively used (refer to Table 3.3). This spread of 
excitation wavelengths was selected in order to target the absorption maxima of every 
fluorescent dye and fluorophore used in the study. Exposure timing of the camera was 
set at 0.01 seconds with four averages recorded for each field.  
 
 
 
Figure 3.11. The 13 excitation wavelengths applied for generation of the fluorescence 
intensity images in the amalgamated dataset (refer to Figure 3.12A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.3. Combinations of excitation wavelengths and corresponding emission filters used. 
Excitation wavelength (nm) Emission filter 
460 Longpass 500 nm 
465 Longpass 500 nm 
470 Longpass 500 nm 
475 Longpass 500 nm 
480 Longpass 500 nm 
482 Longpass 550 nm 
485 Longpass 550 nm 
500 Longpass 550 nm 
510 Longpass 550 nm 
520  Longpass 550 nm 
530 Longpass 600 nm 
540 Longpass 600 nm 
560 Longpass 600 nm 
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3.3.4.2. Imaging results 
 
Results from MFI of collagen gel tissue phantoms in this section were processed using 
only the FR-IsoMap dimensionality reduction technique. Data extracted from multiple 
imaging runs of fluorescent collagen gel phantoms produced an amalgamated image 
dataset that was subsequently used to generate the fixed reference colour map. These 
imaging runs consisted of data recorded from multiple laboratory sessions and repeated 
collagen sample preparations both with and without scattering spheres included to 
simulate tissue scattering. A ‘pre-processing’ step was performed to subtract the 
background image, followed by normalisation using the integrated fluorescence (bright-
field images) from all 13 images on a pixel-by-pixel basis as in section 3.3.3.2. 
 
 
 
Figure 3.12. The amalgamated fluorescence image dataset (A) used to create the FR-IsoMap 
colour map (B) of collagen gel tissue phantoms embedded with fluorescent dyes and 
fluorophores. Dye/fluorophore abbreviations are as described in the text, and wells labelled 
with an asterisk contain both scattering microspheres and haemoglobin. The black wells are 
tissue phantoms that have been masked out due to insufficient fluorescence emissions so as 
to not interfere with the final FR-IsoMap embedding. 
 
Figure 3.12A is an example input image dataset comprising stitched greyscale 
fluorescence intensity images of fluorescent collagen gel phantoms imaged at various 
excitation wavelengths. Consistent colouring is seen for identical fluorophores in the 
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processed images in Figure 3.12B both with and without scattering microspheres and 
haemoglobin present. Good contrast was also achieved between different 
dye/fluorophore samples, even for those with similar excitation spectra. Scattering 
microspheres are especially evident in some wells in Figure 3.12B where they have 
agglomerated in the middle of those wells. This occurrence has significantly altered the 
optical properties of the wells at these locations and has resulted in a change in colour in 
those parts of the wells, hence the dyes/fluorophores in those wells are not accurately 
and clearly delineated in the fixed reference map. The presence of non-agglomerated 
scatterers in other locations does not appear to have significantly altered the colour. The 
presence of haemoglobin and scattering microspheres resulted in an alteration of the FR-
IsoMap classification for some wells containing identical fluorophores, an effect 
attributed to absorption of green fluorescence by haemoglobin. 
 
  C334 CV FAD FL PpIX R6G RB 
C334 5.04 1714.54 656.87 43.43 1368.15 3826.77 2337.65 
CV 1714.54 2.95 436.56 1230.06 150.88 1786.08 170.22 
FAD 656.87 436.56 14.73 401.14 152.06 1620.43 1020.17 
FL 43.43 1230.06 401.14 0.32 967.85 3211.41 1804.51 
PpIX 1368.15 150.88 152.06 967.85 18.06 1372.90 567.97 
R6G 3826.77 1786.08 1620.43 3211.41 1372.90 0.70 2908.86 
RB 2337.65 170.22 1020.17 1804.51 567.97 2908.86 1.08 
 
Table 3.4. Matrix of Mahalanobis distances (MDs) for different wells selected from within 
Figure 3.9B. Shaded boxes indicate intraclass MDs within individual dyes, while unshaded 
boxes represent the interclass MDs between different dye types in different wells.  
 
To evaluate the effect of the presence of noise within the fixed reference map, 
MANOVA analysis was applied to calculate the MDs from each pixel to the mean of its 
region within each well together with a matrix containing the average MDs between pairs 
of pixel region means in different wells (see section 3.3.3.2 for a more detailed 
explanation). Typical results from MANOVA analysis of representative wells from 
Figure 3.12B are shown in Table 3.4, where significant interclass MDs between different 
dye/fluorophore samples and small intraclass MD variation within individual samples 
(diagonal elements) are evident. A graphical representation of this information is also 
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shown in Figure 3.13 of the C334, FAD and PpIX, showing clear discrimination between 
these fluorophores that possess similar excitation maxima.  
   
 
 
Figure 3.13. Histogram of the interclass distances between three selected fluorophores: C334 
(black curve), FAD (red curve) and PpIX (blue curve), showing excellent discrimination. 
 
 
3.4. Summary 
 
Experiments in this chapter have demonstrated our excitation resolved fluorescence 
imaging system’s ability to effectively illuminate and detect fluorescence spectra over a 
wider field of view as compared to conventional point-based fluorescence spectroscopy 
systems. The end goal of our regional sampling approach would be the recording of 
intensity images of biological tissues undergoing illumination at multiple excitation 
wavelengths via a rigid or flexible endoscope. By subsequent processing of these intensity 
images with FR-IsoMap, a representative RGB colour map of the interrogated tissue 
regions would be generated that would highlight areas with the most variability. This 
therefore takes into account quantitative spectral data, whilst allowing the imaging results 
to be presented in an easily accessible colour map format for more straightforward 
qualitative assessment.  
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By comparing image processing results of PCA and FR-IsoMap from fluorescent dye 
solutions, we have shown that both dimensionality reduction techniques can provide 
accurate separation of dyes by their respective fluorescence emissions. At lower dye 
concentration levels i.e. lower fluorescence intensities, FR-IsoMap processing produced 
larger separation values (MDs) between dyes and smaller interclass MDs within dyes 
when compared to PCA. This indicates that dye types were better distinguished by FR-
IsoMap under these conditions, and also implies that the technique would be able to 
better discriminate the various endogenous fluorophores present in biological tissue at 
low fluorescence intensity levels. Besides being able to distinguish between different dyes 
in mixtures, FR-IsoMap was also shown to be relatively independent of concentration at 
lower dye concentrations, hence exhibiting the operational robustness of this technique 
under normal physiological conditions.  
 
Having shown the improved discrimination ability of the FR-IsoMap technique over 
PCA, the former was subsequently employed for the processing of image data obtained 
from MF imaging of fluorescent collagen gel tissue phantoms. The resulting fixed 
reference colour maps displayed excellent contrast across different dye/fluorophore gel 
phantoms and consistent colouring between identical samples, as analysed via 
MANOVA. 
 
We believe that our imaging-based approach could be a more intuitive, and consequently 
more effective, method for the classification of spectrally distinct samples based on their 
fluorescence emission profiles than spectroscopy alone. One of the next steps is the 
validation of the technique using actual tissues from both animal models and humans, as 
well as further modification of the supercontinuum laser system to acquire an additional 
mode of imaging: hyperspectral reflectance imaging (HRI) as discussed in the next 
chapter.    
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4.1. Introduction 
 
This chapter discusses the development of an in vivo, in situ multimodal optical imaging 
system for performing laser-induced excitation-resolved multispectral fluorescence 
imaging (MFI) and hyperspectral reflectance imaging (HRI) designed for cancer 
detection. Following initial system calibration and characterisation of fluorescence from 
solutions and collagen gel phantoms in the previous chapter, imaging experiments in this 
section were aimed at further developing the system as a minimally-invasive optical 
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biopsy tool for discrimination between neoplastic and non-neoplastic tissues within the 
human body. Additionally, all acquired fluorescence and diffuse reflectance images were 
processed by the FR-IsoMap dimensionality reduction technique, resulting in the 
generation of a red-green-blue (RGB) colour map for more intuitive interpretation of the 
final imaging results.  
 
Initial multimodal imaging experiments employed MFI in the visible and near-infrared 
(visible/NIR) wavelength range on fluorescent dye-stained ex vivo lamb kidneys for 
demonstration of the system’s ability to discriminate between different exogenous 
fluorophores as well as the discriminatory effectiveness of FR-IsoMap processing. This 
was also to assess future potential applications of the system such as aiding in vivo 
delivery of exogenous markers e.g. dye-antibody/peptide conjugates and fluorescent 
protein probes, and as a ‘red-flag' technique for tracking cancerous growths via 
fluorescence from tumour-specific photosensitisers e.g. protoporphyrin IX (PpIX).  
 
The MFI system was then later applied to imaging of freshly resectioned human small 
cell lung cancer (SCLC) tissue treated with the photosensitiser pro-drug 5-aminolevulinic 
acid (5-ALA). This was to evaluate the ability of the system to differentiate between 
photosensitiser-treated and untreated tissues based on fluorescence emissions from 5-
ALA induced PpIX, and to display that difference with FR-IsoMap processing of the 
acquired fluorescence intensity images.  
 
In a second set of experiments, the potential of a combined MFI-HRI approach was 
investigated to determine if this dual combination could be used as a means of 
discrimination between healthy and cancerous untreated human colorectal tissues using 
only autofluorescence and reflectance signals. As a gold standard comparison test, 
fluorescence intensity graphs and FR-IsoMap images from respective MFI and HRI of 
the colorectal tissues were assessed against results from histopathology to determine 
overall accuracy and effectiveness of the dual MFI/HRI endoscopic imaging technique 
for cancer detection.   
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4.2. Imaging fluorescence from various biological tissues 
 
Three different types of biological tissues were used in our imaging experiments: ex vivo 
dye-stained lamb kidneys, 5-ALA photosensitised small-cell lung cancer (SCLC) tissue 
and untreated human colorectal cancer tissue. This was obtained from various sources 
and prepared in different ways for subsequent MFI procedures with our supercontinuum 
laser imaging setup. Imaging results in the form of greyscale intensity images for each 
tissue type are then subject to data processing by the FR-IsoMap dimensionality 
reduction technique for presentation of the final results as RGB colour images.   
 
4.2.1. Optical instrumentation  
 
The supercontinuum fibre laser based imaging system used for excitation-resolved MFI 
and HRI work in this chapter was almost identical to the setup previously employed in 
section 3.3.4 of chapter 3 with a few slight modifications. A liquid light guide was used to 
deliver excitation light to the horizontal sample and a rigid laparoscope (Olympus, Japan) 
positioned about 70 mm above the sample was used to collect the spectrally filtered 
fluorescence emissions. The emitted fluorescence spectra were passed through 600, 650 
or 700 nm longpass filters for MFI or a crossed polariser to minimize specular reflections 
for HRI. The filtered spectra were eventually focused by the exit aperture onto a CCD 
camera (QImaging Retiga EXi) for recording of the resultant intensity images. A diagram 
of this multimodal imaging system is shown in Figure 4.1.  
 
For respective MFI and HRI experiments, two different sets of excitation wavelengths 
were applied, each with a different combination of central wavelengths, excitation 
bandwidths, inclusion of different filters (longpass emission or cross polarising) and 
camera integration times (see Table 4.1).  
 
For MFI, 30 different excitation wavelengths from 465 to 645 nm were applied to the 
tissue samples, each with excitation bandwidths of between 3 and 15 nm. Owing to the 
use of narrower excitation bandwidths, less light was transmitted through the system and 
the camera integration time was thus set at 3.0 seconds to allow for brighter recorded 
images. Longpass filters with cut-on wavelengths of 600, 650 and 700 nm were also 
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included in the setup for this first imaging modality to allow for transmission and 
recording of fluorescence signals above that emission wavelength.  
 
For HRI, a total of 31 excitation wavelengths from 466 to 641 nm were applied, each 
with a broader excitation bandwidth of between 30 and 40 nm. Due to the higher 
amounts of light being transmitted, camera integration time was set to a shorter 0.5 
seconds compared to the MFI setup. Only a cross polarising filter was used for this 
second modality.   
 
 
 
Figure 4.1. Diagrammatic representation of the multimodal image acquisition optics. DMD: 
digital multimirror device. 
 
Imaging modality 
Excitation 
wavelengths 
Excitation 
bandwidth 
Emission  
filter 
Integration  
time (sec.) 
     
Multispectral 
fluorescence 
imaging (MFI) 
30 wavelengths: 
465 to 645 nm 
3 to 15 nm 
Longpass  
600, 650 
and 700 nm  
3.0 
     
Hyperspectral  
reflectance  
imaging (HRI) 
31 wavelengths:  
 466 to 641 nm 
30 to 40 nm 
Crossed 
polariser 
0.5 
          
 
Table 4.1. Imaging modalities and their respective combinations of excitation wavelengths, 
bandwidths, longpass emission or cross polarising filters and camera integration times. 
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4.2.2. Data processing technique 
 
As with chapter 3, use of this multimodal imaging system resulted in the acquisition of a 
large quantity of closely spaced spectral images. The challenge was to find a method to 
best present the resultant stack of monochromatic images in a meaningful and easily 
comprehensible manner. We therefore employed the FR-IsoMap algorithm that was 
employed previously in section 3.3.2 for processing of intensity images of fluorescent 
dyes and a collagen gel tissue phantom. Once again, dimensionality reduction by FR-
IsoMap resulted in the multi-point spectrum of each pixel being mapped to three data 
dimensions containing the most meaningful data parameters of the original manifold. 
Each of the three dimensions was later assigned to the red, green and blue channels of an 
RGB colour image and were presented as such for more intuitive interpretation of the 
diseased tissues. As before, some pre-processing was performed on the raw intensity 
images prior to FR-IsoMap analysis involving background subtractions and 
normalisation with bright-field images. This was to eliminate spatial variation in 
illumination and also account for the variation in laser output intensities across all 
wavelengths.   
 
4.2.3. Dye-stained ex vivo lamb kidneys 
 
Ex vivo lamb kidneys stained with exogenous fluorescent dyes were used as tissue 
phantoms for MFI in the visible and near-infrared (visible/NIR) spectral range. These 
initial experiments were to demonstrate the system’s ability to discriminate between 
different exogenous fluorophores as well as the discriminatory effectiveness of FR-
IsoMap processing. Another objective of the MFI experiment was to assess future 
potential applications of the system such as aiding in in vivo delivery of exogenous 
markers e.g. dye-peptide conjugates and fluorescent protein probes, and for tracking of 
cancerous growths via fluorescence from tumour-specific photosensitisers e.g. 
protoporphyrin IX (PpIX).  
 
4.2.3.1. Tissue staining and imaging procedure  
 
Fresh lamb kidneys that had not been previously frozen were obtained from a local 
butcher and prepared within two hours of their purchase. Each kidney was coronally 
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sectioned with a surgical scalpel, dividing the kidney into two equal halves. The freshly 
sectioned inner sides of each bisected kidney were then gently washed with distilled water 
to remove any stray tissue pieces and dabbed dry with disposable paper towels. 
Following this, the fluorescent dyes rhodamine 6G (R6G; 530 nm absorption maxima) 
and rhodamine B (RB; 552 nm absorption maxima) were carefully applied in two 
separate bands to the bisected inner side of one kidney half-section. The relative 
positions of the applied dyes on the inner kidney surface were noted prior to MFI. Our 
experimental aim was to demonstrate both the laser excitation and image acquisition 
abilities of our multimodal imaging system as well as the discriminatory effectiveness of 
the FR-IsoMap technique for differentiating the two dyes.  
 
4.2.3.2. Imaging results 
 
As observed from the lamb kidney images in Figure 4.2, good discrimination was 
achieved from emitted fluorescence of the two different dyes applied following FR-
IsoMap processing. These are visible as two distinct coloured bands that run across the 
kidney’s surface in the FR-IsoMap colour image (Figure 4.2B) – the pink and yellow 
coloured bands belonging to R6G and RB respectively. Upon closer inspection, it is also 
evident that the applied fluorescent dyes highlighted various anatomical features of the 
internal kidney by non-specific binding/accumulation, e.g. the major and minor calyces 
and renal pyramids. Such results thus indicate the potential of the MFI system for 
visualising specific tissue structures in clear detail together with the added advantage of 
detecting fluorescence emissions associated with that particular tissue e.g. from quantum 
dots, dendrimers or tissue-specific dye-antibody tags. Based on this observation, a 
possible area of application of our MFI approach is in minimally invasive fluorescence 
detection of sentinel lymph nodes; previous studies have successfully demonstrated the 
use of fluorescence from the near-infrared indocyanine green (ICG) fluorophore for 
successful identification of sentinel lymph nodes during incidences of breast or gastric 
cancers (Miyashiro et al., 2008; Murawa et al., 2009). 
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Figure 4.2. Conventional white light reflectance (A) and FR-IsoMap (B) images of the 
coronal section of an ex vivo lamb kidney. Two fluorescent dyes of different excitation 
wavelengths were painted across the coronally sectioned kidney’s inner surface prior to 
MFI. This is observed in the FR-IsoMap image as two differently coloured bands – pink 
(rhodamine 6G) and yellow (rhodamine B). The black patches in (B) are regions of saturated 
fluorescence, which were masked out from the original intensity images prior to FR-IsoMap 
processing. 
 
4.2.4. 5-ALA treated ex vivo human small-cell lung cancer tissue 
 
5-aminolevulinic acid (5-ALA) is a photosensitising pro-drug that induces an increased 
endogenous accumulation of the autofluorescent fluorophore protoporphyrin IX (PpIX) 
in cancerous tissues. The phenomenon occurs due to a breakdown in the haeme 
biosynthetic pathway in cancer cells, which is otherwise intact in normal cells. The aim of 
this experiment was to evaluate the ability of our imaging system to detect differences in 
PpIX contents between 5-ALA treated and untreated human small-cell lung cancer 
(SCLC) tissue using MFI, and to subsequently display that difference using FR-IsoMap 
processing of the acquired intensity images akin to a photodynamic diagnostic approach.   
 
4.2.4.1. Tissue preparation and imaging procedure 
 
Human SCLC tissue samples were obtained from routine surgical resectioning of lung 
cancer patients undergoing clinical evaluation at the Royal Brompton Hospital (Royal 
Brompton & Harefield NHS Trust, London, UK) by Dr Pallav Shah, Consultant 
Physician and Honorary Senior Lecturer, National Heart and Lung Institute, Imperial 
College London. Informed consent was obtained from all patients before the 
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commencement of surgery.  All imaging experiments involving ex vivo human tissues in 
this sub-section and the next were performed under ethical approval from the Outer 
West London Research Ethics Committee, National Research Ethics Service, UK (REC 
reference number 08/H0719/37).   
 
Human SCLC tissue were first placed in a clean Petri dish containing sterile Dulbecco’s 
modified Eagle’s medium (DMEM) immediately after resectioning and processed within 
the aseptic environment of a flow hood.  These were then transferred into a separate dish 
filled with 25.0 ml sterile phosphate buffered saline (PBS) and gently washed by dripping 
PBS over them using a sterile Pasteur pipette. The samples were next placed in another 
clean Petri dish containing 25.0 ml DMEM and 10% Pen-Strep solution (penicillin and 
streptomycin antibiotics solution); these were again gently washed in the same drip 
fashion using DMEM/Pen-Strep solution from the same dish. Tissue samples were left 
to immerse for a further 2 minutes before washing was repeated to kill any remaining 
foreign agents before being cut into small roughly 5 mm by 5 mm sizes and placed in a 
cell culture flask containing 25.0 ml of DMEM containing 10% foetal bovine serum 
(FBS), 1.0% Pen-Strep solution and 2.0 mM glutamine. At this point, 5-ALA was added 
into the mixture to a final concentration of 1.0 mM before the flask was placed in an 
incubator set at 37.0 ºC and 5.0% CO2 and left to incubate for a period of 24 hours 
before MFI was performed. 
 
4.2.4.2. Imaging results 
 
Following a 24-hour incubation period with 5-ALA, human SCLC tissue samples were 
removed from their culture flask and washed with sterile PBS before MFI was 
performed. The resultant intensity images obtained were subject to FR-IsoMap 
processing and these are presented in Figures 4.3B and 4.3D. Under normal white light 
conditions, both SCLC tissue samples appeared virtually identical (refer to Figures 4.3A 
and 4.3C). However with multispectral excitation, the SCLC tissue sample treated with 5-
ALA produced a strong fluorescent signal (Figure 4.3B), as opposed to only a very faint 
signal visible in the untreated control sample (Figure 4.3D). This observation was 
expected, i.e. the observation of strong fluorescent signals from 5-ALA treated SCLC 
tissue is due to accumulation of larger amounts of 5-ALA induced PpIX as compared to 
lower quantities of endogenously present PpIX in the untreated control cancer tissue.  
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Figure 4.3. White light photographs and FR-IsoMap images of human small-cell lung cancer 
(SCLC) tissues. The tissue sample in (A/B) was imaged following a 24-hour incubation 
period with the photosensitiser 5-ALA, whereas the untreated control sample in (C/D) was 
left to incubate without any drug for 24 hours in DMEM alone. The FR-IsoMap image of 
fluorescent collagen tissue phantoms from the previous chapter (Figure 3.12) is included (E).   
 
Owing to the use of a similar colour visualisation scheme and fixed reference dataset for 
embedding, the 5-ALA treated SCLC tissue (Figure 4.3B) appeared similar in colour to 
that of endogenous PpIX embedded in a collagen gel tissue phantom from the previous 
chapter (Figure 4.3E, within dashed-green box). Good correlation between the two 
different PpIX samples in different media effectively shows that FR-IsoMap can 
accurately and consistently map (classify) fluorescence from PpIX to the same discrete 
location within the defined 3D RGB colour space in different environments. Imaging 
results from this round of MFI experiments are clinically significant as they imply the 
possibility of detecting the presence of fluorescent exogenous markers amidst a highly 
scattering/absorbing environment of biological tissues. Besides demonstrating the 
possibility of using our supercontinuum imaging system as a photodynamic diagnostic 
tool, this paves the way for further MFI experiments for the detection of tumour-specific 
fluorescence signals.        
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4.2.5. Untreated ex vivo human colorectal tissue 
 
Frozen ex vivo human colorectal tissue samples were obtained from a tissue bank for the 
ensuing MFI experiments. Currently, the application of exogenous fluorophores still 
poses clinical issues with regards to target specificity and overall toxicity. The aim of 
performing MFI in this section was therefore to excite detectable levels of 
autofluorescence from endogenous fluorophores such as porphyrins and flavin adenine 
dinucleotide (FAD) from both cancer and healthy colorectal tissues as a means of 
distinguishing between the two classes.  
 
4.2.5.1. Tissue preparation, imaging and histopathology procedure 
 
Human colorectal tissue samples were sourced from Mr Kenneth Miller, Manager, the 
Cancer Research UK Primary Colorectal Tissue Bank situated at St Mark’s Hospital, 
Northwick Park (North West London Hospitals NHS Trust, London, UK). 7 frozen 
colorectal tissue samples were obtained in total, comprising 3 pieces of normal mucosa 
and 4 pieces of adenocarcinoma at various stages of differentiation. The tissues measured 
approximately 0.5 to 1.5 cm in each dimension. Prior to MFI and subsequent HRI 
procedures, colorectal tissue samples were stored in a -80.0°C freezer and thoroughly 
thawed before commencement of imaging.  
 
After completion of all MFI and HRI experiments, colorectal tissue samples were sent 
for histopathological analysis. This was for comparison of this current gold standard 
screening technique against FR-IsoMap processed HRI colour images as shown later in 
Figure 4.6. The tissue samples were processed via standard histopathology techniques 
and a consultant histopathologist blinded to the clinical details of the colorectal tissues, 
Dr Robert Goldin from the Department of Histopathology at Imperial College London, 
later confirmed the pathological diagnosis for all tissue samples. 
 
4.2.5.2. Imaging and histopathology results 
 
FR-IsoMap colour maps produced from MFI intensity images of ex vivo colorectal tissues 
did not manage to provide any conclusive differences between the various samples. This 
was possibly due to the low amounts of endogenous fluorophores present in the thawed 
tissue, leading to low levels of autofluorescence. Another factor was light absorption by 
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haemoglobin, which would cause an attenuation of the overall detected fluorescence 
signal. Since fresh (never frozen) ex vivo colorectal tissue sections have been shown to 
emit autofluorescence in previous studies at 442, 450 and 488 nm excitation (Bottiroli et 
al., 1995; Zavadil et al., 2005; Horak et al., 2006), it is presumed the freezing process led to 
a change in tissue fluorophore content and consequently the overall autofluorescence 
contribution.  
 
As such, the acquired greyscale intensity images were used to construct a fluorescence 
intensity graph for extraction of indicative scores across all individual samples as shown 
in Figure 4.4. The graph was created by calculating the average fluorescence intensity for 
each greyscale image at the respective excitation wavelengths, followed by normalisation 
using the ‘area under the curve’ technique to obtain an indication of the relative 
fluorescence emissions at each excitation wavelength. This graphical format of presenting 
the tissue fluorescence results is akin to that from conventional fluorescence 
spectroscopic studies. 
 
Two distinct peaks are seen around the 510 and 567 nm excitation points on the graph 
for all colorectal cancer tissues. At the 510 nm peak, dysplastic/cancerous tissues seemed 
to emit a lower amount of autofluorescence than normal tissues. One probable 
explanation for this occurrence are a reduction in FAD content (450 and 520 nm 
excitation maxima) and corresponding increase in NADH – an indication of higher 
metabolic activity in dysplastic/cancerous tissues as compared to normal tissues (Chance, 
1989; Banerjee et al., 1998; Drezek et al., 2001; Sokolov et al., 2002; Wu et al., 2006). At the 
567 nm peak, dysplastic/cancerous tissues were found to emit higher autofluorescence 
than normal tissues. At first, it was suspected that these peaks may have arisen due to 
troughs in the graphs caused by haemoglobin (Hb) absorption. However this was not 
found to be the case since Hb absorption bands only occur at around 415 nm, 542 nm, 
572 nm and 930 nm. This may therefore be attributed to the occurrence of a higher 
concentration of lipid bodies in tumours, which have been found to serve as sites for 
synthesis of prostaglandin-E2. This forms part of a group of hormone-like substances 
known to be involved in colorectal carcinoma cell growth and motility (Sheng et al., 2001; 
Accioly et al., 2008). 
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Figure 4.4. Normalised average autofluorescence intensity graph of human colorectal tissue 
samples. Two distinct peaks are seen around 510 and 567 nm excitation in all tissue samples, 
which are attributed to FAD and lipid bodies respectively. (Tissues disease states as reported 
by Dr Robert Goldin) 
 
Ratiometric scores were generated as a means of discrimination between normal and 
dysplastic/cancerous colorectal tissue samples. This was performed by dividing the 
normalised average fluorescence intensity values at the second 567 nm peak by that of 
the first 510 nm peak for all samples, results of which are shown in Table 4.2 together 
with histopathology reports from both histopathologists. From this 567/510 nm ratio, 
there is clear evidence that dysplastic/cancer tissue samples possess higher scores than 
normal samples, although the difference is relatively small. Representative H&E stained 
histopathology sections from selected colorectal tissues are also presented (see Figure 
4.5). These were selected to display examples of surface epithelia, crypt patterns and 
lamina propria mucosae from the various colorectal tissue disease states: normal (tissue 
T3), dysplastic adenoma (tissue T2) and moderately differentiated adenocarcinoma (tissue 
T6) (refer to Table 4.2).  
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Histopathology results 
Sample 
Tissue 
Type 
As reported by 
St Mark’s Hospital 
histopathologist of 
tissues resectioned from 
a neighbouring area to 
the actual biopsied site  
As reported by  
Dr Robert Goldin  
of actual biopsied 
tissues                
567/510 nm 
ratio 
T1 Rectum 
Moderately differentiated 
adenocarcinoma,  
Dukes C1 
Carcinoma 2.0003 
T2 
Sigmoid 
colon 
Moderately differentiated 
adenocarcinoma,  
Dukes C1 
Dysplastic adenoma 2.0655 
T3 Colon Normal mucosa Normal mucosa 1.9563 
T4 
Sigmoid 
colon 
Moderately differentiated 
adenocarcinoma,  
Dukes B 
Dysplastic adenoma 
and possible 
carcinoma 
2.0927 
T5 Right colon 
Poorly differentiated 
adenocarcinoma,  
Dukes B 
Normal mucosa 1.9563 
T6 
Descending 
colon 
Moderately differentiated 
adenocarcinoma,  
Dukes D 
Moderately 
differentiated 
adenocarcinoma 
1.9864 
T7 Colon Normal mucosa Normal mucosa 1.9562 
 
Table 4.2. List of tissue types, 567/510 nm ratiometric scores and disease states of the imaged 
ex vivo human colorectal tissue samples as evaluated by two separate histopathologists. 
 
 
 
Figure 4.5. Selected representative H&E stained histopathology sections of the imaged 
human colorectal tissue samples. Each is an example of a different disease state: normal 
mucosa (T3); dysplastic adenoma (T2); moderately differentiated adenocarcinoma (T6) 
(based on the histopathology report from Dr Robert Goldin).  
  
124 
MFI experiments performed in section 4.2 utilised excitation spectra generated by a 
supercontinuum fibre laser between the wavelengths of 465 and 645 nm. This spectral 
range is recognised to be towards the longer end of biological autofluorescence interest. 
More autofluorescence could have been elicited from endogenous fluorophores present 
in colorectal tissue such as the structural proteins collagen and elastin, and the amino 
acids tryptophan and tyrosine if spectral coverage of the laser was tuned to below 400 
nm. This hypothesis warrants further experiments employing a different optical setup, 
although this may raise several biological safety issues mostly concerning exposure to 
ultraviolet (10 to 400 nm) radiation. In addition, different illumination fibres would have 
to be used in our endoscope since those currently in use would cause significant 
attenuation of any excitation light below 400 nm.    
 
 
4.3. Detecting diffuse reflectance signals from ex vivo colorectal cancer 
tissues 
 
Hyperspectral reflectance imaging (HRI) was performed on all healthy and cancerous ex 
vivo human colorectal tissue samples. For ease of data manipulation and analysis, 
individual images obtained from each tissue sample per excitation wavelength were 
stitched together to form a single combined intensity image. FR-IsoMap was then used 
to process the whole stack of combined greyscale intensity images to generate a final 
RGB colour map image as shown in Figure 4.6, where obvious differences in colour and 
contrast are discernable between the various tissue samples. This is most likely due to 
structural variation between different tissue disease states, e.g. mucosal thickening and 
increased microvasculature in tumour tissues, ultimately resulting in changes in optical 
absorption and scattering properties. This led to different diffuse reflectance signals 
being recorded from healthy and cancer tissues.  
 
An obvious trend is noticeable in the HRI FR-IsoMap image (Figure 4.6): cancerous and 
dysplastic tissues (i.e. samples T1, T2, T4 and T6) appear a dull pink or purplish colour as 
compared to the more contrasting and brightly coloured blue and greenish normal tissue 
samples (samples T3 and T7). With the exception of colorectal tissue sample T5, FR-
IsoMap processed HRI images therefore displayed good correlation with histopathology 
results on the whole (refer to Table 4.2). This demonstrated the ability of our imaging 
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system to elicit spectral differences in both healthy and cancerous human colorectal 
tissues, as well as demonstrates the discriminatory effectiveness of the FR-IsoMap 
processing technique.  
 
 
 
Figure 4.6. FR-IsoMap image obtained from the processing of amalgamated intensity image 
datasets acquired during HRI of human colorectal cancer tissue. Note: The HSV 
representation value plane of the final image was modified to account for the integrated 
fluorescence intensity at each pixel.   
 
There was however an inconsistency with tissue sample T5, which had differing disease 
classifications: the sample given the grading of “moderately differentiated 
adenocarcinoma, Dukes B” by the histopathologist from St Mark’s Hospital, whilst our 
histopathologist collaborator, Dr Robert Goldin, diagnosed it as “normal mucosa” (refer 
to Table 4.2). This could have been due to natural tissue variation and the sampling of 
tissue from neighbouring biopsy sites by the St Mark’s histopathologist as opposed to the 
actual piece of biopsied tissue that was tested by Dr Goldin. Based on the FR-IsoMap 
image, our technique has classified sample T5 as being similar to the other dysplastic 
adenomatous tissue samples, namely samples T4 and T6, with similar colour and contrast 
visible between all three (Figure 4.6). Such histopathological discrepancies in interpreting 
disease states highlight the ongoing challenge in validating the effectiveness of various 
biophotonic techniques - an issue affecting the field as a whole of which no satisfactory 
solution has been found at present. Barring intra- and inter-observer variability, it is only 
through a standardised grading scheme that a conclusive outcome may be reached.    
 
An integral part of colorectal cancer diagnosis is staging of the disease according to how 
far the cancer has spread in the body. Staging is performed following various clinical tests 
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such as a barium enema, sigmoidoscopy or colonoscopy, or imaging procedures e.g. 
MRI, CT or ultrasound. Two common colorectal cancer grading systems are in use: 1) 
the Dukes grading system, consisting of four stages from A to D in increasing order of 
disease severity, and 2) the TNM (Tumour Node Metastasis) classification system, which 
is gradually taking over from the Dukes system - T (1 to 4) describes the size of the 
tumour and its degree of invasiveness through the mucosal wall, N (1 or 2) describes the 
presence of cancer cells in the lymph nodes and M (0 or 1) gives an indication as to 
whether the cancer has spread to other organs throughout the body (i.e. undergone 
metastasis).  
 
Since different colours in the FR-IsoMap RGB images correspond to different tissue 
disease states, increased utility of the technique could be achieved by matching different 
colours to those of various tissue stages from either the Dukes (only stages A and B) or 
TNM classification systems. Such colour coding according to established cancer staging 
systems will speed up diagnosis rates and allow for more straightforward correlation 
between imaging results and histopathology should the need arise. To attain such 
accurate degrees of correlation, further MFI and HRI experiments should be performed 
on different in vivo and ex vivo tissues of varying disease states for more complete spectral 
characterisation with our imaging system. This would also lead to the generation of a 
more comprehensive FR-IsoMap training set for added precision in colour mapping of 
different disease classes.  
 
 
4.4. Summary 
 
MFI and HRI experiments performed in this chapter were geared towards further 
development of our proposed in vivo, in situ multimodal optical imaging system using ex 
vivo biological tissue samples. As a follow-up from earlier experiments involving 
fluorescent dyes and collagen tissue phantoms, ex vivo imaging was carried out on dye-
stained healthy lamb kidney tissue, 5-aminolevulinic (5-ALA) photosensitiser-treated 
human small-cell lung cancer (SCLC) tissue and untreated healthy and cancerous human 
colorectal tissues for characterising and understanding the spectral signals that would be 
obtained during future in vivo procedures. As before, all acquired greyscale intensity 
images of the ex vivo tissues were subject to further processing using the FR-IsoMap 
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dimensionality reduction algorithm, resulting in the generation of an RGB colour map of 
the imaged region for qualitative disease assessment.  
 
MFI performed on ex vivo dye-stained kidneys showed that the ‘regional’ tissue sampling 
approach of our macroscopic imaging technique could be used as an effective ‘red-flag’ 
to target tumour tissue-specific fluorescent agents for further optical or physical biopsies. 
Examples of these exogenous fluorophores include quantum dots, dendrimers and dye-
antibody tags.  
 
The ability of the multimodal imaging system to function as a photodynamic diagnostic 
(PDD) tool was also effectively demonstrated via successful detection of 5-ALA induced 
tumour-specific protoporphyrin IX (PpIX) fluorescence from ex vivo SCLC tissue 
samples. 5-ALA treated and untreated SCLC tissues were clearly differentiated based on 
differences in photosensitiser fluorescence during MFI. 
 
MFI experiments were carried out on untreated ex vivo healthy and cancer human 
colorectal tissues to ascertain if discrimination between different disease states could be 
achieved using only autofluorescence and diffuse reflectance signals. MFI did not detect 
sufficient autofluorescence from the tissue samples for a conclusive FR-IsoMap analysis. 
Therefore, fluorescence intensity graphs were constructed, which managed to allow 
discrimination between the different tissue disease states based on autofluorescence 
peaks from FAD and possibly lipid bodies (510 and 567 nm respectively). A ratiometric 
analysis was also performed on fluorescence intensities obtained at these peaks, resulting 
in different ratiometric scores obtained between the different colorectal tissue samples. 
In addition to MFI, HRI was also performed on the untreated ex vivo colorectal tissue. 
Good discrimination was obtained from the resulting FR-IsoMap RGB image with 
dysplastic/cancerous and normal tissue samples appearing differently coloured.  
 
HRI FR-IsoMap images and MFI intensity graphs achieved good correlation with 
histopathology overall. In the long term, greater utility is expected from the technique by 
coupling of FR-IsoMap classification with established disease staging systems such as 
Dukes or TNM. Further ex vivo and in vivo MFI and HRI experiments are expected so as 
to properly characterise the system and build up a comprehensive FR-IsoMap training 
set for more efficient and accurate colour mapping of disease conditions.      
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5.1.  Introduction 
 
This chapter presents preliminary results from imaging work performed on various in 
vitro human hepatocellular and ovarian cancer cell lines with the CellvizioGI fluorescence 
confocal endomicroscope system. Our aim was to evaluate the microscopic cellular 
imaging properties of the system as a method for ex vivo cellular analysis and also to 
better understand the contrast found during future in vivo in situ work. A short 
introduction is included, which covers the principles behind conventional fluorescence 
confocal microscopy and the development of novel in vivo confocal imaging systems. 
Various motivations supporting fluorescence confocal endomicroscopy (FCE) as a 
technique for early cancer detection and diagnosis are also discussed.  
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The first series of FCE experiments set out to evaluate the overall image quality and 
contrast obtained when applying a selection of different exogenous fluorescent contrast 
agents during imaging. The fluorescent agents used, namely fluorescein (FL), acriflavine 
hydrochloride (AH) and acridine orange (AO), were assessed during FCE imaging of an 
in vitro human hepatocellular carcinoma cell line, HepG2, with the aim of selecting the 
optimal contrast agent for all future FCE experiments. 
 
Imaging results are also presented from FCE imaging of three in vitro human ovarian 
adenocarcinoma cell lines – SKOV-5, OVCAR-5 and IGROV-1 – that had earlier been 
exposed to the platinum-based chemotherapy drug cisplatin. The aim of this study was to 
explore the use of FCE as a possible method for monitoring cisplatin chemotherapy 
response of ovarian adenocarcinoma cells at the cellular level in vivo. Response to 
chemotherapy was determined over a five-day drug exposure period by assessment of 
both cell numbers and cellular morphology using FCE.  
 
 
5.2. Classical fluorescence confocal microscopy and the move towards 
novel in vivo systems 
 
Classical fluorescence confocal microscopy was born out of the need for a more effective 
and higher-resolution method for viewing biological specimens, especially thicker 
diffusing samples of tissue (Webb, 1996; Wilson, 2003). The method offers a marked 
improvement over conventional light microscopy in that it allows a greater reduction in 
out-of-focus light – extraneous signals produced from structures present on top of and 
below the desired focal plane – providing a clear, fine-detailed and focused image from a 
thin section within the tissue sample (White et al., 1987). This is achieved due to the 
specimen being illuminated by a point source of light, usually a laser beam, which is 
focused to a single spot in the sample, with the emitted fluorescence signals detected via 
a spatially restricted pinhole detector (Wilson, 2003) (Figure 5.1). Since interior sections 
of thicker tissue pieces (up to ~500 !m) can be effectively imaged, this eliminates the 
need for physical sectioning and mounting of the specimen on a microscope slide, hence 
allowing samples to be viewed in their natural state. The possibility of scanning deeper 
through samples point-by-point in various optical sections also allows a three-
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dimensional image of the tissue specimen to be reconstructed for more complete 
visualisation.  
 
 
 
Figure 5.1. Diagrammatic representation of fluorescence confocal microscopy (A) and 
conventional light microscopy (B) techniques. The presence of the pinhole aperture in the 
confocal microscope system enables rejection of out-of-focus light rays, resulting in the 
production of a clearer, finer detailed and more focused image from a thin section within the 
specimen than conventional light microscopy. Absence of a pinhole aperture in the latter 
system allows collection of both in-focus and out-of-focus light from a thicker plane of the 
specimen, resulting in obscuration of finer details in the ensuing image. 
 
Recent advances in the field have enabled miniaturisation of the bench-top fluorescence 
confocal microscope into a more portable probe-based imaging system for use in an 
endoscopic setting (Evans and Nishioka, 2005; Kiesslich et al., 2007; Kiesslich and Tajiri, 
2010). Such systems, known as fluorescence confocal endomicroscopes or fluorescence 
endoconfocal microscopes, enable minimally invasive imaging of the human body in vivo 
and in situ, generating real-time cellular-level en face images with a similar resolution to 
histology – a procedure termed the ‘optical biopsy’. There are two such fluorescence 
confocal endomicroscope systems currently in commercial production, one produced 
jointly between Pentax (Tokyo, Japan) and Optiscan (Victoria, Australia), and the other 
by Mauna Kea Technologies (Paris, France) and known as the CellvizioGI. Though 
similar in function, the systems differ in optical instrumentation setup: the 
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Pentax/Optiscan system comprises a complete endoscope with a miniaturised scanning 
confocal microscope incorporated at its tip, while the CellvizioGI is a probe-based 
system whose confocal miniprobe can be inserted down the accessory channel of any 
standard endoscope (Dunbar and Canto, 2008). In the interest of compatibility with 
current research in our group, we have chosen to work with the CellvizioGI system for 
all our FCE experiments.  
 
The CellvizioGI system is compatible with most existing endoscope systems and consists 
of three core components: 1) a laser scanning unit (LSU), 2) a desktop computer unit 
containing the system controls and image processing software, and 3) a flexible fibered 
confocal miniprobe that is placed in contact with tissue surfaces during image acquisition 
(Laemmel et al., 2004, Wang et al., 2007). Different confocal miniprobes are available 
depending on the diagnostic application: the GastroFlex for oeso-gastro-duodenoscopy, 
the CholangioFlex for endoscopic retrograde cholangiopancreatography (ERCP), the 
ColoFlex for colonoscopy and the AlveoFlex for bronchoscopic procedures; these have 
lateral resolutions of 3.5 !m. In addition, ultra high definition (UHD) variants of the 
GastroFlex and ColoFlex miniprobes are available, which have lateral resolutions of 1.4 
!m.  
 
Two classes of the Cellvizio LSU exist, one emitting laser excitation at 488 nm and the 
other at 660 nm, with the latter system used more widely used in small animal imaging 
procedures in a setup known as the CellvizioLAB.  The CellvizioGI LSU used in our 
group emits at a wavelength of 488 nm (collection bandwidth between 500 to 650 nm), 
allowing for the elicitation of autofluorescence from tissue structures containing 
endogenous fluorophores such as elastin (420 and 500 nm absorption) flavin adenine 
dinucleotide (FAD; 450 nm absorption) and porphyrins (400 to 450 nm absorption). 
One limitation however is that tissue structures not naturally autofluorescent around the 
488 nm excitation wavelength have to be first stained with exogenous fluorescent agents 
such as fluorescein or acridine orange for creating imaging contrast, leading to possible 
toxicity concerns and ethical approval issues.  
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5.3. Motivations for tissue diagnosis with fluorescence confocal 
endomicroscopy 
 
 
 
Figure 5.2. Morphological changes occurring in the uppermost layers of tissue mucosa with 
cancer progression. 
 
For most human cancers, the earliest morphological changes occur at the uppermost 
layers of tissue. These are usually confined to the epithelium of the diseased organ, 
located within the first 150 to 200 !m of the mucosal surface (Figure 5.2). Carcinoma in 
situ (CIS) is the intermediate premalignant stage between normal and invasive/metastatic 
carcinoma, where any malignant cells remain contained within the epithelium and have 
yet to penetrate the underlying basement membrane – a process known as metastasis 
(Zhuang et al., 1995; Arpino et al., 2005). Disease progression from normal to invasive 
carcinoma has been estimated to take roughly 5 to 20 years, with the long developmental 
period between normal to CIS presenting as a possible window for early detection, 
diagnosis and treatment (Pierobon et al., 2007).  
 
Current methods for cancer diagnosis in hollow organs such as the lung, bladder and 
gastrointestinal tract involve a multi-step process: Firstly, imaging of the diseased organ is 
carried out via conventional approaches such as X-ray, CT or ultrasound to localise the 
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tumour or suspected cancerous regions. Since it is not possible to extract microscopic, 
cellular-level information from the diseased tissue via these modalities, further analysis 
has to be carried out on the tissue histologically. Therefore, pinch biopsies of the suspect 
regions are next performed minimally-invasively using a pair of endoscopic forceps. This 
stage of the sampling process may be random in nature, for instance due to the white-
light imaging approach of the video endoscope, which makes it difficult to differentiate 
normal from diseased tissue even for the most experienced of operators, especially 
during early cancer onset. Consequently, biopsied tissue samples are then sent to a 
pathologist where they are fixed, sectioned and mounted on a microscope slide for 
histological examination. It is essential to note however that such processing eliminates 
the opportunity to obtain morphological and functional features of tissues that would 
have otherwise been present in its fresh and unprocessed form, resulting in a possible 
loss of important diagnostic information. Although it can be performed intrasurgically, 
this process from initial imaging of suspect tissue regions to confirmation of the disease 
by a pathologist typically requires several weeks to complete, leading to a delay in the 
implementation of treatment.  
 
To date, FCE has been employed by various groups for the successful visualisation of 
malignant tissue changes in the upper- and lower-gastrointestinal tract (Hoffman et al., 
2006), lungs (Thiberville et al., 2007), ovaries (Tanbakuchi et al., 2008) and bladder (Sonn 
et al., 2009). Compared to conventional screening methods, FCE has the potential to 
detect cancers earlier during the course of the disease and in a shorter amount of time. 
Via this optical biopsy approach, in vivo information on tissue morphology can be 
accurately obtained in real time and at high resolution, dramatically reducing patient 
waiting times and eliminating the requirement for random tissue biopsies. Another 
distinct advantage of the FCE system is its ease of operation and portability, allowing for 
use even by non-expert operators. In the long run therefore, patients will benefit from 
having reduced waiting times as well as lowered healthcare costs. 
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5.4. Fluorescence confocal endomicroscopy for cellular characterisation 
 
5.4.1. Optical instrumentation and image acquisition 
 
The CellvizioGI fluorescence confocal endomicroscope system is based on the principles 
of classical fluorescence confocal microscopy and was designed to complement currently 
available imaging techniques such as MRI, CT, PET, ultrasound, SPECT, etc., effectively 
serving as the link between macroscopic imaging modalities more commonplace in the 
clinic with conventional bench-top microscope systems popular in the field of biology.  
All our experiments utilised the GastroFlex Type Z confocal miniprobe.  
 
During data acquisition, the excitation beam produced by the 488 nm semiconductor 
laser of the laser scanning unit (LSU) is scanned by two mirrors located at the proximal 
end of the miniprobe: a 4 kHz oscillating mirror that scans horizontally (line scanning) 
and a 12 kHz galvanometric mirror that scans vertically (frame scanning). The laser beam 
is thereby raster scanned across the proximal face of the GastroFlex Type Z confocal 
miniprobe (2.6 mm outer diamter) containing about 30,000 individual optical fibres at a 
resultant frame rate of 12 kHz. The laser beam that is directed sequentially into each 
optical fibre is then focused onto the target specimen by a distally-located gradient index 
micro-objective lens that has a 0 !m working distance, 600 !m field of view, and lateral 
and depth resolution of 3.5 !m and 15 !m respectively. Images are acquired en face at a 
rate of 12 frames per second at a depth of between 80 to 120 !m and in 70 !m optical 
sections. The resulting fluorescence from the excited specimen is subsequently collected 
by the micro-objective lens and is refocused back into the same illumination fibre that 
was used for excitation. The confocality of the CellvizioGI system is conferred by the 
small diameter of each optical fibre core (1.9 !m), which effectively functions as a 
pinhole, restricting out-of-focus light during both initial excitation and image acquisition. 
The final raw image is then reconstructed from the fluorescence intensity measurements 
detected by an avalanche photodiode, with a longpass filter in place to reject any 
reflected excitation light. 
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5.4.2. Optimal contrast agent selection using hepatocellular carcinoma cells 
 
Initial FCE experiments were performed on HepG2 hepatocellular carcinoma cells 
originating from the liver of a 15-year-old Caucasian male (Knowles et al., 1980). The 
cells were stained with different fluorescent contrast agents to establish the dye that 
provided optimal image contrast during FCE imaging. Three popular contrast agents 
were investigated: acridine orange (AO), fluorescein (FL) and acriflavine hydrochloride 
(AH). AO is a commonly used fluorescent agent for confocal microscopy and 
endomicroscopy that preferentially stains nuclear DNA and cytoplasmic RNA (Rouse 
and Gmitro, 2000; Gareau et al., 2008). FL has many applications in biomedicine, e.g. 
fluorescein angiography for examination of the retina of the eye and also for cell labelling 
during flow cytometry procedures (Flowers, 1973; Darzynkiewicz et al., 2000). FL has 
been found to stain the cell cytoplasm as well as the extracellular matrix (Paramsothy and 
Leong, 2010). AH is the next most widely used contrast agent after FL, which binds 
predominantly to nuclear DNA with high affinity (Roth et al., 1967; Paramsothy and 
Leong, 2010).     
 
With regards to health and safety concerns of the contrast agents used, FL and AH 
exhibit very low risk of cytotoxicity, with both dyes approved by the United States Food 
and Drug Adminstration (FDA) – the former for in vivo applications and the latter for use 
in a number of selected in vivo procedures. AO has also recently been awarded FDA 
approval (investigational new drug 102603) for in vivo imaging of the ovaries within an 
endobag (Tanbakuchi et al., 2010). In this manner, the contrast agent is contained within 
the endobag during imaging and is thus prevented from spreading to other neighbouring 
organs. Nonetheless, AO has been recognised to be moderately cytotoxic in nature, 
which limits its in vivo application in humans. 
 
5.4.2.1. Sample preparation and imaging procedure 
 
HepG2 carcinoma cells were obtained from Dr Eileen Gentleman, Research Associate, 
Department of Materials, Imperial College London and cultured in 35 mm diameter 
plastic cell-culture dishes containing sterile Dulbecco's Modified Eagle’s Medium 
(DMEM) solution, 10% foetal bovine serum (FBS) and incubated at 37°C and 5% CO2. 
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The cells were allowed to grow until a confluent layer was formed, a process taking about 
2 to 3 days, before FCE imaging was carried out.  
 
All three contrast agents chosen for comparison were made up in different 
concentrations – FL: 0.05 mM, AH: 0.05% w/v and AO: 3.0 !g/ml. These 
concentrations were chosen after a survey of the literature to identify commonly used 
concentrations for each respective dye. Contrast agents were topically applied into each 
cell-culture dish containing 2 ml of HepG2 cells and culture media until the desired final 
concentration was attained approximately two minutes before FCE imaging was 
performed. It was thought originally that DMEM might possibly interfere with the 
recorded signal, requiring it to be removed from the cell-culture dishes and replaced with 
1x phosphate buffered saline (PBS) and contrast agents prior to imaging. Upon several 
attempts however, it was observed that a large proportion of cells were being dislodged 
from the surface of the dish during removal of the liquid. DMEM was therefore left in 
the dish with the cells, whilst contrast agents were gently introduced directly with a 
pipette since DMEM was not found to be fluorescent at 488 nm and as such did not 
interfere with the final results. 
 
The CellvizioGI system was switched on 15 minutes prior to imaging to allow for 
warming up of the confocal miniprobe and semiconductor laser. Automatic control of 
the laser’s output power by the system was also disabled under the image acquisition 
software’s preferences panel so that the final images obtained would not be automatically 
adjusted for minor intensity variations that might arise as a result of the sample itself. 
Prior to system calibration, the miniprobe lens head was first washed with 70% ethanol 
followed by distilled water before being wiped dry with a soft paper towel. Calibration 
was performed with the miniprobe’s head pointing away from any object and held in air. 
This process took roughly 45 seconds and was performed each time a different sample 
was being imaged or once every 20 minutes if it was the same sample that was being 
studied. During image acquisition, the miniprobe was held in place using a miniature V-
clamp (VH-1; Thorlabs, Ltd., Cambridgeshire, UK) and was lowered steadily until the 
miniprobe’s lens was in contact with the sample, i.e. until the sample came into view on 
the computer screen. For imaging of cells, the plastic cell-culture dishes in which they 
were grown were placed on top of a small translation stage (NanoMax MAX302/M; 
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Thorlabs, Ltd., Cambridgeshire, UK), allowing for minute translational adjustments in 
the X, Y and Z axes during image acquisition with the confocal miniprobe.  
 
5.4.2.2. Imaging results  
 
Performing FCE imaging with the three aforementioned contrast agents produced results 
of markedly differing image quality and contrast (Figure 5.3). Visual inspection of the 
results showed that FL produced images with the lowest contrast, which resulted in the 
background noise appearing more significant (Figure 5.3A). Imaging with AH produced 
images with slightly improved contrast (Figure 5.3B). Optimal image contrast i.e. clear 
visual distinction between the brightly fluorescent HepG2 cells and dark background was 
achieved when imaging with AO, resulting in images with the appearance of no or very 
low background noise (Figure 5.3C).  
 
 
 
Figure 5.3. HepG2 human hepatocellular carcinoma cells stained with different contrast 
agents during FCE imaging: fluorescein (FL; 0.05 mM) (A), acriflavine hydrochloride (AH; 
0.05% w/v) (B) and acridine orange (AO; 3.0 !g/ml) (C). Optimum image contrast is 
achieved when imaging with AO. 
 
Since no quantitative information on pixel intensity was available at this point, FCE 
images were further analysed using MatLab (The Mathworks, Inc., MA, USA) to 
determine the signal intensity to background ratios (SBRs) for all three image sets. This 
provides an indication of how distinct the fluorescence signal was from the background: 
the greater the ratio, the better the image contrast achieved. This was performed by 
calculating the mean intensity of an approximately 15 by 15 pixel region of cells in the 
image, and dividing this by the standard deviation of the pixel intensities from a 
neighbouring background region of the same area size. Results from this analysis are 
presented as a bar chart in Figure 5.4: FCE imaging with FL and AH produced images 
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with an average SBR of about 35 and 62 respectively. On the other hand, imaging with 
AO resulted in images with an average SBR of about 150 – more than twice that 
achieved with AH. Conclusively, AO was found to provide optimal image contrast out of 
all three contrast agents during FCE. 
 
 
 
Figure 5.4. Bar chart representing the signal to background ratios (SBRs) obtained when 
HepG2 cells are stained with different contrast agents during FCE imaging. FCE images of 
HepG2 cells stained with acridine orange (AO) (Figure 5.3C) have the largest SBRs, as 
compared to fluorescein (FL) and acriflavine hydrochloride (AH) (Figures 5.3A and 5.3B 
respectively), indicating comparatively better image contrast. 
 
5.4.3. Evaluating chemotherapy response of ovarian adenocarcinoma cells 
 
Ovarian cancer is currently the fifth most common cancer amongst women in the UK 
with epithelial ovarian cancer – or cancer of the outer ovarian tissue layer - making up 
90% of all reported cases (CancerHelp UK website). Like most cancers, treatment 
involves either surgery, radiotherapy, chemotherapy or a combination of these methods, 
depending on the stage of the disease.  
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Assessing the variable response of ovarian cancer to chemotherapy typically takes several 
months using currently available detection methods. These include radiological scans 
such as CT and ultrasound, as well as blood tests for the CA 125 tumour marker. 
Recently, the minimally invasive second-look laparascopy technique has also generated 
significant interest for detecting ovarian cancer recurrence (Davila and Estape, 2001). 
However this white light-based imaging approach has also been shown to have high 
false-negative detection rates of about 55%, with limited sensitivity and optical resolution 
for detecting small residual tumour nodules (Zhong et al., 2009).     
 
Since it is possible to perform imaging at the cellular level with FCE, earlier assessment 
of chemotherapy response could be achieved by monitoring the morphological changes 
occurring within the tumour during chemotherapy via such a minimally invasive (MI) 
endoscopic imaging modality. Our hypothesis was that there would be quantifiable 
evidence of cellular attrition across all ovarian adenocarcinoma cell lines following 
incubation with cisplatin, together with a noticeable change in cellular morphology. 
Therefore as a prelude to future imaging experiments involving chemotherapy-treated 
ovarian cancer tissue, we first ascertained if response to chemotherapy could be detected 
from cisplatin-exposed in vitro human ovarian adenocarcinoma cell lines using FCE 
imaging. Possible parameters evaluated in vitro included cellular morphology and 
fluorescence signal changes with different cisplatin doses as well as what signals that 
could be expected when imaging cells undergoing apoptosis (programmed cell death) as a 
result of cisplatin exposure.  
 
5.4.3.1. Sample preparation and imaging procedure 
 
Cisplatin (cis-diamminedichloroplatinum(II)) is a platinum (II) complex consisting of a 
central platinum ion surrounded by two ammonia groups (-NH3) in the cis position and 
two chloride (-Cl) ligands that dissociate when the molecule becomes bound to duplex 
DNA (Figure 5.5) (Go and Adjei, 1999). Cisplatin, together with carboplatin and 
oxaliplatin, make up a class of platinum-based chemotherapy drugs currently in 
widespread clinical use for the treatment of human malignancies (Alderden et al., 2006). 
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Figure 5.5. The 3D molecular structure of the cisplatin (cis-diamminedichloroplatinum(II)) 
molecule consisting of a central platinum ion surrounded by two ammonia groups in the cis 
position and two chloride ligands (the ‘leaving’ groups). 
 
Since the serendipitous discovery of its anticancer activity by Rosenberg and colleagues at 
the University of Michigan in the 1960s, cisplatin has been demonstrated to be highly 
effective against several cancers, particularly those of the testes and ovaries, with overall 
cure rates for testicular cancer exceeding 90% and reaching nearly 100% if the disease is 
treated in its early stages and following additional surgery (Wang and Lippard 2005, 
Alderden et al., 2006). In addition, cisplatin has shown significant efficacy during 
chemotherapeutic treatments for cancers of the head and neck, cervix, bladder, 
oesophagus, as well as both small- and non-small cell lung cancers (Go and Adjei 1999, 
Wang and Lippard 2005).   
 
Various studies have indicated that cisplatin mediates its anticancer activity by forming a 
variety of covalent DNA adducts, whereby the central platinum ion becomes bound to 
the N7 positions of adjacent purine bases, guanine and/or adenine, which make up the 
DNA backbone (Hambley 1997, Go and Adjei 1999, Zamble and Lippard 1995, 
Alderden et al., 2006). This predominantly results in the formation of two major 
intrastrand bifunctional adducts: one with GpG sequences (60% or more) and the other 
with ApG sequences (about 25%); other crosslinks that may form occasionally include 
monofunctional intrastrand, interstrand and protein-DNA adducts (Figure 5.6) (Zamble 
and Lippard 1995, Lippert, 1999).  
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Figure 5.6. Cisplatin molecule binding to DNA to form various adducts: intrastrand 
bifunctional adduct (A); interstrand bifunctional adduct (B); monofunctional adduct (C); 
protein-DNA adduct (D). X denotes the purine base i.e. guanine or adenine, which becomes 
bound to the central platinum ion of the cisplatin molecule. (Figure adapted from Zamble 
and Lippard, 1995) 
 
The consequence of this is tumour cell-cycle arrest at the G1, S or G2 phases of cell 
division and ultimately apoptosis due to a breakdown in DNA repair mechanisms 
(Lippert, 1999, Go and Adjei 1999, Alderden et al., 2006). Other cellular events 
influenced by the action of cisplatin may include the inhibition of sodium-potassium 
dependent adenosine triphosphate (ATP) hydrolysis activity, altered mitochondrial and 
calcium channel functioning, and altered amino acid transport (Go and Adjei, 1999; 
Shionoya et al., 1986; Guarino et al., 1979; Vassilev et al., 1987; Gordon and Gattone, 
1986). 
 
In order to assess the signals expected both ex vivo and in vivo in situ, we set out to 
characterise the response of human ovarian adenocarcinoma cells to the chemotherapy 
drug cisplatin. Three cell lines were studied: SKOV-5, OVCAR-5 and IGROV-1, all of 
which were sourced from our clinical collaborator at Hammersmith Hospital (Imperial 
College Healthcare NHS Trust), Dr Sadaf Ghaem-Maghami, Clinical Senior Lecturer, 
Division of Surgery, Oncology, Reproductive Biology and Anaesthetics, Imperial College 
London. SKOV-5 adenocarcinoma cells are clones of the SKOV-3 cell line derived from 
the ovarian carcinoma ascitic fluid of a 64-year-old Caucasian female (Fogh et al., 1977); 
OVCAR-5 adenocarcinoma cells were established from an ovarian cancer patient who 
had not received prior chemotherapeutic intervention (Hamilton et al., 1989); IGROV-1 
adenocarcinoma cells were obtained from the tumour of a 47-year-old Caucasian woman 
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suffering from stage III ovarian cancer (Bénard et al., 1985). All three cells lines have 
been documented to be sensitive to the cisplatin chemotherapy drug in the literature.   
 
Cells were cultured in 35-mm plastic cell-culture dishes containing sterile RPMI 1640 
medium, 10% foetal bovine serum (FBS) and penicillin-streptomycin antibiotics. Each 
cell line was incubated at 37°C and 5% CO2 for a period of five days together with 
varying concentrations of the platinum-based chemotherapy agent cisplatin (Teva UK 
Limited): 0 !M, 2.5 !M, 5.0 !M, 25.0 !M and 75.0 !M. For OVCAR-5 adenocarcinoma 
cells, the lowest 2.5 !M cisplatin dose was replaced with a 150.0 !M concentration to see 
if there was any discernible difference at this high drug dose. Imaging was performed in 
the same manner as described in section 5.4.3.1, with cell samples placed on top of a 
translation stage during image acquisition with the confocal miniprobe.  
 
5.4.3.2. Imaging results  
 
To test our hypothesis that there would be quantifiable cellular attrition and changes in 
cell morphology with cisplatin chemotherapy, FCE imaging was performed on each 
cisplatin-exposed cell line after topical staining with acridine orange contrast agent (AO; 
3.0 !g/mL), which was previously shown to in section 5.4.2.2 to provide optimal image 
contrast during imaging of HepG2 hepatocellular carcinoma cells. FCE imaging was 
carried out approximately every 24 hours from initial addition of cisplatin up till a total 
period of five days for all ovarian adenocarcinoma cell lines incubated with different 
concentrations of the chemotherapy drug. Qualitative assessment of cellular morphology 
was done by eye and cell numbers were recorded. Given the possibility that cells would 
reach a large number over the five days of incubation and potentially make quantification 
difficult especially for control populations, the area for recording of cell numbers was 
limited to approximately 0.3 mm2 – or " the field of view of the CellvizioGI confocal 
miniprobe. Bias during the quantification process was avoided by shifting the miniprobe 
to 16 different, regularly spaced pre-determined spots in the cell culture dish for all cell 
lines by placing a white card with inked markings below the culture dish as a positioning 
guide.  
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As seen in Figure 5.7, apart from control populations, all ovarian adenocarcinoma cell 
lines incubated with cisplatin displayed greater attrition rates as a result of increased 
cellular apoptosis following the rise in chemotherapy drug concentrations. 
 
SKOV-5 cells displayed excellent response to cisplatin treatment. Although cells 
incubated with 75.0 !M cisplatin reached a higher number on day four than those 
incubated with 25.0 !M cisplatin, the trend in cell number variation and final cell counts 
obtained at the end of the experiment on day four were generally proportional to the 
concentration of cisplatin applied (Figure 5.7A). One might expect the final cell numbers 
obtained on day four with 75.0 !M and 25.0 !M cisplatin to be reversed; however this 
can be explained by the high concentration of cisplatin used (75.0 !M) which may have 
had a physiological effect on the cells, thus leading to an alteration in the trend of results, 
or perhaps also due to unequal pipetting of cells into the culture dishes at the beginning 
of the experiment.   
 
OVCAR-5 cellular attrition exhibited a similar trend to the SKOV-5 cells (see Figure 
5.7B). A higher 150.0 !M concentration of cisplatin was included in the experiment 
although the overall trend of cellular attrition remained unchanged.    
 
Like SKOV-5 and OVCAR-5, IGROV-1 also responded in a similar fashion to the 
anticancer effects of cisplatin. From Figure 5.7C, it is noticeable that the rate of cellular 
attrition is proportional to the concentration of cisplatin applied: untreated control 
populations displayed a slight general increase in cell numbers across days zero to four, 
whilst cisplatin-treated populations showed a decreasing trend with the rate of attrition 
related more or less to the level of cisplatin concentration. The IGROV-1 cell line grows 
and divides at a faster rate than SKOV-5 and OVCAR-5 cells, thus explaining the larger 
average number of 10.4 cells per 0.3 mm2 imaged area at the beginning of the experiment 
on day zero.  
 
For understanding the in vivo imaging of ovarian cancer cells it is also useful to observe 
the shapes and morphology of the cells. Cisplatin-treated ovarian adenocarcinoma cell 
lines exhibited elongated and enlarged pseudopodial protrusions - a trait that was 
particularly evident when cells were incubated with lower 2.5 !M and 5.0 !M cisplatin 
concentrations, especially in SKOV-5 and OVCAR-5 cell populations (see Figures 5.8 – 
 147 
10). Pseudopodial protrusions play an active role in tumour cell motility and migration 
(Jia et al., 2005) and their enlargement/elongation at lower cisplatin concentrations may 
not be directly linked to the effects of cisplatin alone, since such lower drug 
concentrations do not totally inhibit tumour cell growth and division as evidenced from 
Figure 5.7. It is possible that this pseudopodial enlargement/elongation occurred in 
response to normal cell growth but due to the formation of adducts by cisplatin DNA 
binding, cell division did not take place successfully. Hence the end result is larger 
individual cells containing cisplatin-bound DNA and more cytoplasmic content in the 
form of enlarged pseudopodial protrusions. Further evidence for this is that cells 
exposed to the lower cisplatin concentrations (2.5 !M and 5.0 !M) displayed distinctly 
larger cell nuclei compared to the untreated controls, providing further evidence that the 
drug mediates its anticancer effects via various binding interactions with cellular DNA as 
mentioned earlier in section 5.4.3.1.  
 
Overall, it appeared that cell size and morphology was significantly affected at the higher 
cisplatin concentrations of 25.0 !M, 75.0 !M and 150 !M: with the exception of 
IGROV-1 cells, all ovarian adenocarcinoma cells were visibly reduced in size at these 
high concentrations compared to control populations, with much smaller nuclei and no 
or very little observable pseudopodial protrusions. Owing to the small size of IGROV-1 
cells (~10 to 30 !m) and the high uptake of AO contrast agent in their nuclei, it was 
difficult to distinguish any visible difference in morphology between the controls and 
treated cells across all five days of the experiment (see Figure 5.10). As this could also be 
due to the spatial resolution of our current confocal miniprobe (3.5 !m), it would be 
useful in future work to perform this experiment again using an ultra high definition 
miniprobe with a smaller spatial resolution of 1.0 !m for improved cellular visualisation.  
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Figure 5.7. Graphs showing the average attrition rates of ovarian adenocarcinoma cell lines 
after incubation with various concentrations of cisplatin. Cells numbers were recorded 
approximately every 24 hours over a five-day period and within pre-determined areas on the 
cell culture dish: SKOV-5 cells (A), OVCAR-5 cells (B), IGROV-1 cells (C). All curves are 
coloured in the same manner according to its relative concentration within that graph. 
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Figure 5.8. FCE images of AO-stained SKOV-5 ovarian adenocarcinoma cells incubated 
with various concentrations of cisplatin over a five-day period. Cells exhibited 
elongated/enlarged pseudopodial protrusions and larger cell nuclei at 2.5 µM and 5.0 µM 
cisplatin concentrations. Cell growth was arrested above this concentration level with most 
cells appearing smaller in size than the control populations at days 3 and 5.     
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Figure 5.9. FCE images of AO-stained OVCAR-5 ovarian adenocarcinoma cells incubated 
with various concentrations of cisplatin over a five-day period. Cellular nuclei and 
pseudopodia exhibited size increases in line with cisplatin concentration increases between 0 
and 5.0 µM. Growth was inhibited at 25.0 µM and 75.0 µM cisplatin concentration, with 
treated cells appearing morphologically smaller than control populations at days 3 and 5.    
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Figure 5.10. FCE images of AO-stained IGROV-1 ovarian adenocarcinoma cells incubated 
with various concentrations of cisplatin over a five-day period. High uptake of AO contrast 
agent in addition to the small size of individual cells made it difficult to evaluate the effects 
of cisplatin based on cell morphology alone. Most cells appeared similar in size and shape 
across all five days of incubation with different cisplatin concentrations.  
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5.5. Summary  
 
Preliminary FCE experiments in this chapter have effectively demonstrated the system’s 
ability to visualise various cancer cells in high resolution and at µm scales. Imaging 
experiments involving the use of various commonly applied fluorescent contrast agents 
have also established AO as the optimal contrast agent for cellular imaging, with AO 
images having larger signal to background ratios (SBRs) achieved compared to the other 
dyes. Good uptake of AO was readily observed across all cell lines within two minutes of 
dye application with excellent staining of cell nuclei clearly visible; the strongly 
fluorescent nuclei allowed easy identification of individual cells.  
 
In addition, we have successfully shown the potential application of FCE for effective 
assessment of chemotherapy treatment outcomes. This was demonstrated on three 
cisplatin-exposed human ovarian adenocarcinoma cell lines over a five-day period, with 
chemotherapy response evaluated via changes in cellular morphology and by 
quantification of cell numbers using FCE imaging. There was an issue however with the 
morphological visualisation of IGROV-1 cells due to their small sizes and strongly 
fluorescent nuclei obscuring any fine cellular details. As a solution, we intend to use a 
higher definition confocal miniprobe with a smaller spatial resolution of 1.0 !m for 
imaging of these cells at a later date.     
 
FCE results obtained in this chapter have demonstrated the possibility of assessing 
adenocarcinoma cellular response to cisplatin chemotherapy by quantification of cell 
numbers and visualisation of cellular morphology. These will serve as useful background 
work for future studies on cancer tissues, allowing a better understanding of the signals 
and contrast that will be obtained during imaging experiments on ex vivo tissue samples 
and in vivo in situ in animal models of human cancer. 
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6.1. Introduction 
 
This chapter describes the application of fluorescence confocal endomicroscopy (FCE) 
for the characterisation of cancer and healthy states in both ex vivo and in vivo tissues from 
humans and animal models of disease. Coupled with this are preliminary FCE imaging 
studies involving in vitro primary cancer cell lines; these serve as foundation work for 
understanding signals that will be acquired during the ensuing tissue-based procedures. 
All imaging experiments were designed to interrogate the morphological or functional 
properties of cells or tissues under investigation.  
 
The chapter begins with imaging experiments on ex vivo healthy porcine tissues to study 
various biological tissue staining protocols during FCE using different fluorescent 
contrast agents, namely fluorescein (FL), acriflavine hydrochloride (AH) and acridine 
orange (AO). With the optimal contrast agent established, further FCE imaging was 
performed on ex vivo human ovarian and bladder cancer tissues following topical dye 
application. This was to characterise morphological features of tumour tissues for 
enhanced discrimination. Imaging experiments in this section were carried out to 
investigate a protocol for ex vivo tissue staining that can be eventually used in vivo, and 
also for evaluating the use of FCE as a method of performing real-time intrasurgical 
histopathology. 
 
The FCE technique was then explored as a potential photodynamic diagnostic (PDD) 
modality during imaging of 5-aminolaevulinic acid (5-ALA) photosensitiser treated in vitro 
human ovarian cancer primary cell lines, ex vivo human pharyngeal and small-cell lung 
cancer tissues, and in vivo murine tumour tissue. Our aim was to ascertain if 5-ALA 
induced protoporphyrin IX (PpIX) fluorescence originating from cancer cells and 
tumour tissues could be detected using the FCE confocal miniprobe.  
 
The possibility of imaging across different resolution scales in conjunction with positron 
emission tomography (PET) imaging was also explored by applying FCE imaging for 
detection of the tumour-specific fluorescent optical biomarker 2-[N-(7-nitrobenz-2-oxa-
1,3-diaxol-4-yl)amino]-2-deoxyglucose (2-NBDG). 2-NBDG is a fluorescently labelled 2-
deoxyglucose molecule analogous to 2-deoxy-2 [18F] fluoro-D-glucose (FDG) used in 
PET imaging that is readily taken up by actively metabolising cancer cells. Although well 
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established in the field of oncology, FDG PET imaging suffers from poor spatial 
resolution, which poses a considerable limitation especially for the purposes of early 
cancer detection. FCE imaging with 2-NBDG was thus investigated to determine if 
cellular level resolution could be achieved using the technique both in vitro and in vivo in 
human ovarian cancer cells and a murine model of ovarian cancer respectively.  
 
In addition, a novel multimodal endoscopic viewfinder (MEV) imaging approach based 
on the combination of multispectral fluorescence imaging (MFI), hyperspectral 
reflectance imaging (HRI) and FCE imaging modalities is proposed as a potential 
method for more accurate and targeted tissue diagnosis. We demonstrate this technique 
on 5-ALA photosensitiser-treated ex vivo human bladder cancer tissues. 
 
 
6.2. Characterising the morphological appearance of ex vivo healthy 
porcine tissues and human cancer tissues 
 
6.2.1. Instrumentation and imaging procedure 
 
FCE imaging was performed on in vivo healthy porcine and ex vivo human cancer tissues 
with the CellvizioGI fluorescence confocal endomicroscope system (Mauna Kea 
Technologies, France). The system’s laser emitted at 488 nm excitation and imaging was 
performed with the GastroFlex Type Z confocal miniprobe as described in section 5.4.1 
of the previous chapter.  
 
During in vivo FCE imaging of various healthy porcine internal organs, the target organ 
was held steadily by hand while the miniprobe was gently placed on the organ and 
translated slowly across its surface. Figure 6.1 shows the procedure being performed on a 
porcine ovary. Ex vivo FCE imaging of human cancer tissues were performed with the 
tissues placed in 60 mm diameter cell culture dishes. The entire imaging procedure was 
carried out by hand with the confocal miniprobe placed gently on the surface of the 
tissues and slowly moved around. It should be noted that this stage of the procedure is 
very delicate and difficult to perform due to the highly pressure-sensitive nature of the 
acquisition optics; too strong a pressure applied with the miniprobe on the tissues and 
the final FCE images obtained would be out of focus.  
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Figure 6.1. Photograph showing fluorescence confocal endomicroscopy (FCE) of a porcine 
ovary in the gloved hand of an operator. Note that the FCE confocal miniprobe is in contact 
with the surface of the ovary during image acquisition. 
 
6.2.2. In vivo imaging of healthy porcine tissues 
 
In vivo FCE imaging was performed on a terminally anaesthetised sow at the Northwick 
Park Centre for Medical Research, North West London Hospitals NHS Trust, where a 
midline laparotomy was performed on the animal to allow access to its internal organs. 
The procedure was carried out under an Animal License from the Home Office Animals 
for Scientific Procedure Act 1986 (License No. PPL 80/2297 – “The Validation of a 
Flexible Endoscopic Robot for Use in Human NOTES Applications”). Healthy in vivo 
porcine tissues imaged by FCE included those of the ovaries, bladder, peritoneum and 
spleen. Three contrast agents were topically applied to the surfaces of the animal’s target 
organs five minutes prior to imaging using a plastic Pasteur pipette: 1) acridine orange 
(AO; 10.0 !g/mL in 1x PBS), 2) acriflavine hydrochloride (AH; 0.05% w/v in 1x PBS) 
and 3) fluorescein (FL; 0.05 mM in 1x PBS). This was to find the dye that provided 
optimal image contrast during FCE imaging of biological tissues. The reader is directed 
to section 5.4.2 and its listed references for a more detailed description of each contrast 
agent and its cellular binding targets. 
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Figure 6.2. FCE images of healthy in vivo porcine tissues following topical application of 
various fluorescent contrast agents, namely acridine orange (AO; 10.0 !g/ml), fluorescein 
(FL; 0.05 mM) and acriflavine hydrochloride (AH; 0.05 % w/v). 
 
Imaging results in Figure 6.2 exhibit the varied extents by which each contrast agent 
stains the different in vivo porcine tissues. Upon visual inspection, it is evident that AO 
provides the best image contrast out of the three dyes: FCE images of AO-stained tissues 
are clear and in focus with bright fluorescent dots highlighting cell nuclei, especially in 
ovarian and splenic tissues (Figures 6.2A and I). Images of FL and AH-stained tissues on 
the other hand appear ‘hazy’ and out of focus, with limited discernable cellular features. 
Unfortunately, FCE images of AH-stained ovary and spleen were not saved due to an 
electrical error. During the FCE procedure however, AH tissue images were found to be 
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of a (poor) quality similar to that of bladder and peritoneal tissue (Figures 6.2E and H). 
As such, the final experimental outcome remained unaffected. Based on these results, 
AO was chosen as the optimal contrast agent for all subsequent FCE imaging 
experiments in this chapter.  
 
6.2.3. Ex vivo imaging of human cancer tissues 
 
Surplus and anonymised fresh human cancer tissue samples were sourced via routine 
resectioning procedures through our clinical collaborators at the Imperial College 
Healthcare NHS Trust hospitals. Informed consent was obtained from all patients prior 
to tissue resectioning and all experiments were carried out with ethical approval from the 
Outer West London Research Ethics Committee, National Research Ethics Service, 
United Kingdom (REC Reference No. 08/H0719/37 – “Multimodal Optical and 
Spectroscopic Imaging of Human Cancer Tissues Ex Vivo”).  
 
The ex vivo human cancer tissues imaged for this part of our study were obtained from 
various hospitals:  
 
i. Ovarian cancer tissue – sourced from Hammersmith Hospital, Imperial 
College Healthcare NHS Trust from Dr Sadaf Ghaem-Maghami, Clinical 
Senior Lecturer, Division of Surgery, Oncology, Reproductive Biology and 
Anaesthetics, Imperial College London, and   
ii. Bladder cancer tissue – sourced from St Mary’s Hospital and Charing Cross 
Hospital, Imperial College Healthcare NHS Trust from Mr Erik Mayer, 
Clinical Research Fellow, Division of Surgery, Oncology, Reproductive 
Biology and Anaesthetics, Imperial College London, and Mr Daniel Cohen, 
Clinical Research Fellow, Department of Surgery and Cancer, Imperial 
College London.  
 
6.2.3.1. Ovarian cancer tissue 
 
Surplus ex vivo human ovarian cancer tissue harvested during ovarian cancer debulking 
surgery were subjected to FCE imaging. The tissues were topically stained with AO (10.0 
!g/mL in 1x PBS) using a plastic Pasteur pipette five minutes prior to the start of 
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imaging; this was performed within one hour after tissues were excised from patients. 
The ovarian cancer tissues imaged measured approximately 1.0 to 3.0 cm in diameter and 
ranged from either softer stromal to firmer cyst-like specimens. Uptake of contrast agent 
was found to be excellent with various microscopic tissue structures clearly visible after 
about three minutes of AO application.  
 
 
 
Figure 6.3. FCE images of ex vivo human ovarian cancer tissues demonstrating a 
heterogeneous morphology. Imaging was performed following topical application of AO 
contrast agent (10.0 !g/mL): Softer stromal tissue regions displaying irregular cellular 
clusters and spongy, frond-like structural contours (A to C); Firmer cyst-like tissue regions 
exhibiting a diffuse, fibrous appearance with clear evidence of cellular pleomorphism and 
nuclear hyperchromatism (D to F). 
 
FCE images obtained of ex vivo ovarian cancer tissues clearly demonstrated the 
heterogeneous morphological nature of the tissues (Figure 6.3). Images recorded of the 
softer ovarian stromal tissue showed clusters of irregularly shaped cells (Figure 6.3A) and 
spongy, frond-like tissue contours (Figures 6.3B and C). The firmer cyst-like ovarian 
cancer tissue presented a more diffuse and fibrous appearance (Figures 6.3D and E) with 
evidence of cellular pleomorphism - the occurrence of many different cellular forms, and 
nuclear hyperchromatism, referring to the degeneration of cell nuclei (Figure 6.3F). As 
with healthy ex vivo porcine tissues imaged earlier in section 6.2.2, extra care had to be 
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taken during imaging to achieve the right amount of contact pressure at the tip of the 
confocal miniprobe for obtaining optimal focus and image quality.   
 
These ex vivo FCE results give a good indication as to what fluorescent signals and image 
contrast we would acquire during future in vivo tissue imaging procedures. Since ovarian 
tissue samples were imaged fresh and within one hour of surgical removal, we expect to 
visualise similar tissue microstructures in vivo. Using FCE we have managed to 
successfully characterise the morphology of cancerous ovarian tissue, demonstrating the 
possibility of applying the technique for in vivo diagnosis of diseased tissue states. Based 
on encouraging results from chapter 5 involving chemotherapy-treated ovarian 
adenocarcinoma cells, a further in vivo application of FCE could be the assessment of 
cancer tissue response to chemotherapy. This would allow the drug response of cancer 
tissues to be known in a much shorter amount of time than conventional assessment 
methods such as MRI, PET and CT imaging.   
 
6.2.3.2. Bladder cancer tissue 
 
Excess human bladder cancer tissue was obtained with informed consent from patients 
undergoing routine TURBT (transurethral resection of bladder tumour) procedures for 
removal of superficial cancerous growths on the bladder wall. The procedure involves 
insertion of a rigid tube called a cystoscope up the urethra and into the bladder, followed 
by the introduction of either a wire loop or biopsy forceps through the cystoscope for 
tissue removal. With the former, an electric current is passed through the wire loop and 
is used to ablate any tumour tissue whilst cauterising and sealing off the wound 
simultaneously – a process known as diathermy.  The use of the latter is termed a cold-
cut biopsy because tumour tissue is cut away without any burning occurring. All TURBT 
procedures were performed with patients under general or regional anaesthesia. 
 
Bladder cancer tissues were imaged with the FCE miniprobe within one hour after 
removal from the patient and topically stained with acridine orange (AO) dye (10.0 
!g/mL in 1x PBS) prior to imaging. Both cold-cut and diathermy-excised bladder cancer 
tissues were imaged and the results are presented in Figure 6.4. As with ovarian cancer 
tissues imaged previously, there was fast uptake of AO within about three minutes of 
application with cellular structures clearly visible in cold-cut samples (Figures 6.4B and 
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C). The characteristic irregular and polymorphic appearance of cancer tissues could also 
be made out (Figure 6.4C). Unstained cold-cut samples displayed only weak specks of 
autofluorescence (Figure 6.4A). This was however the opposite case for diathermy 
samples, which exhibited strong autofluorescence from the diathermied surfaces of 
unstained tissue (Figure 6.4D). The level of autofluorescence was high enough such that 
application of AO did not appear to have any effect on the acquired FCE images 
(Figures 6E and F). This was an unexpected result, and after further investigation it was 
found that the reason for autofluorescence originating from diathermied tissues may be 
attributed to heat denatured collagen and elastic fibres in the tissue dermal layers (Vo et 
al., 2001; Lin et al., 2006). This has important implications for the possible application of 
FCE for intrasurgical imaging, since thermally induced fluorescence from diathermy 
tissue dissections may obscure fluorescence emissions from the applied contrast agent. 
 
 
 
Figure 6.4. FCE images of ex vivo human bladder cancer tissues excised via transurethral 
cold-cut biopsy (A to C) or diathermy (D to F). Tissues were imaged both unstained and 
after topical application of acridine orange dye (AO; 10.0 !g/mL): unstained (A and D); AO-
stained (B, C, E and F).  
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6.3. Photodynamic diagnostic imaging of photosensitised cancer cells and 
tumour tissues 
 
The aim of this series of experiments involving the photosensitiser pro-drug 5-
aminolevulinic acid (5-ALA) was to assess the potential of applying FCE as a 
photodynamic diagnostic (PDD) modality. Using 5-ALA-treated in vitro human ovarian 
cancer cell lines, ex vivo human cancer tissues and in vivo murine tumour tissues, our aim 
was to ascertain if 1) the FCE system could effectively detect 5-ALA induced 
protoporphyrin IX (PpIX) fluorescence emissions from cancer cells and tissues, and 2) 
to track the variation in PpIX fluorescence signals in these cells and tissues over time. 
The purpose of the latter was to establish the most favourable imaging time window 
where highest fluorescence intensities could be obtained for achieving optimal image 
contrast. An additional objective was to exploit the high spatial resolution of the confocal 
miniprobe for resolving PpIX localisation in specific organelles within photosensitised 
cells in vitro and within tissues; this could serve as a possible method for distinguishing 
between different cell types and their respective functions.  
 
At the time of experiment, no suitable protocol for PDD imaging with FCE using a 
fibered confocal miniprobe had been established in the literature. As such we began 
initial FCE-PDD imaging experiments by first imaging photosensitised cell lines to 
ascertain detection of PpIX fluorescence before moving on to whole ex vivo and in vivo 
tissues. FCE imaging experiments were conducted as far as possible within an 
environment maintained at physiological conditions: cell lines were imaged in vitro within 
an incubator set at 37°C temperature and 5% CO2; ex vivo tissues were left to incubate 
with 5-ALA at 37°C temperature and 5% CO2 in an incubator most of the time and taken 
out of the solution only at 15 minute intervals for FCE imaging procedures lasting no 
longer than 30 seconds; photosensitised murine tissues were imaged in vivo immediately 
after culling of the animals.   
 
6.3.1. Photodynamic diagnosis (and therapy) 
 
The photochemotherapy of superficial tumours, a treatment modality popularly known 
as photodynamic therapy (PDT), involves administration of a class of tumour-localising, 
light-activated drugs called photosensitisers or a photosensitising pro-drug to induce 
oxidative cellular damage mediated by the reactive oxygen species for a curative or 
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palliative outcome (Dougherty et al., 1998; Henderson and Gollnick, 2003; Vrouenraets et 
al., 2003).  
 
PDT has many distinct advantages over conventional therapeutic approaches for the 
treatment of solid tumours. Since it can be implemented as a convenient outpatient 
procedure, this will correspondingly translate to shortened treatment times and lowered 
hospitalisation costs. PDT also does not adversely affect other standard cancer therapies 
such as radiotherapy and chemotherapy and can hence be applied either before, after or 
even adjuvantly. Another advantage is that PDT is cosmetically superior to surgery, 
leaving no scarring during tissue removal. Additionally, the method possesses double 
selectivity, requiring both the application of drug and the delivery of light to the affected 
area (endoscopically, if the target tissue is within the body); either component on its own 
will not induce any damaging cytotoxic effects on tissues. Most importantly, PDT can be 
repeated without the build up of toxicity or inducement of any tumour resistance and 
tissue hypersensitivity. One characteristic disadvantage of the technique however is the 
development of skin photosensitivity, requiring the patient to stay indoors and to avoid 
exposure to bright light for a few days. This side effect has since been greatly improved 
upon with each new generation of photosensitisers developed. 
 
Widely used photosensitisers such as hematoporphyrin derivative (HpD) and Photofrin 
II exhibit preferential accumulation in tumour tissue. Like all chemotherapeutic 
interventions, tissue selectivity of the applied drug is of utmost importance to ensure as 
minimal damage as possible to healthy regions of tissue surrounding the tumour. Various 
hypotheses have been put forth linking this accumulation selectivity to differences 
between normal and tumour tissue properties, although the exact mechanisms for this 
phenomenon are still unclear (Dougherty et al., 1998; Wilson, 2002). Owing to the high 
degree of tissue specificity of photosensitisers, fluorescence detection of these molecules 
has been exploited as a means of distinguishing tumour from normal tissues for the 
purpose of surgical guidance and monitoring of PDT treatment outcomes (Wilson, 2002; 
Kelty et al., 2002).  
 
A large number of PDT/PDD studies have been reported by various groups, mostly for 
the photodynamic detection and treatment of cancers in the human body. Such examples 
include PDD imaging of tumour tissues in the gastrointestinal tract (Mayinger et al., 1999; 
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Endlicher and Messmann, 2004), oesophagus (Mayinger et al., 2001; Claydon and 
Ackroyd, 2004), bladder (Denzinger and Burger, 2008; D'Hallewin et al., 2002; Bordier et 
al., 2010), breast (Ladner et al., 2001; Frei et al., 2004), oral cavity (Zheng et al., 2004; 
Hamad et al., 2009), pharyngo-larynx (Csanady et al., 2003) and ovary (Löning et al., 2004; 
Zeisser-Labouèbe et al., 2006; Zhong et al., 2009). 
 
6.3.2. 5-aminolevulinic acid and protoporphyrin IX  
 
Of the various photosensitisers currently in clinical application for PDT, much research 
has been focused around the use of the photosensitiser pro-drug 5-ALA. Unlike other 
PDT agents, 5-ALA itself does not bring about a photosensitising effect, but rather gets 
processed intracellularly to produce the endogenous photosensitiser molecule PpIX.  
 
 
 
Figure 6.5. The haem biosynthetic pathway showing the various enzymatic reactions and 
metabolic precursors involved leading to the production of haem in normal cells. 
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Both 5-ALA and PpIX are naturally occurring metabolic precursors present along the 
pathway for haem biosynthesis (Kennedy et al., 1992; Peng et al., 1997; Barto"ová and 
Hrkal, 2000) (refer to Figure 6.5). Synthesis of 5-ALA is the initial step in this three-stage 
process, which occurs in the mitochondrial matrix between succinyl-coenzyme A 
(succinyl-CoA) and the amino acid glycine, and is catalysed by the enzyme ALA-synthase 
(ALAS). In the next stage, 5-ALA migrates from the mitochondrial matrix into the 
intercellular cytosol where its two molecules undergo a condensation reaction in the 
presence of the cytosolic enzyme ALA-dehydratase (ALAD) to form porphobilinogen 
(PBG). PBG goes through a further series of sequential reactions involving catalysis by a 
host of different enzymes – deamination (by PBG-deaminase), decarboxylation (by 
uroporphyrinogen-decarboxylase) and then oxidation (by coproporphyrinogen-oxidase 
and protoporphyrinogen-oxidase) – to produce PpIX. The final stage of the pathway 
involves the incorporation of iron (Fe2+) to PpIX to produce haem, a reaction localised 
in the mitochondrial matrix and catalysed by the inner-membrane enzyme ferrochelatase. 
 
The haem biosynthetic pathway has been found to be disrupted during malignant tissue 
transformations, resulting in altered enzymatic activity. For instance, the activity of 
porphobilinogen-deaminase (PBGD), which converts PBG to uroporphyrinogen, was 
found to be elevated in certain tumours (Schoenfeld et al., 1988; Kondo et al., 1993), 
whereas that of the ferrochelatase enzyme, which catalyses haem production from iron 
and PpIX, was found to be lowered (Rubino et al., 1966; Kondo et al., 1993; El-Sharabasy 
et al., 1992; van Hillegersberg et al., 1992). As a consequence, increased PpIX 
accumulation was observed in tumour cells, indicating that these are significantly more 
photosensitised than normal cells and are as such natural targets for PDT. This implies 
that the introduction of more 5-ALA into the pathway would cause a corresponding 
increase in the amount of PpIX being produced in these malignant tumour cells, hence 
allowing for more targeted detection of cancer tissue via photodynamic detection of 
PpIX fluorescence.  
 
6.3.3. Instrumentation and imaging procedure  
 
As with section 6.2.1, FCE imaging was performed with the CellvizioGI system from 
Mauna Kea Technologies (France) using the GastroFlex Type Z confocal miniprobe. 5-
ALA photosensitised in vitro human cancer cell lines and ex vivo human cancer tissues 
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were examined using a time-lapse imaging approach with images acquired every five 
minutes per cell/tissue sample. The setup of the imaging procedure was identical to 
section 5.4.2.1, with cancer cells imaged on a fixed translation stage for fine !m lateral 
adjustment of the culture dishes and the utilisation of a V-clamp to hold the confocal 
miniprobe firmly in place. Ex vivo cancer tissue samples and in vivo murine tissues were 
imaged by hand, with the former procedure performed in 60 mm diameter plastic dishes 
(as in section 6.2.1). Automatic control of the CellvizioGI system’s laser was set to the 
‘off’ mode to prevent automated adjustment of laser power for boosting signal strength 
during episodes of low fluorescence. This was to allow for a fair comparison of intensity 
values across all images and samples. 
 
6.3.4. In vitro imaging of photosensitised human ovarian cancer cells 
 
Three human primary ovarian cancer cell lines studied previously i.e. SKOV-5, OVCAR-
5 and IGROV-1 (see chapter 5.4.3) were chosen as targets for photodynamic diagnosis 
with FCE-PDD imaging. These were cultured under standard physiological conditions in 
35 mm plastic cell-culture dishes containing sterile RPMI 1640 media, 10% foetal calf 
serum (FCS), penicillin-streptomycin antibiotics and the photosensitiser pro-drug 5-ALA 
(1.0 mM). Cell lines were incubated over a period of 240 minutes and imaged in vitro at 
five-minute intervals with the FCE miniprobe. This time-lapse imaging approach was to 
allow for observation of 5-ALA-induced PpIX fluorescent signal levels to establish an 
optimal imaging time window for future imaging experiments where PpIX fluorescence 
was at its highest.  
 
Visual examination of the imaging results in Figure 6.6 demonstrates an improvement in 
image quality and contrast with increasing 5-ALA incubation time across all 
adenocarcinoma cell lines. Although not comparable to images of acridine orange (AO)-
stained cells in terms of clarity and contrast (first row of Figure 6.6), 5-ALA-treated cell 
images still exhibited sufficient contrast for clear distinction between individual cells. 
This improvement in image quality over time can be quantified as an increase in the 
signal to background ratios (SBRs) of the acquired FCE images, which reached a peak at 
t = 60 minutes across all cell lines with optimal image contrast achieved between t = 25 
and 75 minutes (Figure 6.7). This was calculated in the same manner using MatLab (The 
Mathworks, Inc., MA, USA) as described in section 5.4.2.2 of the previous chapter. We 
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expect to observe a similar trend in detected PpIX fluorescence when imaging 
photosensitised tissues over time, but with even stronger fluorescence intensities during 
FCE imaging in vivo. This is due to the lack of FCS in biological tissues, whose presence 
has been shown to cause the efflux of PpIX from in vitro 5-ALA-treated cell cultures 
(Weir et al., 1995; Barto"ová and Hrkal, 2000). 
  
 
 
Figure 6.6. Time-lapse FCE images of three in vitro primary human ovarian cancer cell lines 
incubated with 5-ALA (1.0 mM) for up to a period of 240 minutes. Cells were also stained 
with acridine orange (AO) contrast agent (3.0 !g/mL) to provide a ‘gold-standard’ 
comparison with signals obtained from 5-ALA induced PpIX fluorescence. 
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Figure 6.7. Change in signal to background ratios of FCE images with 5-ALA incubation. 
Peak contrast is reached at t = 60 mins with optimal contrast achieved from t = 25 - 75 mins. 
  
6.3.5. Ex vivo imaging of photosensitised human cancer tissues 
 
With the optimal time window for observing PpIX fluorescence established in the 
previous section from FCE-PDD imaging of photosensitised in vitro primary cancer cells, 
the next experimental phase was to perform the same imaging approach on 
photosensitised ex vivo human cancer tissues to observe a similar 5-ALA-induced PpIX 
fluorescence effect.  
 
Since 5-ALA has to be converted to PpIX intracellularly, we had to ensure that the 
excised ex vivo cancer tissues were maintained alive for a few hours during the course of 
our imaging experiments to achieve viable results. To verify if this was possible, we first 
performed a quick survey of the literature and found that similar ex vivo imaging 
experiments had previously been performed:  
 
Karrer et al. incubated ex vivo samples of perilesional skin and basal cell carcinomas 
excised from human patients with 9-acetoxy-2,7,12,17-tetrakis-(ß-methyoxyethyl)-
porphycene (ATMPn), a photosensitiser pro-drug (Karrer et al., 1997). The depth of 
ATMPn penetration was later measured at 2, 6, 16 and 20 hours after application by 
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observation of red PpIX fluorescence emitting from the epidermal tissue layer. In a 
separate study, Maisch and colleagues demonstrated the successful conversion of 5-ALA 
to PpIX in an ex vivo normal porcine skin by comparing PpIX fluorescence intensity and 
depth of penetration following incubation with a 5-ALA cream and an emulsion 
containing an ester of 5-ALA (aminolevulinate methyl ester hydrochloride) (Maisch et al., 
2009). PpIX fluorescence was detected from three hours after initial cream/emulsion 
application with increases in fluorescence intensity measured up to the end of 
observation at 12 hours.  
 
Various fresh, surplus ex vivo human cancer tissues were imaged with the FCE-PDD 
technique: small-cell lung cancer (SCLC), pharyngeal cancer and bladder cancer tissues. 
These were sourced through various routine resectioning procedures from patients who 
had given their informed consent. As before, all imaging work was performed under 
ethical approval from the relevant Research Ethics Committee (REC Reference No. 
08/H0719/37). The sources of human cancer tissues imaged in this section were as 
follows: 
 
i. SCLC and pharyngeal cancer tissues – sourced from the National Heart and 
Lung Institute, Royal Brompton Hospital, Royal Brompton & Harefield 
NHS Foundation Trust from Dr Pallav Shah, Consultant Physician and 
Honorary Senior Lecturer, National Heart and Lung Institute, Imperial 
College London; and 
ii. Bladder cancer tissue – sourced from St Mary’s Hospital and Charing Cross 
Hospital, Imperial College Healthcare NHS Trust as mentioned previously 
in section 6.2.3. 
 
Resectioned tissues were immediately placed in chilled Hartmann’s solution after surgical 
removal. Thirty minutes or less thereafter, tissues were transferred into a 50 ml incubator 
flask containing warm Hartmann’s and 5-ALA photosensitiser pro-drug (1.0 mM) and 
placed in an incubator set at 37°C and 5% CO2. Tissues were removed from the 
incubator flask at various time intervals for FCE imaging up till a maximum of 120 
minutes. Image acquisition lasted about 30 to 45 seconds per sample, and these were 
immediately returned to warm Hartmann’s/5-ALA solution for continued 
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photosensitiser exposure. All cancer tissue samples showed good correlation with 
histopathological results (not shown). 
 
6.3.5.1. Small-cell lung cancer tissue 
 
Human small-cell lung cancer tissues were incubated in Hartmann’s/5-ALA solution up 
to a maximum of 120 minutes. The tissues measured 0.3 to 0.5 cm in diameter and were 
imaged by FCE at various time points throughout incubation: t = 0, 15, 30, 45, 60 and 
120 minutes.  
 
Lung cancer tissues exhibited some degree of autofluorescence from the outset of FCE 
imaging prior to 5-ALA incubation. This was attributed to the presence of pulmonary 
elastin fibres, which constitute a large percentage of the total protein content present in 
the lung interstitium (Starcher, 1986). Tissue fluorescence was seen to increase 
progressively from basal levels with incubation time, most likely due to the rise in 
amounts of 5-ALA-induced PpIX in tumour cells (refer to Figure 6.8). FCE image 
quality improved correspondingly, with optimal contrast achieved at around t = 45 
minutes. At this time point, cellular-level details were visible in the tissue images with 
individual cells clearly discernable. Beyond 45 minutes of 5-ALA incubation, image 
contrast started to deteriorate gradually in line with the drop in fluorescence signal levels 
– this is observed in the FCE images from time point t = 60 minutes onwards. 
 
Overall, detected PpIX fluorescence in lung tissue reached peak intensity between t = 30 
and 60 minutes, as evident from the increase in both mean and maximum fluorescence 
signal levels measured during this time window (see graph in Figure 6.9). PpIX 
fluorescence also peaked at identical time points (t = 45 minutes) for both the mean and 
maximum fluorescence. This was calculated using the Cellvizio Viewer statistical 
histogram software, which allows for quantification of statistical data from the acquired 
FCE images.  
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Figure 6.8. Time-lapse FCE images from ex vivo human small-cell lung cancer tissue 
incubated with 5-ALA (1.0 mM) for up to a period of 120 minutes. Detected PpIX 
fluorescence reached peak intensity between t = 30 and 60 minutes, as evident from the 
improved image contrast and higher mean/maximum fluorescence during this time window. 
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Figure 6.9. Graph showing the mean and maximum values of fluorescence intensities at 
various FCE imaging time points for 5-ALA-incubated human small-cell lung cancer tissues. 
 
6.3.5.2. Pharyngeal cancer tissue 
 
As with lung cancer tissues, human pharyngeal cancer tissues were incubated similarly in 
warm Hartmann’s solution containing the 5-ALA photosensitiser pro-drug (1.0 mM). 
Incubation was carried out at 37°C and 5% CO2 for a total duration of 90 minutes, with 
the tissues taken out of the incubator flask at 15 or 30 minute intervals for FCE imaging. 
Pharyngeal cancer tissues obtained were much larger in size compared with lung cancer 
tissues, measuring 1.0 to 1.5 cm in diameter.   
 
FCE imaging results in Figure 6.10 exhibit a gradual rise in the detected tissue 
fluorescence from the outset till the end of image acquisition at t = 90 minutes. This led 
to a consequent improvement in image contrast over time with some tissue structural 
detail discernible in the FCE images from t = 30 minutes onwards. These are seen as fine 
tissue striations and are most likely due to the presence of elastic fibres in pharyngeal 
tissue, which allow for movement and structural support during swallowing and 
respiration (Kim et al., 1998). The rise in tissue fluorescence was quantified as before 
using the Cellvizio Viewer statistical histogram software, where mean and maximum 
values were calculated as shown in the graph in Figure 6.11. Both mean and maximum 
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fluorescence values displayed similar trends with peak levels attained after about 60 
minutes of 5-ALA incubation. This was attributed to the increase in 5-ALA-induced 
PpIX produced by cells in the imaged cancer tissue over time.    
 
 
 
Figure 6.10. Time-lapse FCE images from ex vivo human pharyngeal cancer tissue incubated 
with 5-ALA (1.0 mM) for up to 90 minutes. PpIX fluorescence intensity increased gradually 
from the start of incubation, with an observable improvement in image contrast and signal 
to noise ratios over time up until t = 90 minutes. 
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Figure 6.11. Graph showing the mean and maximum values of fluorescence intensities at 
various FCE imaging time points for 5-ALA-incubated human pharyngeal cancer tissues.   
 
6.3.6. In vivo imaging of photosensitised murine tissues 
 
Following on from earlier FCE-PDD imaging experiments involving 5-ALA treated in 
vitro ovarian adenocarcinoma cells and ex vivo human cancer tissues, the next stage was in 
vivo validation of the technique on photosensitised tumours in a murine ovarian cancer 
model. Ethical approval for this section of the study was granted by the UK Home 
Office under the Animals (Scientific Procedures) Act 1986 (Project License Number PIL 
70/22548 – “Immunotherapy and Imaging in Ovarian Cancer”). 
 
Six-eight week old SCID-beige mice (n = 2) were chosen as the tumour model, each 
injected subcutaneously in the upper right thigh with IGROV-1 human ovarian cancer 
cells (1x107) cultivated following standard methods. Imaging was performed about ten 
days after injection of cancer cells, where tumours reached a size of approximately 5.0 
mm in diameter. Mice were injected with 5-ALA (250 mg/kg body weight; titrated with 
sodium hydroxide to pH 6.5 in 1x PBS) intravenously via the tail vein while being 
anaesthetised by inhalation. All tumour-bearing animals were killed by cervical 
dislocation before FCE imaging was performed in vivo on tumour tissues and normal 
organs at 90 and 180 minutes after 5-ALA injection. As a positive control (PC), FCE 
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imaging was performed on the normal organs of a non tumour-bearing naive mouse 120 
minutes after 5-ALA injection. A negative control (NC) mouse was also imaged, which 
did not receive any 5-ALA injection. 
 
Example in vivo FCE-PDD imaging results from murine tissue are shown in Figure 6.12, 
with fluorescence signals quantified using the Cellvizio Viewer statistical histogram 
software as before (section 6.3.5.1) and presented in graphical form (Figure 6.13). Very 
low levels of detectable 5-ALA induced PpIX fluorescence signals were seen from 
subcutaneous IGROV-1 tumours at both the 90-minute (Figure 6.12A) and 180-minute 
(Figure 6.12H) imaging time points, with mean intensity levels remaining around that 
measured from the negative control tumour (Figure 6.13, teal dotted line). This was 
unexpected as the CellvizioGI system’s ability to excite and detect PpIX fluorescence 
was demonstrated using in vitro cancer cells and ex vivo tissue in preceding sections of this 
chapter. Various groups have also reported on the fluorescence detection of PpIX at 
imaging time points between 2 and 5 hours post 5-ALA injection in rat models of 
ovarian cancer (Major et al., 1997; Chan et al., 2002; Regis et al., 2007). Furthermore, a 
250-mg/kg body weight 5-ALA dosage was used in our experiment - this was 2.5 times 
higher than these studies, implying that correspondingly stronger PpIX signals should be 
observed. One possible physiological explanation is our choice of the IGROV-1 cell line 
for tumour induction, whose tumours may not demonstrate effective conversion of 5-
ALA to PpIX at high enough levels in vivo for detection by our FCE instrument; the 
three aforementioned groups all used the NuTu-19 human ovarian cancer cell line for 
tumour induction. Future work will include FCE-PDD imaging experiments using 
alternative cancer cell lines for further validation of the technique in vivo.  
 
Most of the FCE-detected fluorescence came from normal murine tissues. The highest 
fluorescence signals were seen in kidney images (Figures 6.12C, F and J), due most likely 
to the excretion of 5-ALA induced PpIX, a large fraction of which is cleared via this 
organ (Kennedy, 2006). This is seen as a quantifiable increase in fluorescence signal in 
Figure 6.13 (red solid line), which rises from mean basal levels (about 320 a.u.) in the 
negative control mouse kidney to a high of 680 a.u. at 180 minutes after 5-ALA injection 
in the tumour mouse. No fluorescence was visible from the liver images (Figures 6.12D, 
G and K) of both tumour-bearing and naive animals although a small signal was 
quantified (Figure 6.13, green dashed-dotted line). This is an interesting result since the 
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liver was previously found to have five times the rate of PpIX build-up than tumour 
tissues (Jacques et al., 1995). It could be that PpIX accumulation in the liver and tumours 
had already reached its peak before the first imaging time point at 90 minutes and was 
already in the process of being excreted from the animal. Faint signals were visible in the 
spleen (Figures 6.12B, E and I) - an observation that is corroborated by previous reports 
of minute PpIX accumulations found in the spleens of 5-ALA treated human patients 
and animals (van den Boogert et al., 1998; Kennedy, 2006). This is visible as quantifiable 
PpIX signals from the splenic images, which increases slightly from basal levels at the 90 
minute imaging time point and then returns to near-original levels again at 180 minutes 
(Figure 6.13, blue dashed line). Spleen and liver tissues exhibit lower levels of 
fluorescence signal intensities at the 180 time point than that recorded from the negative 
control mouse (refer to Figure 6.13). A likely explanation for this could be the different 
rates at which PpIX is processed in these organs between the different animals imaged. 
 
 
 
Figure 6.12. Example FCE images of murine healthy and IGROV-1 tumour tissues in vivo 
acquired at different time points after intravenous injection of 5-ALA (250 mg/kg body 
weight). Tumour mouse (post 90 minutes) – tumour (A), spleen (B), kidney (C), liver (D); 
Naive mouse (post 120 minutes) – spleen (E), kidney (F), liver (G); Tumour mouse (post 180 
minutes) – tumour (H), spleen (I), kidney (J), liver (K).  
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Figure 6.13. Mean fluorescence intensities obtained from FCE images of various 
photosensitised murine tissues in vivo at different time points after intravenous injection of 
5-ALA (250 mg/kg body weight). NC: negative control mouse, T: tumour mouse, PC: 
positive control mouse. 
 
 
6.4. Probing fluorescent signatures from a tumour-specific PET imaging 
optical analogue 
 
The possibility of imaging across different resolution scales in conjunction with positron 
emission tomography (PET) imaging was later explored by applying fluorescence 
confocal endomicroscopy (FCE) for detection of the tumour-specific fluorescent optical 
biomarker 2-[N-(7-nitrobenz-2-oxa-1,3-diaxol-4-yl)amino]-2-deoxyglucose (2-NBDG). 2-
NBDG is a fluorescently labelled deoxyglucose analogous to 2-deoxy-2 [18F] fluoro-D-
glucose (FDG), the widely used molecule during whole-body FDG-PET imaging 
procedures for cancer detection. The motivation behind FDG-PET is that tumours have 
a higher degree of glucose utilisation compared to normal tissues due to increased 
metabolic activity. This results in upregulation of cellular intermembrane glucose 
transporters like GLUT-1 and hexokinase in tumours, leading to an increased 
accumulation of detectable FDG specifically in these tissues (Gambhir, 2002).  
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One setback FDG-PET imaging suffers from however is poor spatial resolution (1 to 2 
mm) (Weissleder and Pittet, 2008), posing a considerable limitation especially for the 
purposes of early cancer detection where morphological tissue changes occur at the 
microscopic levels. The recently developed radiolabeled 2-NBDG optical analogue by 
Yoshioka and colleagues (Yoshioka et al., 1996) may offer a potential solution: besides 
being detectable by conventional PET imaging, its detection may also be extended to 
optical imaging methods such as confocal laser scanning microscopy and FCE. This 
results in several advantages such as no ionising radiation from the optical imaging 
procedure, high spatial and temporal resolution, and the possible translation of the 
technique to minimally invasive and intraoperative settings (Sheth et al., 2009). We 
applied FCE imaging to determine if cellular level resolution could be achieved using the 
technique in both 2-NBDG-treated in vitro human ovarian cancer cells and a murine 
model of ovarian cancer in vivo.  
 
6.4.1. Instrumentation and imaging procedure 
 
As with previous sections of this chapter, imaging of 2-NBDG fluorescence from in vitro 
human ovarian cancer cell lines and in vivo murine tissue was performed with the 
CellvizioGI FCE system using the GastroFlex Type Z confocal miniprobe. 488 nm (blue 
light) excitation from the CellvizioGI laser system unit was sufficient to elicit 
fluorescence emissions from the fluorescent labelled 2-NBDG glucose analogue, which 
absorbs at 465 - 470 nm and emits fluorescence at around 540 nm (O’Neil et al., 2005; 
Sheth et al., 2009). Cells were imaged with the FCE confocal miniprobe in their culture 
dishes whilst placed on top of a fine-adjustment translational stage. The miniprobe was 
held firmly in place throughout the imaging procedure using a mini V-clamp as before. In 
vivo murine tissues were imaged by hand with the animal carcass secured horizontally on 
a Styrofoam board with the aid of metal pins. 
 
6.4.2. In vitro imaging of fluorescent labelled human ovarian cancer cells  
 
Human ovarian cancer cells used previously, namely OVCAR-5, SKOV-5 and IGROV-
1, were incubated under standard conditions in 35 mm plastic cell-culture dishes 
containing sterile RPMI 1640 media, 10% foetal calf serum (FCS), penicillin-
streptomycin antibiotics and the fluorescently labelled deoxyglucose analogue 2-NBDG 
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(500 nM). 30 minutes after the start of incubation, the growth media was carefully 
removed using a 1.0 mL pipette and the cells gently washed once with 1x PBS before 
FCE imaging was performed in vitro.  
 
 
 
Figure 6.14. FCE images from 3 different human ovarian cancer cell cultures showing either 
control or fluorescent 2-NBDG-incubated populations incubated for 30 minutes prior to 
imaging. Uptake of 2-NBDG appears to be highest in IGROV-1 cells, which exhibit the 
brightest fluorescence out of the three different cell populations.  
 
Results from this imaging experiment are shown in Figure 6.14, where differential uptake 
of 2-NBDG by the three ovarian cancer cell types is clearly evident. FCE images of 2-
NBDG incubated cell lines show a much higher number of fluorescent cells in the 
IGROV-1 population as compared to the OVCAR-5 and SKOV-5 populations – an 
indication that 2-NBDG was uptaken the most by IGROV-1 cells. This observation is 
quantified by calculating the signal to background ratios (SBRs) for each of the three cell 
types using MatLab as described in section 5.3.1, with greater SBRs signifying higher 
fluorescence contrast and hence most likely greater 2-NBDG uptake. Results from this 
 184 
analysis are presented as a bar chart in Figure 6.15, where IGROV-1 FCE images are 
seen to possess the highest SBRs (average of about 91) compared with OVCAR-5 and 
SKOV-5 images (average SBRs of about 14 and 24 respectively). Based on these 
findings, the IGROV-1 cell line was chosen for inducement of subcutaneous tumours in 
a murine model of ovarian cancer for in vivo FCE imaging experiments in the next sub-
section.  
 
 
 
Figure 6.15. Bar chart representing the signal to background ratios (SBRs) from FCE 
images of three different human ovarian cancer cell populations incubated with 2-NBDG: 
OVCAR-5, SKOV-5 and IGROV-1. 
 
6.4.3. In vivo imaging of tumour-specific fluorescent biomarkers from 
murine tumour tissue 
 
The ability of FCE imaging to detect tumour-specific fluorescent signatures from 
biomarkers in vivo was investigated using a murine tumour model of ovarian cancer. 
Ethical approval for the study was granted by the UK Home Office under the Animals 
(Scientific Procedures) Act 1986 as stated in section 6.3.6. Tumours were induced by 
subcutaneous injection of IGROV-1 human ovarian cancer cells in anaesthetised 
SCID/beige mice, with imaging performed about ten days after tumour cell injection. 
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Before commencing FCE imaging, mice were anaesthetised by inhalation and injected 
intravenously via the tail vein with 2-NBDG (500 nM in 1x PBS). Three mice were used 
in this experiment – two tumour-bearing mice, with one serving as the negative control, 
and another naive non tumour-bearing mouse. All animals were starved for 18 hours 
prior to dye injection to allow for optimal uptake of the fluorescent 2-NBDG glucose 
analogue by actively metabolising cells. FCE imaging was performed 20 minutes after 
intravenous injection of 2-NBDG.  
 
 
 
Figure 6.16. Example FCE images of healthy and IGROV-1 tumour murine tissues in vivo 20 
minutes after intravenous injection of the fluorescent deoxyglucose analogue 2-NBDG. 
Negative control (NC) tumour mouse - tumour (A), spleen (B), liver (C), kidney (D); Naïve 
non tumour-bearing mouse – spleen (E), liver (F), kidney (G); Tumour mouse – tumour (H), 
spleen (I), liver (J), kidney (K).   
 
Figure 6.16 shows FCE imaging results from tumour and normal tissues of 2-NBDG- 
exposed murine cancer models 20 minutes post-injection. As expected, no detected 2-
NBDG fluorescence signals were visible in tissues of the negative control tumour mouse 
(Figure 6.16A-D) with mean basal fluorescence signals of between 280 to about 350 a.u., 
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as quantified using the Cellvizio Viewer statistical histogram software (Figure 6.17). 
Fluorescence was observed in all other 2-NBDG treated tissues, both tumour and 
normal, with fluorescent regions seen in all images (Figure 6.16E-K). 2-NBDG treated 
murine tumour tissues displayed regions of weak fluorescence (Figure 6.16H), shown 
statistically to only be about 20% brighter than the untreated tumour tissue (336 vs 278 
a.u.; Figure 6.17). Splenic tissue exposed to 2-NBDG also exhibited regions of weak 
fluorescence (Figures 6.16E and I); these appeared similar to the 2-NBDG tumour image 
in Figure 6.16H with mean fluorescence intensities of between 280 and 369 a.u.. Liver 
tissues of 2-NBDG treated mice displayed the least fluorescence (Figures 6.16F and J), 
with mean fluorescence intensities similar for both treated and untreated mice (mean 
intensity average of 334 a.u.; refer to Figure 6.17). The highest 2-NBDG fluorescent 
signals were seen in the kidneys (Figure 6.16G and K), which are one of the main sites 
for glucose clearance. Mean fluorescence intensity in the kidney tissues sampled had 
values of 671 and 655 a.u. for the naive and tumour mouse respectively (Figure 6.17).  
 
 
 
Figure 6.17. Bar chart representing mean fluorescence intensities from FCE images of 
various in vivo murine tissues obtained 20 minutes after intravenous injection of 2-NBDG 
(500 nM).  
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Various fluorescence studies have shown that tumour tissues display more rapid uptake 
of 2-NBDG as a result of higher metabolic activity compared to normal tissue, evidenced 
by increased DNA and protein synthesis and glycolysis (Warburg, 1956; Weber, 1977). 
This feature is widely exploited in FDG-PET imaging to distinguish between tumour and 
healthy tissues (O’Neil et al., 2005; Nitin et al., 2009). However, in vivo FCE imaging 
performed in this study on normal and tumour murine tissues demonstrated otherwise: 
2-NBDG fluorescence was visible in both murine tumour tissue as well as in normal 
tissues of the spleen, liver and kidney. The non-specific 2-NBDG accumulation may 
have most likely occurred due to relatively similar levels of metabolic activity in both 
tumours and normal murine tissue types. Tumours exhibit different phases of growth, 
with exponential growth rates at the outset and more linear growth thereafter (Mackillop, 
1990; Simeoni et al., 2004). It was probable that the IGROV-1-induced murine tumour 
had already reached its linear growth phase ten days after initial cancer cell injection; this 
is the time-point when our FCE/2-NBDG experiment was performed. Barring further 
studies on IGROV-1 tumour growth kinetics and optimal 2-NBDG imaging time points, 
the low levels of detected fluorescence and poor image contrast seen in the FCE images 
(Figure 6.16) indicate that 2-NBDG is not an ideal tumour marker candidate for the 
purposes of cancer detection with FCE at this point. 
 
 
6.5. Multimodal endoscopic viewfinder imaging technique 
 
Imaging experiments performed up till this point in the thesis explored three different 
optical techniques for early cancer detection and diagnosis, namely multispectral 
fluorescence imaging (MFI), hyperspectral reflectance imaging (HRI) and fluorescence 
confocal endomicroscopy (FCE). To briefly recapitulate, MFI and HRI are both 
imaging-based spectroscopic approaches, allowing the sampling of fluorescence and 
diffuse reflectance signals respectively from larger regions of tissue compared with 
conventional methods. Since there is no direct tissue contact with the imaging probe 
positioned a few centimetres away from the interrogated region, probe-tissue contact 
pressure effects are also effectively eliminated. FCE is a point-based imaging modality 
that captures high resolution, cellular-level detail with image qualities approaching that of 
histology, permitting morphological and functional assessment of tissue disease states in 
real time. With the diagnostic effectiveness of each technique validated in earlier chapters 
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of this thesis, we next set out to apply them in concert to demonstrate a multimodal 
endoscopic viewfinder (MEV) imaging approach for the in vivo detection and diagnosis of 
tissue disease states. 
 
Individually, each imaging technique has its limitations. Although MFI and HRI can 
effectively visualise the “big picture” through regional sampling of in vivo tissues, neither 
of these techniques have the spatial resolution to elucidate minute cellular-level tissue 
surface details where the earliest cancerous changes first occur. Conversely, FCE has 
high spatial resolving power and the ability to visualise tissues at the fine cellular level. 
Being a point imaging method however, it suffers from the inherent problems of such an 
approach e.g. the need to acquire data from multiple points to allow for sampling of a 
larger tissue area, hence leading to longer procedure times and also a high rate of 
sampling error due to the random nature of the data acquisition process. In combination 
therefore, these three techniques complement each other, resulting in a holistic and 
comprehensive imaging approach for early cancer detection and diagnosis without the 
need for tissue biopsies.  
 
Figure 6.18 shows a series of images collected from separate imaging experiments to 
illustrate the proposed the MEV imaging technique. In line with routine practice, an 
endoscopist first employs conventional white-light endoscopic (WLE) imaging to survey 
the suspect diseased tissue region (Figure 6.18B). With the system in MFI/HRI mode, 
real-time image processing with the FR-IsoMap algorithm identifies a suspect cancerous 
lesion on the tissue mucosa (Figure 6.18C). The lesion appears a different colour in the 
FR-IsoMap colour image due to it possessing different spectral properties from the 
healthy surrounding tissue. For real-time histological confirmation, FCE imaging is next 
performed on the suspect lesion. This is done by inserting the FCE confocal miniprobe 
through the endoscope’s accessory channel (Figure 6.18A) and placing it in gentle 
contact with the tissue surface. The resulting in vivo FCE images provide cellular-level 
morphological confirmation of the tissue disease state akin to a ‘virtual histology’ (see 
example in Figure 6.18D), thus allowing the clinician to swiftly decide upon the next 
course of therapeutic action.  
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Figure 6.18. Images illustrating the proposed multimodal endoscopic viewfinder (MEV) 
imaging technique. The confocal miniprobe is inserted down the accessory channel of a 
flexible endoscope during in vivo FCE tissue imaging (A). Initial white light endoscopic 
(WLE) imaging shows a suspect cancerous lesion (dashed white circle) (B). This lesion 
appears in the FR-IsoMap image as a different colour from the surrounding healthy tissue 
due to differences in spectral properties; the tip of the FCE miniprobe is visible in the field 
of view as it approaches the lesion (C). Example FCE image of the interrogated cancerous 
lesion tissue providing real-time disease confirmation via a ‘virtual histology’ (D). Note that 
these images are compiled from different experiments and were not acquired from an actual 
MEV imaging procedure. (Figure 6.18A adapted from MedGadget.com; Figures 6.18B and 
C courtesy of Mr Richard Newton, Clinical Research Fellow, Imperial College London)  
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6.5.1. Instrumentation and imaging procedure 
 
The MEV imaging approach employed two previously demonstrated systems for tissue 
diagnosis: 1) the supercontinuum fibre laser-based imaging system as described in section 
4.2 of the thesis for MFI and HRI procedures, and 2) the CellvizioGI fluorescence 
confocal endomicroscope system detailed earlier in section 5.4 for FCE imaging. During 
the MEV imaging procedure, MFI and HRI were the first imaging techniques to be 
applied followed by FCE in this order. The rationale behind this two-part approach was 
that larger tissue regions measuring approximately 10 cm squared area are imaged first 
using MFI and HRI for the identification of suspect lesional areas, before zooming in to 
these lesions using FCE to allow for more finely detailed !m-scale histological 
assessment for disease confirmation.  
 
MFI and HRI were performed using a rigid laparoscope with the supercontinuum laser 
emitting at 16 excitation wavelengths between 416 and 518 nm, each possessing 
bandwidths of about 4 to 8.5 nm (see Figure 6.19). For MFI, a 600 nm longpass filter 
was included to only allow transmission and recording of fluorescent signals above this 
emission wavelength; no longpass filter was used during HRI. FCE imaging was 
performed with the GastroFlex Type Z fibered confocal miniprobe, which transmitted 
488 nm laser excitation from the laser system unit to the imaged tissue sample.  
 
 
 
Figure 6.19. The 16 excitation wavelengths applied during MFI and HRI for eliciting 
respective fluorescence and diffuse reflectance signals from tissues during MEV imaging.  
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6.5.2. Viewfinder imaging of photosensitised ex vivo bladder cancer tissue 
 
Ex vivo human bladder tissue samples imaged during the endoscopic viewfinder imaging 
procedure were excised via cold-cut biopsy from a patient undergoing a routine TURBT 
procedure for bladder cancer surveillance as in section 6.2.3.2. Informed consent was 
obtained before surgery and all imaging work was performed under ethical approval as 
before (REC Reference No. 08/H0719/37). A total of five bladder tissue samples with 
different disease conditions were imaged ex vivo: two healthy samples, two tumour 
samples and one necrotic tumour sample, each measuring approximately 0.5 to 1.5 cm in 
diameter. The tissues were incubated with Hartmann’s solution containing 5-ALA (1.0 
mM) at 37°C temperature and 5% CO2 for 60 minutes, within half an hour of surgical 
removal from the patient.  
 
For MFI and HRI experiments, ex vivo human bladder tissues were placed on top of a 
non-reflective black plastic tray with the tip of the laparoscope positioned about 70 mm 
above it during data acquisition. The laparoscope served the dual function of delivering 
the spectrally filtered excitation light to the tissue samples as well as for collection of 
emitted fluorescence and diffuse reflected signals. For FCE imaging experiments, the 
bladder tissues were imaged by hand with the confocal miniprobe in gentle contact with 
the tissue. As before, extra care had to be taken to ensure the right amount of contact 
pressure was applied by the confocal miniprobe tip on the surface of the tissue for 
obtaining optimal focus and image quality and contrast. The tissue sampling arrangement 
for MEV imaging is MFI and HRI first followed by FCE, with the ensuing imaging 
results presented in this order. 
 
Results from MFI of the ex vivo bladder tissues are presented in Figure 6.20 as a graph of 
fluorescence spectra normalised by area under the curve against the corresponding 
excitation wavelengths applied. Between the excitation wavelengths of about 416 and 443 
nm, 5-ALA-treated tumour and necrotic tumour tissues displayed the highest relative 
amounts of fluorescence. This is most likely due to the 5-ALA-induced production of 
protoporphyrin IX (PpIX; 400 to 450 nm absorption maxima), which has been 
previously shown to accumulate preferentially in tumour cells and tissues. Lower relative 
fluorescent signals were seen in the 5-ALA-treated healthy tissue and non-treated healthy 
and tumour tissues. This was possibly as a result of no to very little accumulation of the 
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fluorescent PpIX photosensitiser. Above 443 nm, tissue samples exhibited a higher 
relative amount of autofluorescence signals overall. However instead of 5-ALA-treated 
tissues showing higher relative levels of fluorescence, it was the untreated tissue samples 
this time round between the excitation wavelength range of 443 to 486 nm. A possible 
explanation for this is additional contributions to the overall detected fluorescence signal 
by endogenous tissue fluorophores present in bladder tissue such as flavin adenine 
dinucleotide (FAD), elastin and the lipopigments. Note that this is the case due to the 
normalisation of the spectra so that the areas under the curve are equal, and the actual 
amounts of fluorescence emitted by the samples is not comparable. Both healthy bladder 
tissue samples displayed higher relative fluorescence levels at around the 449 to 472 nm 
excitation range, most likely due to emission from FAD, which is characteristic of such 
actively metabolising healthy tissues. Conversely, tumour and necrotic tumour tissue 
exhibited lower relative fluorescence at this excitation range. 
 
 
 
Figure 6.20. Graph of normalised fluorescence spectra plotted against excitation wavelength 
for respective 5-ALA- and non photosensitiser-treated ex vivo human bladder tissue samples 
with various disease conditions.  
 
HRI results obtained from the ex vivo bladder tissues proved inconclusive, with no 
significant differences observed in terms of diffuse reflectance spectra between the 
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samples. Diffuse reflectance signals are affected to a considerable extent by the 
oxyhaemoglobin (HbO) and deoxyhaemoglobin (HbR) content of tissues, which serve as 
strong light absorbers especially in the visible range of the electromagnetic spectrum (400 
to 700 nm). Changes in the relative concentrations of these chromophores often reflect 
changes in the physiological and pathological conditions of a particular organ or tissue 
region. Results from HRI consequently imply the need to image live tissues in vivo, i.e. 
ones with an active blood supply and circulation. This would allow detection of viable 
differences in the diffuse reflectance spectra between tumour and healthy tissues owing 
to variations in mucosal vasculature and associated haemoglobin content. As such, we 
expect to achieve effective discrimination between tumour and healthy tissues with our 
HRI approach in vivo in situ.  
 
 
 
Figure 6.21. Example FCE images of 5-ALA treated and untreated ex vivo human bladder 
tissue after 60 minutes of incubation at 37°C temperature and 5% CO2: 5-ALA treated 
tumour tissue (A); 5-ALA treated necrotic tumour tissue (B); 5-ALA treated healthy tissue 
(C); untreated normal tissue (D); untreated necrotic tumour tissue (E). 
 
FCE images of 5-ALA-treated and untreated ex vivo bladder tissues in Figure 6.21 are 
included to demonstrate the cellular-level diagnostic information that can be obtained 
after follow-up FCE imaging in the second part of the MEV imaging approach. Regions 
of bright fluorescence are visible in the 5-ALA-treated ex vivo tumour and necrotic 
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tumour tissues (Figure 6.21A and B), implying the occurrence of PpIX synthesis in these 
tissues even under such less-than-optimal physiological conditions. We would therefore 
anticipate stronger PpIX fluorescence detected and hence achieve better imaging contrast 
during future in vivo FCE imaging procedures of a similar nature.  
 
 
6.6. Summary  
 
Initial experiments in this chapter have established AO as the optimal contrast agent for 
fluorescence confocal endomicroscopy (FCE) imaging using ex vivo porcine tissues. AO 
was subsequently applied to FCE imaging of ex vivo human ovarian cancer and bladder 
cancer tissues, which resulted in the successful characterisation of cancer tissue 
morphology. This demonstrated the possibility of performing FCE imaging for real-time 
intrasurgical histopathology.  
 
FCE was next explored as a photodynamic diagnostic (PDD) modality during FCE-PDD 
imaging of 5-ALA photosensitised in vitro human ovarian cancer cell lines, ex vivo human 
pharyngeal, bladder and small-cell lung cancer tissues and in vivo murine tumour tissues. 
From time-lapse FCE-PDD experiments of in vitro cell lines and ex vivo tissues, the 
possibility of detecting PpIX fluorescence by the system was demonstrated and the 
optimal imaging time window of highest PpIX fluorescence was established for each 
imaging sample. In vivo murine FCE-PDD imaging results were not a good reflection of 
that obtained in vitro and ex vivo however. This was possibly due to the use of a different 
cell line for tumour inducement, IGROV-1, compared to other similar successful studies 
in the literature.  
 
The use of FCE as a complementary technique to FDG-PET imaging was investigated 
using the fluorescent 2-NBDG glucose molecule analogous to FDG. IGROV-1 ovarian 
cancer cells showed good uptake of 2-NBDG in vitro and were subsequently used for in 
vivo tumour inducement in a murine model. In vivo imaging results however showed non-
specific accumulation of 2-NBDG in both normal and tumour tissues, possibly due to 
similar metabolic activity in the two tissue types. With better understanding of tumour 
growth kinetics and optimal imaging time points, we expect the utility of FCE/2-NBDG 
imaging to be fully realised as an effective means of cancer detection in vivo.  
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As a conclusion to the chapter, the combined application of multispectral fluorescence 
imaging (MFI), hyperspectral reflectance imaging (HRI) and FCE as a multimodal 
endoscopic viewfinder (MEV) imaging approach was proposed. This novel imaging 
concept was demonstrated on 5-ALA photosensitiser-treated healthy and cancerous 
human bladder tissue as a possible technique for early cancer diagnosis. 
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                         7 
Conclusions and Future Outlook  
 
 
 
The work discussed in this thesis spans three different optical imaging modalities – 
multispectral fluorescence imaging (MFI), hyperspectral reflectance imaging (HRI) and 
fluorescence confocal endomicroscopy (FCE) – with accompanying experiments 
performed within the contexts of early cancer detection and diagnosis. Samples under 
investigation ranged from fluorescent dye solutions and tissue phantoms to ex vivo tissue 
specimens, finally culminating with in vivo work in animal tumour models. Our aim was to 
establish the clinical utility of these optical imaging techniques as potential ‘red flag’ and 
‘optical biopsy’ methods for minimally invasive in vivo in situ disease monitoring.  
 
The MFI and HRI techniques surveyed in chapters 3 and 4 utilised a custom-built 
supercontinuum fibre laser system. The system, incorporating either a motor-controlled 
slit or digital multimirror device (DMD), allows for laparoscopic acquisition of diagnostic 
images based on the principles of conventional fluorescence spectroscopy (FS) and 
diffuse reflectance spectroscopy (DRS). Further image processing with the FR-IsoMap 
data dimensionality reduction technique allowed for selection of the most meaningful 
data parameters for generation of an RGB colour map of the imaged region. We note 
that MFI of unstained colorectal tissue samples in chapter 4 did not produce conclusive 
FR-IsoMap results, possibly as a result of low tissue autofluorescence emissions that 
were not efficiently captured by our imaging system. This highlights one of the particular 
difficulties in performing MFI on tissues both ex vivo and in vivo, a challenge that we 
believe will be addressed in the near future given more sophisticated detection optics and 
image processing algorithms.  
 
By spanning the fields of both wide-field macroscopic imaging and localised point-based 
techniques, our unique MFI and HRI approach allows for the generation of macroscopic 
‘regional’ images whilst taking into account fluorescence and diffuse reflectance signals 
acquired from the respective tissue regions. Hence, diagnostic information incorporating 
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spectral properties of each sampled area is relayed to the operator in terms of a more 
intuitive and qualitative image-based format. Possible correlation of imaging results in the 
form of FR-IsoMap colour maps with established cancer classification systems such as 
the Dukes’ grading or TNM systems will also potentially allow for greater effectiveness 
of disease discrimination in vivo in situ. We anticipate that our easily-accessible MFI and 
HRI diagnostic approach to find many applications in the clinic, either as a stand-alone 
or complementary technique to currently-established clinical imaging modalities such as 
MRI, PET and CT imaging. 
  
One key challenge we foresee during further development and future implementation of 
our dual MFI/HRI technique is the difficulty in acquiring large amounts of spectral 
information in vivo for a comprehensive diagnosis. When imaging inside a living patient, it 
is also inevitable that various image artefacts may arise due to respiratory movements and 
tissue deformation. For the method to be viable, it is therefore necessary to not only 
speed up the entire image acquisition process but to also ensure that only the most 
meaningful and accurate diagnostic data is collected. This can be addressed in the 
following ways:  
 
i. Complete characterisation of various cancerous tissues with the imaging 
techniques ex vivo before in vivo implementation. This would allow for 
further validation of the techniques and better understanding of signals that 
would be acquired in vivo as well as generation of a comprehensive training 
set for effective discrimination of tissue states by the FR-IsoMap algorithm; 
ii. Using a spectral selection method for choosing only the most diagnostically 
meaningful spectra to be applied during imaging. An example of this would 
a Bayesian framework for feature selection (BFFS) previously demonstrated 
by our group on MFI data (Wood et al., 2008). The method uses receiver 
operating characteristic (ROC) curves for determining the optimal 
combination of excitation wavelengths to be applied. This would 
consequently result in faster acquisition of a smaller in vivo image data set 
yielding the most pertinent data for a more comprehensive diagnosis; and 
iii. Performing image registration to allow correct alignment of images from a 
moving surface. This method is currently being investigated by our group 
using a customised trinocular (three-channel) rigid endoscope. The unique 
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approach allows for combined stereoscopic visualisation and multispectral 
imaging, thereby resulting in simplified navigation and more straightforward 
3D identification of tissue regions of interest (Clancy et al., 2010). 
 
Apart from performing additional ex vivo tissue characterisation with our dual MFI and 
HRI technique, future work will also include in vivo tissue imaging in animal models of 
cancer. This is to familiarise ourselves with the detected signals in preparation for future 
in vivo in situ MFI/HRI procedures in patients. Possible modifications to the 
supercontinuum laser system may also be performed to allow additional modalities such 
as multispectral polarised light imaging to be carried out. In addition, various parts of the 
system may be upgraded: e.g. the laser system could be changed to one of a higher power 
for a greater excitation signal and also a newer, more sensitive camera could be included 
with the ability to detect lower fluorescence signals than at present. 
 
FCE experiments presented in chapters 5 and 6 have utilised the commercial CellvizioGI 
system. Previous studies in the literature have applied the technique for ‘virtual histology’ 
in a range of different tissue types (refer to section 2.5.4 for more details). Besides 
characterising the morphology of healthy and cancerous tissues both ex vivo and in vivo, 
we have further extended the facility of the technique towards more novel functional 
imaging applications.  
 
With FCE, we have successfully demonstrated the technique’s potential to assess 
chemotherapy response at the cellular level in vitro over a short five-day period. This has 
implications for ovarian cancer screening, enabling faster knowledge of treatment 
outcomes than currently employed methods e.g. MRI and the CA-125 tumour marker. 
Of slight concern however is the application of acridine orange (AO) dye for attaining 
optimal image contrast during imaging. Although approved by the FDA for use in an 
endobag (see section 5.4.2 and Tanbakuchi et al., 2010), its recognised cytotoxic 
properties will still hinder widespread application in patients. As such, additional work 
has to be carried out to uncover a suitable and less/non-toxic dye substitute, or to 
evaluate situations where the use of such a mildly toxic agent may still be appropriate in 
vivo.  
 
 204 
The use of FCE as a photodynamic diagnostic (PDD) tool was also effectively 
demonstrated. In line with various reports in the literature, we have managed to observe 
5-aminolevulinic (5-ALA)-induced protoporphyrin IX (PpIX) fluorescence from both 
cells (as previously reported by Barto!ová and Hrkal, 2000; Betz et al., 2002) and ex vivo 
tissues (see section 6.3.5 and Karrer et al., 1997; Maisch et al., 2009). Apart from the two 
ex vivo studies mentioned, we have yet to find others in the literature where PpIX was 
induced ex vivo following 5-ALA application. We believe our work on 5-ALA-treated 
human small cell lung cancer (SCLC) and pharyngeal cancer tissues to be the first 
example of ex vivo-induced PpIX fluorescence detected in cancerous tissues by FCE-
PDD. In the process, we have also established a protocol for incubation of ex vivo tissues 
with 5-ALA, which could be extended for the characterisation of other photosensitisers 
in ex vivo tissue.    
 
FCE-PDD results obtained from 5-ALA-treated in vivo murine ovarian cancer models 
were unexpected, with no to very little PpIX signals observed from tumours. We hope to 
address this in future work by looking at different parameters that may result in a positive 
PpIX signal, for example:  
 
i. Ensuring tumours are at their most active stage of growth during the time 
of imaging i.e. the exponential or log phase, for optimal 5-ALA intracellular 
conversion; 
ii. Imaging at different time points below 90 minutes from the start of 
intravenous injection of 5-ALA. Strong PpIX signals were observed in the 
healthy kidneys and spleen of the sacrificed animals from 90 minutes after 
5-ALA injection, indicating that PpIX accumulation in tumours may already 
have reached its peak and was being processed and excreted from the 
animal; and 
iii. Using an alternative cell line for in vivo tumour induction such as the NuTu-
19 ovarian carcinoma cell line, whose tumours have exhibited positive 5-
ALA-induced PpIX signals in vivo (refer to section 6.3.6 and Major et al., 
1997; Chan et al., 2002; Regis et al., 2007). 
 
FCE imaging of the tumour-specific fluorescent-labeled 2-NBDG optical biomarker in in 
vivo murine tissues produced results conflicting with that in the literature. Previous 
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studies have demonstrated more rapid and greater uptake of 2-NBDG in tumours 
compared to normal tissues as a result of higher metabolic activity (O’Neil et al., 2005; 
Nitin et al., 2009). FCE images from our study however displayed visible 2-NBDG 
fluorescence in both murine tumours and normal tissues such as that from the spleen, 
liver and kidney. We have attributed this observation to similar metabolic activity in both 
tumour and normal tissues. Further tests on tumour growth kinetics are required so as to 
determine a more optimal imaging time-point for better exploitation of the technique in 
vivo.   
 
On the whole, we have shown the possibility of detecting fluorescence originating from 
photosensitisers and fluorescently labelled biomarkers in vivo with FCE. It would be 
difficult however to further validate the full effectiveness of these different functional 
FCE imaging approaches given the spatially limited point-imaging nature of the 
procedure. Hence, a macroscopic optical viewfinder method is first needed to visualise 
larger tissues regions in vivo before subsequently applying FCE for more microscopic 
detection. 
 
One particular challenge when imaging with the FCE confocal miniprobe was the precise 
amount of pressure that had to be applied for obtaining optimal image quality and 
contrast. This could possibly have arisen due to the requirement of a minimum working 
distance between the miniprobe and the target surface, or to prevent deformation of the 
imaged surface. We have managed to avoid the problem during in vitro cellular imaging by 
holding the miniprobe in place with a miniature V-clamp and translating the cell samples 
with a moveable mechanical stage. With ex vivo and in vivo tissues however, imaging had 
to be performed by hand, making the application of a constant probe pressure a delicate 
and at times frustrating process. Future in vivo FCE imaging procedures with the confocal 
miniprobe inserted down an endoscope port would be an even greater challenge since 
the operator would receive possibly no haptic feedback throughout. A solution to this 
would be to perform FCE imaging in vivo with the aid of a force sensor such as that 
employed by Noonan and colleagues: the group incorporated a force/torque sensor at 
the tip of a robotic endoscope to maintain an optimal force applied by their fluorescent 
imaging probe (Noonan et al., 2010). In this manner, it would therefore be possible to 
maintain a constant pressure with the probe on tissue surfaces in vivo, hence allowing for 
the acquisition of FCE images with consistent quality and contrast.  
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FCE is still in its infancy, with first demonstration of the technique on colorectal cancer 
tissues in vivo published only in late 2004 by Kiesslich and colleagues (Kiesslich et al., 
2004). Rising interest in the technique will see further system improvements, more 
tumour-specific molecular contrast agents developed and a possible standardisation of 
FCE image interpretation through both preclinical and clinical trials (Bisschops and 
Bergman, 2010). Though FCE will not entirely replace standard histology, this will 
eventually result in greater adoption of the technique in routine clinical practice.  
 
Some limitations of our imaging studies included: 
 
i. The poor availability of ex vivo tissue samples for proper validation of our 
imaging techniques.  
Initial MFI and HRI experiments were performed on frozen colorectal 
tissue obtained from an NHS-approved tissue bank. Though not a good 
reflection of in vivo imaging conditions, imaging work was carried out on 
these frozen tissues because ethical approval had not been granted at that 
point for the use of freshly resectioned ex vivo samples. Once approval was 
granted, we proceeded to image fresh surplus ex vivo tissues obtained from 
routine surgical resections; these were sourced from our clinical 
collaborators and consisted of cancerous tissues from the pharynx, lung, 
bladder and ovaries. We note that tissues from these organs may not be in 
line with our end goal of imaging more easily accessible hollow organs 
minimally invasively. Due to the constraint of tissue availability however, a 
compromise had to be made to use these tissue samples at hand. Future 
work would therefore involve expanding our base of clinical collaborators 
to ensure that fresh tissues from more relevant organs are obtained for 
imaging studies.  
 
ii. The quantification of cell numbers with FCE during in vitro characterisation 
of cell function and morphology.  
FCE was performed with the main purpose of characterising morphological 
response of in vitro cancer cells to cisplatin-based chemotherapy. As an 
added parameter for assessing drug response, tracking of cellular attrition 
rates was also decided upon. We note that this is not the gold standard 
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approach to quantifying cells in vitro. Should the need arise in the future, a 
more proper technique will be employed such as using a haemocytometer 
and the Trypan blue stain. 
   
The last ten years has seen enormous strides made in biomedical engineering with 
concomitant advances in the imaging sciences. Buzzwords such as ‘optical biopsy’ and 
‘virtual histology’ are fast becoming commonplace in every a clinician’s daily vocabulary. 
Helped along by excellent results from preclinical imaging trials involving animal models 
of disease, it is without doubt that optical imaging techniques will play a pivotal role in 
medicine. Apart from disease classification, such techniques will also provide greater 
insight into the molecular basis of disease in model organisms as well as aid in the 
development of novel cancer therapies (Contag, 2007).  
 
Just as we have suggested a multimodal endoscopic viewfinder (MEV) imaging approach, 
so will the manner in which cancer is detected and diagnosed. We envision the likely 
combination of two complementary techniques for early cancer detection: a wide-field 
optical imaging approach such as MFI or narrow-band imaging (NBI) as the initial ‘red 
flag’ technique, followed closely by a localised point-based method like FCE or 
endocytoscopy for more accurate disease confirmation based on cellular morphology 
(Anandasabapathy, 2008). Coupled with the development of more tumour-specific 
tracking agents such as dye-peptide conjugates (Ye et al., 2006), nanoparticles (Achilefu, 
2004) and fluorescent-labeled dendrimers (Backer et al., 2005), optical imaging 
approaches are set to become the modalities of choice for routine cancer screening and 
surveillance in the near future. 
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